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Abstract  
 
This research project has been aimed to investigate human neocortical development in 
healthy and diseased subjects by analyzing and comparing the transcriptional profiles 
and cellular morphologies of human neocortical cells derived from induced pluripotent 
stem cells (iPSCs).  
 
Given the importance to rely on a solid and highly reproducible iPSCs-based 
differentiation protocol that generates authentic neocortical neurons in vitro with high 
efficiency before applying it as a model system of human neurodevelopmental disorders, 
in the first phase of this study we performed a comprehensive transcriptional, cellular 
and physiological characterization of the in vitro neurodevelopmental paradigm. The 
transcriptional dynamics regulating in vitro neocortical development have been 
investigated by performing RNA-sequencing (RNA-seq) at both population and single- 
cell level in combination with several bioinformatics analyses including principal 
component analysis (PCA), differential gene expression analysis and weighted gene co-
expression network analysis (WGCNA). The transcriptional results were corroborated by 
the widespread positivity for a selected panel of informative cell-fate and cell-stage 
specific markers detected through immunocytochemistry and the physiological maturity 
of our iPSCs-derived neocortical neurons was further confirmed by their ability to 
generate action potentials, develop complex firing patterns and sustain excitatory and 
inhibitory spontaneous synaptic activity. Overall, these results fully validated the 
reproducibility of the differentiation protocol and its efficiency and reliability in generating 
physiologically mature authentic neocortical neurons. 
 
Subsequently, we applied this extensively characterized neocortical differentiation 
paradigm to model in vitro two human neurodevelopmental disorders caused by 
symmetrical copy number variations (CNVs) of the Williams-Beuren syndrome 
chromosome region (WBSCR) located on the long arm (q) of chromosome 7 at position 
11.23 (7q.11.23 locus). 7q11.23 CNVs are of special interest as the two disorders 
resulting from the deletion (Williams syndrome, WS) and duplication (7q.11.23 
duplication syndrome, 7q11DUP) of this region exhibit cognitive and behavioral 
phenotypes marked by both similar features and symmetrically opposite traits. The 
association of 7q11DUP to complex neurodevelopmental disorders such as autism 
spectrum disorder and schizophrenia, while WS is a well-characterized syndrome 
without clear overlap to complex neurodevelopmental disorders make the study of this 
locus extremely interesting to identify the molecular mechanisms unique to each clinical 
condition, common to both syndromes and shared with other complex 
neurodevelopmental disorders. To this aim, we generated several iPSCs lines from a 
large cohort comprising WS individuals, 7q11DUP patients and healthy subjects and 
differentiated them into neocortical neurons by applying the previously in-depth 
characterized protocol. Having assessed the quality of our iPSCs-derived neocortical 
neurons, we are currently identifying neuronal subtypes specific genes and gene 
networks having the most statistically significant relationship to these disorders through 
single cell RNA-sequencing analysis. Furthermore, morphometric analysis of WS and 
control iPSCs-derived neocortical neurons has confirmed in humans many neuronal 
morphological abnormalities observed in a mouse knockout for Dnajc30, a previously 
uncharacterized gene contained in the 7q11.23 locus.  
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Chapter 1: Human neocortical development 
1.1 Structural organization of the human postnatal cerebral cortex  
 
The human cerebral cortex, also known as neocortex, is a 1-4.5 mm thick mantle of gray 
matter constituting the outermost surface of the cerebral hemispheres enclosing the 
underlying white matter [1]. The gray matter is composed of a tightly packed network of 
different neurons supported by a diverse range of glial cells and capillaries that 
constitutes up to 80% of the brain mass [2], while the white matter consists of the 
myelinated axons of cortical neurons projecting intra- or extra-cortically and their input 
afferents from subcortical structures. The human neocortex is distinctively characterized 
by an expansion of its surface area combined with a minor increase in its thickness 
compared to other mammals [3-8]. The increase of its surface area confers to the human 
neocortex its folded and convoluted appearance characterized by a complex pattern of 
grooves (sulci) and ridges (gyri), comprising two-thirds and one-third of the cerebral 
cortex respectively [7, 9, 10]. Gyrification appears to be a strategic evolutionary solution 
to minimize the enlargement of the skull while accommodating a larger number of 
neurons [5, 10-12].   
 
 
 
 
Figure 1: Human cerebral cortex and its cytoarchitectonic organization. On the left, 
Nissl-staining of a coronal section of the human brain. The neocortex is the outer gyrified 
layer labeled in dark violet due to the high cell density while the underneath white matter 
displays a clearer stain as being mainly constituted by myelinated axons. Adapted with 
permission from http://www.brains.rad.mus.edu. On the right, three photomicrographs 
from 100 µm thick Nissl-stained sections showing the six cytoarchitectonically distinct 
horizontal laminae of respectively the human frontal (area 10), parietal (area 3b), and 
occipital (area 17) neocortical areas that highlight histological differences between the 
layers organization in distinct areas. Scale bar: 250 µm. Adapted from Ballesteros-Yánez 
et al. [13]. 
 
The human cerebral cortex is estimated to consist of approximately 16.34 billions 
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neurons [14-16] finely interconnected through the establishment of about 164 trillion 
synapses [15, 17] and precisely organized in the radial and tangential planes. In the 
radial dimension the human neocortex is organized into six cytoarchitectonically distinct 
horizontal laminae, also known as cortical layers [18-23]. Originally seen in unstained 
sections of brain tissue by Gennari and Baillarger, the layers have since been 
distinguished on the basis of cell and fiber stainings. These six histologically different 
laminae are numbered in increasing order from superficial to deep with layer I 
constituting the surface of the cerebral hemispheres facing the pia mater and layer VI 
being located more ventrally in contact with the white matter. Along the tangential axis 
the neocortex displays a columnar organization with all the major subtypes of neocortical 
neurons located in layers II to VI establishing stereotypical connections in the vertical 
dimension as visualized in Golgi impregnated and Nissl-stained sections [24-26] and 
assessed through electrophysiological recordings [27]. A cortical minicolumn is the 
smallest level of vertical organization in the neocortex consisting of approximately 80-
100 neurons [24] and it operates as a modular functional processing microcircuit. 
Several synaptically connected minicolumns form larger processing and functional units 
known as macrocolumns. Both minicolumns and macrocolumns display considerable 
heterogeneity between different cortical areas and even within a given macrocolumn, as 
they vary in size, cell composition, internal connectivity, synaptic organization [28] and 
perform different  functions [24, 25]. At a broader level, always along the tangential axis, 
different cortical areas can be distinguished based on their histological structure as 
originally identified and classified through Nissel-staining by Broadmann. Many of the 
Brodmann areas originally identified on the basis of their cytoarchitecture have later 
been correlated to the performance of diverse cortical functions, including sensory areas 
that are the target of subcortical structures and are designated to process sensory 
information, motor areas that coordinate voluntary movements and association areas 
that integrate sensory information to produce more complex cognitive functions. The 
performance of these functions relies on specific connectivity patterns between distinct 
areas. Briefly, primary sensory areas send projections to a set of higher-order unimodal 
secondary and tertiary areas in parallel and following a hierarchical organization. In turn 
higher-order unimodal areas project to multimodal association areas where different 
sensory information are integrated. Subsequently, the axons of the cortical neurons 
located in the multimodal association areas project to other multimodal areas and both 
primary and non-primary motor areas, enabling the direction and coordination of 
movements and behavior.   
1.2 Neurons of the cerebral cortex 
 
The cerebral cortex is the biological substrate that enables humans to perform high 
cognitive functions including reasoning, perception, attention, consciousness, memory, 
language and refined social and emotional skills. To perform these advanced cognitive 
functions, the cerebral cortex is organized into a complex circuitry consisting of a myriad 
of diverse neurons characterized by specific transcriptional identities  and epigenetic 
profiles, distinctive molecular and neurochemical signatures, peculiar 
electrophysiological properties, unique dendritic morphologies and precise axonal 
projections patterns [29, 30] that serve different functions. Broadly, neocortical neurons 
can be distinguished into two major classes according to their connectivity patterns and 
function: excitatory projection neurons and inhibitory interneurons [14, 31]. Excitatory 
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projection neurons constitute approximately 70-80% of all cortical neurons while the 
remaining 20-30% cortical neurons are inhibitory interneurons [32]. Inhibitory 
interneurons are an heterogeneous population of neurons including multiple phenotypes 
that share some common features while being distinctively characterized by unique 
morphological, physiological and neurochemical profiles [33-35]. They are generally 
identified by a cell soma that is smaller than most cortical pyramidal neurons, sparsely 
spiny or aspiny dendrites and a short axon forming local connections as their name 
suggests [36]. They receive both excitatory and inhibitory synapses on their soma, 
dendrites and axon. Through the secretion of the neurotransmitter γ-aminobutyric acid 
(GABA), they exert an inhibitory action on their target neurons that is crucial for the 
modulation of cortical output and plasticity [37, 38]. Differently from excitatory projection 
neurons, inhibitory interneurons are generated from neural progenitors located in the 
lateral, medial and caudal ganglionic eminences of the ventral telencephalon, also 
known as subpallium [36, 39-44]. To reach their final laminar position in the neocortex, 
they first migrate tangentially guided by membrane-bound and secreted factors and 
subsequently, once arrived in the cortical plate, they migrate radially to their final 
destination along with excitatory projection neurons [36, 41, 45]. On the other hand, 
excitatory projection neurons are generated from neocortical progenitors residing in the 
ventricular and subventricular zone of the dorsolateral telencephalon [30, 46, 47] and 
they migrate only radially along the basal process of apical radial glia to reach their 
laminar position following an inside-out gradient [15, 48-50]. Extending long axonal 
projections to other cortical areas and subcortical structures, excitatory projection neuron 
represent the only output system of the cerebral cortex and they constitute also its 
primary input system, being the major target of afferents from subcortical structures. The 
great majority of projection neurons are characterized by the distinctive pyramidal shape 
of their cell bodies from which they are named pyramidal neurons. First discovered and 
characterized by Ramon y Cajal at the end 19th century, pyramidal neurons have been 
investigated in great detail since then [51]. In the human cerebral cortex they are present 
in the neocortical laminae II-VI, with the exception of layer I. Pyramidal neurons display 
considerable variability between different cortical regions and layers [51, 52] but they 
share some common distinctive morphological traits and functional principles [53]. In 
addition to the peculiar triangular shape of their cell body, they are characterized by a 
single axon that extends from the base of the soma towards the white matter branching 
several times to reach multiple targets and by a dendritic tree that exhibits two distinct 
domains, the apical domain and the basal domain. The apical domain originates from 
the apex of the soma and the basal domain consists of multiple dendrites arising from 
the base of the cell body. The basal dendrites are relatively short and extend laterally 
from the cell soma. Instead, the apical domain is generally structured as one large apical 
dendrite stemming from the soma and directed toward the pia mater that bifurcates one 
or more times and gives rise to smaller oblique dendrites with different angular 
orientations before branching in a tuft of dendrites [54]. Pyramidal neurons receive 
different synaptic inputs at distinct cellular domains. Their soma and axon are the targets 
of inhibitory synapses while the dendrites receive both inhibitory inputs from local 
interneurons and excitatory inputs from various cortical and subcortical structures. 
Generally, proximal dendrites receive excitatory inputs from pyramidal neurons located 
in the same or adjacent areas, whereas the distal apical tuft is the target of more distant 
cortical areas and subcortical structures. The distinct morphologies of the dendritic tree 
in different locations suggests that inputs to these domains might be integrated 
differently [53]. Another characteristic feature shared by all pyramidal neurons is that 
their dendrites are covered with thousands of dendritic spines that constitute the 
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postsynaptic terminals of most excitatory glutamatergic synapses. Dendritic spines 
display a great variability in their size and shape [55] and are highly plastic [56] thus 
providing an anatomical substrate for memory storage and synaptic transmission [57-
59].  In addition to pyramidal neurons, the neocortex comprises also a small proportion 
of non-pyramidal excitatory neurons that include the developmentally transient excitatory 
neurons of the subplate and the spiny stellate neurons of layer IV [53, 60]. 
 
 
 
 
 
Figure 2: Schematic representation of the major types of excitatory and inhibitory 
human neocortical neurons. On the left, there are pictured different subclasses of 
spiny neurons that secrete the neurotransmitter glutamate to mediate their excitatory 
action and are characterized by the presence of synaptic spines on their dendrites. A 
first distinction among excitatory neurons is between pyramidal projections neurons 
residing in cortical layers II to VI and stellate neurons mainly located in layer IV of the 
primary sensory areas that are endowed with short axons projecting locally. Each type of 
pyramidal neuron has basal and apical dendrites and an apical tuft but there are 
considerable differences in the morphology and connectivity patterns of pyramidal 
neurons belonging to different cortical layers as can be seen. On the right, it is given a 
panoramic of the different subtypes of aspiny inhibitory interneurons that project locally, 
as their name suggests, and populate selectively different laminae. Adapted from Kwan 
K.Y. et al. [50]. 
 
In the cerebral cortex the transcriptional profiles and hodological properties of pyramidal 
neurons are strictly correlated with their laminar position as neurons belonging to a 
specific cortical layer share similar gene-expression and connectivity patterns. Deep 
layer neurons mainly project to subcortical regions forming corticofugal projections, with 
layer VI neurons sending their axons principally to the thalamus and layer V neurons 
targeting several subcortical structures, including the thalamus, striatum, spinal cord and 
brainstem. A minor subpopulation of deep layer neurons establishes also ipsilateral and 
contralateral connections with other neocortical areas [60]. Layer IV accommodates both 
pyramidal projection neurons and spiny stellate neurons. Neurons located in this layer 
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mainly receive input afferents from both inter-hemispheric cortical areas and subcortical 
regions, especially the thalamus, and they transmit signals to the rest of the column. On 
the other hand, upper layer neurons principally form corticocortical-projections that 
connect one region of the neocortex to another. Corticocortical-projection neurons can 
establish ipsilateral connections between different cortical areas of the same hemisphere 
or they can form commissural connections between the two opposite cerebral 
hemispheres by sending their axons through the corpus callosum. Generally, layer III 
neurons project to adjacent columns while neurons belonging to layer II target more 
distant cortical regions and tend to establish inter-hemispheric connections. 
1.3 Neocortical neurogenesis 
 
Neurogenesis of the human central nervous system (CNS) begins after the fusion of the 
neural folds leading to the formation of the neural tube and proceeds at different rates 
following specific temporal and spatial patterns along the rosto-caudal, dorso-ventral and 
medio-lateral body axes (Mora-Bermu ́dez et al. 2013). The dorsolateral telencephalon 
that will later generate the neocortex derives from the most anterior region of the neural 
tube. The rostral wall of the neural tube that contours the central cavity is initially 
composed of a pseudostratified layer of undifferentiated neuroepithelial cells polarized 
along their apical-basal axis and spanning the entire width of the neuroepithelium. 
Neuroepithelial cells serve as stem and progenitor cells for all the neural lineage 
derivatives, including neurons, astrocytes and oligodendorcytes. They display typical 
epithelial features and are highly polarized along their apical–basal axis [61, 62] as 
reflected by the presence of apical-specific [63, 64] and basolateral-specific [65, 66] 
transmembrane proteins. At the most apical end of the lateral plasma membrane, 
neuroepithelial cells are interconnected by tight junctions and adherens junctions [67-
70]. Their nucleus periodically moves along the apical-basal axis in phase with the cell-
cycle progression, a process known as interkinetic nuclear migration (INM) and mitosis 
occurs near the apical plasma membrane lining the ventricular surface [71-73]. Initially, 
neuroepithelial cells undergo symmetrical proliferative divisions that give rise to two 
daughter cells identical to the mother cell with the effect of increasing the size of the 
progenitor pool and expanding the neuroepithelium in the lateral dimension [74].  
 
Meanwhile, a diversified population of neurons, also known as “pioneer neurons”, 
positions itself between the ventricular zone (VZ) and the pial surface either migrating 
tangentially from the subpallium or through radial migration from the underlying 
ventricular zone, giving rise to a dynamic, evolving, transient developmental structure 
known as preplate (PP) or primordial plexiform layer [75-80]. The diverse population of 
cells constituting the human preplate comprise several types of reelin-expressing cells 
[80-83] including Cajal-Retzius cells [83, 84], predecessor cells [75, 80], different cells 
expressing interneuron markers [81, 82] and other neuronal subtypes [82, 85]. Among 
the cells expressing reelin, Cajal-Retzius cells have particular relevance as they are 
essential for the proper laminar positioning of the developing neocortical neurons and for 
the formation of early synaptic contacts [78, 82, 85]. On the other hand, predecessor 
cells are characterized by long horizontal processes forming an intricate network thought 
to serve as a scaffold for successive cell migration and axon guidance [75, 80].  
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As neuroepithelial progenitors proliferate and expand in number, they progressively 
transform into apical radial glia and change their cell division mode from symmetric 
proliferative to asymmetric differentiative cell division that enable to preserve self-
renewal while generating more lineage-committed neural progenitors [65, 74, 86-88]. 
This transition marks the onset of neurogenesis and it occurs around embryonic day 33 
in the lateral part of the cortical wall in humans [80, 89]. Apical radial glia are neural stem 
cells characterized by residual neuroepithelial features combined with newly acquired 
astroglial properties [61, 65, 88, 90]. As neuroepithelial progenitors, apical radial glia are 
highly polarized cells [63, 91] connected by adherens junctions and their cell body 
continues to reside in the ventricular zone (VZ). They also maintain the expression of 
neuroepithelial markers [87] and their nuclei undergo interkinetic nuclear movements 
(INM) restricted to the cell body with mitosis occuring at the apical ventricular surface 
[65]. In addition to these distinctive neuroepithelial features, apical radial glia express 
also several astroglial markers [88, 92, 93]. They are characterized by a distinctive 
bipolar morphology identified by an ovoid cell body in direct contact with the ventricular 
surface and a long thin radial process, the basal process, that spans the developing and 
thickening cortical wall remaining attached to the basal lamina and that will enable 
neuronal radial migration serving as a scaffold fiber [94, 95]. Concerning their 
proliferative capacity, apical radial glia are neural stem cells able to undergo multiple 
rounds of symmetric proliferative and asymmetric differentiative cell divisions with a 
progressive shift toward asymmetric differentiative cell divisions as neurogenesis 
progress [93, 96-98].  
 
The products of apical radial glia asymmetric differentiative divisions range from neurons 
to other neural progenitors, including apical intermediate progenitors and basal 
progenitors, also known as intermediate progenitors [46, 87, 96-106]. As a consequence 
of the incessant proliferation and generation of this diverse population of neocortical 
progenitors and neurons, the neuroepithelium continues to enlarge both in the lateral 
and radial dimensions becoming a stratified tissue consisting of different cell types that 
are spatially segregated. The cell bodies of apical intermediate progenitors still reside in 
the ventricular zone maintaining direct contact with the ventricular surface and these 
progenitors share with apical radial glia several other features, including the expression 
of characteristic transcription factors like Pax6, interkinetic nuclear migration (INM) and 
the formation of adherens junctions. Distinctively, they downregulate radial glial genes 
and they undergo just one symmetric self-consuming neurogenic division [46, 99, 107]. 
Also their morphology differs from apical radial glia as their basal process is of variable 
length having lost contact with the basal lamina and it is retracted during mitotic divisions 
[46, 75]. While the cell bodies of neuroepithelial cells, apical radial glia and apical 
intermediate progenitors continue to reside in the ventricular zone (VZ), the cell bodies 
of the more fate-committed basal progenitors generated later during corticogenesis form 
a second germinal zone located directly above the ventricular zone named 
subventricular zone (SVZ). Interestingly, an additional type of progenitors known as 
subapical progenitors populate both the VZ and the SVZ. Subapical progenitors undergo 
mitosis at an abventricular location and display an apical process [46, 104]. In humans 
the subventricular zone is distinctively expanded compared to other mammals [4, 108] 
and further specialized into two cytoarchitectonically distinct sublayers, a smaller inner 
SVZ (ISVZ) and a larger outer SVZ (OSVZ) [39, 103, 109-111] separated by a band of 
tangentially orientated axonal fibers known as inner fiber layer (IFL) [108, 112]. The 
outer SVZ is further enclosed externally by an outer fiber layer (OFL). The progenitors 
populating the SVZ can be distinguished into three major types, basal intermediate 
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progenitors and basal radial glia that selectively populate the SVZ and subapical 
progenitors. Both types of basal progenitors have lost contact with the ventricular 
surface along with apicobasal polarity, they are not tight by adherent junctions [46, 98, 
107, 113] and they do not undergo proper interkinetic nuclear movements. Other 
common features shared by both types of basal progenitors are their ability to undergo 
both symmetric proliferative and asymmetric differentiative cell divisions [39, 100, 101, 
111, 113-115] and the expression of specific transcriptional profiles marked by the 
upregulation of the key transcription factors, including Pax6 [101, 103]. Distinctively, 
basal intermediate progenitors lack both the apical and basal processes that are 
retracted while they migrate to the SVZ. On the other hand, basal radial glia are a 
diversified group of basal progenitors that may exhibit nuclear movements preceding 
mitosis similar to interkinetic nuclear movements [39, 100] and they may be further 
distinguished into three subtypes according to the morphology of their apical and basal 
processes. Bipolar radial glia are characterized by a basal process attached to the basal 
lamina and an apical process in contact with the ventricle [101, 104], while monopolar 
radial glia are distinguished either by a long apical process reaching the inner SVZ or the 
VZ but detached from the ventricular surface [39, 101, 103, 116] or by an extended 
basal process that may be in contact with the pia mater [101].  
 
Figure 3: Schematic representation of the cell biological features of neocortical 
progenitor cells (NPCs). In the ventricular zone (VZ), colored in pink, reside the cell 
bodies of apical intermediate progenitors (aIP) and apical radial glia (aRG) while the 
subventricular zone (SVZ), colored in brown, is populated by the different types of basal 
radial glia (bRG) and basal intermediate progenitors (bIPs). The intermediate zone (IZ) is 
not represented for clarity while the nascent cortical plate (CP) is marked in green. 
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Reported in the schematic are also distinctive biological features of each neocortical 
progenitor subtype. Adapted from Wilsch-Brauninger M. et al. [47].                                                   
1.4 Neocortical migration 
 
After generation in the germinal zones all neocortical neurons migrate to reach their final 
laminar position in the neocortex [94, 95, 117-119]. Inhibitory interneurons first migrate 
tangentially from the ganglionic eminences of the ventral telencephalon where they are 
born [36, 39-44] to the marginal zone of the dorsolateral telencephalon and 
subsequently undergo radial migration to arrive at their final laminar position in the 
neocortex [36, 41, 45]. On the other hand, excitatory pyramidal projection neurons are 
generated from the asymmetric differentiative cell divisions of neocortical progenitors 
located in the ventricular and subventricular zones of the dorsolateral telencephalon [46, 
87, 96-106]. The first immature neurons are generated from apical radial glia cells 
located in the ventricular zone at 50-51 post-conceptional days, event that marks the 
onset of neurogenesis [15, 120]. Meanwhile, the subventricular zone (SVZ) starts to 
become populated with basal neocortical progenitors and it continues its expansion 
during early and mid-fetal development progressively becoming organized into two 
cytoarchitectonically distinct areas, the inner SVZ (ISVZ) and the outer SVZ (OSVZ) [4, 
39, 103, 108-111, 121]. The inner subventricular zone (ISVZ) is the first subventricular 
zone compartment to develop followed by the enlargement of the outer SVZ (OSVZ) that 
becomes the major and most expanded proliferative zone with the progression of 
neurogenesis [39, 110, 111]. Immature excitatory neurons generated from the 
neocortical progenitors residing in the germinal zones migrate radially through the 
preplate (PP) using the thin basal process of apical radial glia cells as a scaffold fiber 
[94, 95] and form the nascent cortical plate (CP), a transient developmental structure 
that accomodates the post-migratory pyramidal neurons [50, 122, 123].  
 
The emergence and enlargement of the cortical plate (CP) has the effect of splitting the 
preplate (PP) into two compartments, the marginal zone (MZ) and the subplate (SP), 
located respectively above and below the nascent cortical plate [15, 122, 123]. The 
marginal zone (MZ), that will become cortical layer 1 in the postnatal neocortex, is a 
transient developmental structure positioned directly below the pia mater that serves as 
a corridor for the tangentially migrating interneurons and is important for the proper 
regulation of cortical lamination as it accommodates “pioneer neurons” [75, 80], in 
particular reeling-expressing Cajal-Retzius cells [83, 84, 124]. As shown in studies of the 
mutant mouse reeler, the extracellular matrix protein reelin is essential for the proper 
regulation of radial neuronal migration and its absence cause an inversion of the 
characteristic “inside-out” migration gradient resulting in an inverted positioning of the 
neocortical layers [115, 125]. Also the subplate (SP) is a transient developmental 
structure located right below the cortical plate (CP) and in humans it becomes the most 
prominent embryonic zone of the telencephalon between 15–35 postconceptional weeks 
(pcw), a period known as “subplate stage” [126]. The human subplate is enriched in 
extracellular matrix and consist of some of the earliest born and first mature neurons of 
the cerebral cortex [60, 121, 126-131] along with neurons that are migrating in the radial 
and tangential direction to reach their final neocortical laminar position [128, 132-134] 
and early developing astrocytes, microglia and oligodendrocyte precursors [126]. The 
human subplate is also a dynamic compartment accommodating input fibers from 
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subcortical structures and other developing cortical areas [128-130, 135], including 
ipsilateral and callosal corticocortical afferents [19, 135-137], thalamocortical afferent 
axons [138-140] and basal forebrain cholinergic projections [141], therefore being an 
important station for promoting synaptogenesis [15, 128, 142], the maturation of 
neocortical circuits [131] and for establishing the formation of proper neocortical afferent 
and efferent projections [128-130, 135, 140]. As afferent and efferent projections from 
subcortical structures and other neocortical areas progressively develop, another 
transient structure arise below the subplate (SP), known as intermediate zone (IZ). The 
intermediate zone (IZ) contains tangentially migrating inhibitory interneurons and some 
sparse neurons and consists mainly of afferent and efferent axonal projections that will 
form the white matter of the postnatal neocortex, while neurons found in the white matter 
are supposed to originate from subplate neurons (SP) [60, 126]. 
 
As neurogenesis progress, different types of excitatory projection neurons are generated 
sequentially. Progressively, they migrate in the radial dimension from the germinal zone 
of origin through the intermediate zone (IZ) and the subplate zone (SP) and populate the 
cortical plate (CP) following a precise inside-first outside-last gradient according to which 
the earliest generated neurons will become the future layer 6 and the last-born neurons 
will constitute layer 2 [15, 29, 48-50, 77, 143, 144]. At each wave of neuronal migration, 
newly born neurons pass through the earlier generated deep layers before positioning at 
the interface between the cortical plate (CP) and the marginal zone (MZ) where they 
form a band in the uppermost part of the cortical plate named the dense cortical plate 
[15, 50].  
 
 
Figure 4: Schematic representation of the generation and subsequent migration of 
neocortical excitatory pyramidal neurons. Neuroepithelial cells (NECs), constituting 
the pseudostratified neuroepithelium of the dorsolateral telencephalon, undergo 
interkinetic nuclear migration (INM) and divide symmetrically at the ventricular surface to 
increase the number of neocortical progenitors before transforming into apical radial glia 
cells (aRGCs), event that marks the onset of neurogenesis. Also apical radial glia cells 
Part I: Introduction 
 12 
(aRGCs) divide at the ventricular surface maintaining contact with the basal lamina. As 
neurogenesis progress and the neuroepithelium thickens, the basal plasma membrane 
of apical radial glia cells stretches and becomes a thin radial process, known as basal 
process.  Apical radial glia cells undergo both symmetric and asymmetric cell divisions 
progressively shifting toward asymmetric differentiative cell divisions. The asymmetric 
differentiative cell divisions of apical radial glia cells have the combined effect of 
increasing their number and generating both neurons and other neocortical progenitors, 
including intermediate basal progenitor cells (ICP) and all the different types of basal 
radial glia cells (bRGC) that populate the subventricular zone (SVZ). Neurons migrate 
radially into the cortical plate (CP) using the apical radial glia process as a scaffold fiber 
and split the preplate into the marginal zone (MZ) and subplate (SP). Excitatory 
pyramidal neurons radial migration follows a characteristic “inside-out” gradient, with 
early born neurons occupying the deepest layer 6 and subsequently generated neurons 
giving rise to more superficial layers up to layer 2. Around the 27th postconceptional 
week when neurogenesis is completed, gliogenesis begins with apical radial glia cells 
transforming into astrocytes, oligodendrocites precursors or ependymal cells. Reported 
in the schematic are also the subcortical and intracortical projections characteristic of 
each neocortical layer. Adapted from Shibata et al. [145] and Kwan et al. [50]. 
 
Radially migrating neurons display a stereotypical bipolar morphology characterized by a 
leading process directed basally toward the pia mater and a lagging process pointing 
toward the ventricle [95, 107] and they can migrate either through somal translocation or 
by locomotion [97, 119, 123]. Neurons migrating by somal translocation are bipolar and 
to migrate they first extend and fix to the pia mater or to the marginal zone the long 
basally directed leading process. Subsequently, the nucleus is transported to its final 
laminar destination thanks to the elongations and contractions of the microtubules of the 
basal process, a mechanism also known as nucleokinesis [107, 123, 146, 147]. On the 
other hand, migration through locomotion involves the free movement of the immature 
neuron that climbs with its relatively short leading and trailing processes toward the 
cortical plate along the basal process of apical radial glia that serves as a scaffold fiber 
[107, 118, 119, 147]. 
 
Furthermore, radial migration of newly generated excitatory pyramidal neurons does not 
generally proceeds as a direct movement from the ventricle to the cortical plate but is 
rather a more structured process articulated into four phases [107].  
Figure 5: Schematic representation of the four migration phases undergone by 
newly born neocortical pyramidal neurons. The migration of newly born pyramidal 
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neurons to their final laminar destination can be divided into four phases: 1) initial radial 
migration, 2) arrest in the subventricular zone (SVZ), 3) retrograde migration toward the 
ventricle, 4) secondary radial migration. Adapted from Noctor et al. [107]. 
 
The first phase is characterized by the rapid movement of the new born neuron from the 
ventricular surface to the subventricular zone. Then, it temporary arrests its migration 
before moving backwards toward the ventricule and finally migrating to the cortical plate 
(Figure 4).  Upon reaching their laminar position, neurons stop migrating and detach 
from the basal process of apical radial glia cells. 
 
The processes of radial migration, neural fate determination and neural differentiation 
are finely regulated by specific gene expression patterns [60, 143, 144, 147-151] and 
signaling pathways [152] that mediate a broad range of cellular functions including 
chemoattraction and repulsion, cell adhesion, cell motility, cytoskeletal dynamics and 
aspects of mitotic activity. Once arrived at their final laminar position, neocortical 
neurons continue to differentiate, start to develop the axon and the dendrites and begin 
to establish synaptic connections [153, 154]. The generation of excitatory pyramidal 
neocortical neurons and the majority of inhibitory interneurons terminates around the 
27th postconceptional week [15, 120, 155, 156] while certain subclasses of neocortical 
interneurons are generated also postnatally [157]. Neocortical neurogenesis is then 
followed by gliogenesis that is the process through which apical radial glia cells 
transform into glial cells [75, 158], comprising astrocytes and oligodendrocyte precursor 
cells. Gliogenesis starts in midgestation [15, 159] and continues postnatally [75, 160, 
161]. Along with gliogenesis, also synaptogenesis, myelination, dendrites outgrowth and 
pruning continue in the postnatal period [15, 153, 162]. 
 
1.5 Signaling pathways regulating neocortical development  
 
Human neocortical development is finely orchestrated by specific cell signaling pathways 
and transcriptional programs that act in a spatial and temporal regulated manner to 
coordinate all the stages of neurogenesis, including the generation of different classes of 
neocortical progenitors (NPCs), the balancing of their proliferation, the specification of 
their laminar identity, their progressive cell-fate restriction and the final differentiation 
toward layer-specific mature neocortical neurons. The generation of different 
telencephalic progenitors is articulated in a first neural induction phase characterized by 
the appearance of neuroepithelial progenitors cells lining the central cavity of the neural 
tube followed by a subsequent patterning phase during which the regional specification 
along both the anteroposterior (AP) and dorsoventral (DV) axes takes place resulting in 
the creation of spatially and molecularly distinct neural progenitor domains [163, 164]. 
Later with the onset of neurogenesis, it starts a protracted period of cell fate 
determination and terminal differentiation during which all the major types of neocortical 
projection neurons are generated and migrate to their final laminar position where they 
become fully mature neurons. During each phase of neurogenesis, many cell signaling 
pathways cross-talk and are integrated to direct the selection of a particular neuronal 
subtype identity and each signaling pathway may exert different effects as 
neurodevelopment progress.  
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Neural induction in human embryos is achieved through the inhibition of the transforming 
growth factor-β (TGF-β) signaling combined with the coordinated action of retinoid, 
fibroblast growth factor (FGF), epidermal growth factor (EGF), Wnt and sonic hedgehog 
(Shh) signaling pathways. According to the “default model” of neural induction, 
ectodermal cells have an autonomous tendency to differentiate into neural tissue and 
they acquire neural identities in the absence of cell-cell interactions and bone 
morphogenetic proteins (BMPs), especially BMP4, as first demonstrated by studies 
performed in animal models such as the frog Xenopus laevis [165-171]. These 
researches enabled to identify several molecules with neural inducing activity secreted 
by the primary organizer, including follistatin [166], chordin [167, 168] and noggin [169, 
170], that compete with bone morphogenetic proteins (BMPs) for the binding to their 
cognate receptors, thus inhibiting the activation of the signaling cascades that induce the 
differentiation toward an epidermal fate [171]. Briefly, the transforming growth factor-β 
(TGF-β) signaling pathway is activated by the binding of a ligand belonging to the TGF-β 
superfamily of growth factors to its corresponding receptor [172, 173].  
 
The TGF-β superfamily of ligands in humans consist of 30 growth factors, including 3 
TGF-β isoforms, 4 activin β-chains, the protein nodal, 10 bone morphogenetic proteins 
(BMPs) and 11 growth and differentiation factors (GDFs) [172]. Their cognate TGF-β 
receptors are dimeric transmembrane serine-threonine kinases proteins that can be 
divided into two distinct functional classes, the type I and type II receptors encoded by 
seven and five genes in the human genome respectively [173]. Upon binding of the 
ligand, one type I and one type II receptor bridge together and form an active 
heteromeric receptor complex [174, 175], where the type II receptor kinase 
phosphorylates the type I receptor that in turn recruits and phosphorylates one of the 
receptor-regulated SMADs (R-SMADs), comprising SMAD1, SMAD2, SMAD3, SMAD5 
and SMAD8. Phosphorylated receptor-regulated SMADs are able to form active 
complexes with the common mediator SMAD4 and homomeric complexes [173]. Active 
SMAD complexes translocate to the nucleus, where they cooperate with other 
transcription factors, histone-modifying enzymes and chromatin-remodelling complexes 
to regulate the transcription of target genes. In vitro studies have confirmed that similar 
mechanisms are also at the basis of human neural induction as it was shown that 
treatment of human pluripotent stem cells (hPSCs) with the recombinant protein noggin 
promotes the acquisition of neural stem cell identities [176-178]. Inhibition of the 
transforming growth factor-β (TGF-b) signaling cascade alone is not sufficient to promote 
neural induction in human embryos and for the adoption of neural fates and the 
subsequent acquisition of specific regional and cellular identities it is also required the 
coordinated activation of multiple other signaling pathways acting through both BMP-
dependent and BMP-independent mechanisms, including retinoid, fibroblast growth 
factor (FGF), epidermal growth factor (EGF), Wnt and sonic hedgehog (Shh) signaling 
pathways. 
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Figure 6: Schematic representation of the TGF-β  signaling pathway. In this 
schematic layout of the TGF-β signaling pathway are represented several human 
dimeric ligands belonging to the TGF-β superfamily of growth factors and their cognate 
type I and type II dimeric transmembrane serine-threonine kinases receptors. Binding of 
a TGF-β ligand to its correspondent type II receptor results in the recruitment of a type I 
receptor and the formation of an heteromeric receptor complex that is followed by 
phosphorylation of the type I receptor. As indicated, type I receptors can be subdivided 
into two subgroups that selectively recruit and phosphorylate different receptor-regulated 
SMAD proteins (R-SMADs). Type I ALK1, ALK2, ALK3 and ALK6 receptors selectively 
phosphorylate SMAD1, SMAD5 and SMAD8 while type I ALK4, ALK5 and ALK7 
receptors specifically phosphorylate SMAD2 and SMAD3. Phosphorylated receptor-
regulated SMADs form active complexes with the common mediator SMAD4. Activated 
SMAD complexes translocate to the nucleus where they directly regulate gene 
transcription. Adapted from Schmierer B. and Hill C.S. [172]. 
 
Fibroblast growth factor (FGF) signaling is critically involved in various phases of 
neurogenesis during which it performs different functions [179-181], including the 
regulation of neural stem cells (NSCs) and neocortical progenitor cells (NPCs) 
proliferation and survival, the patterning and specification of their areal identity and the 
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orchestration of their lineage commitment and differentiation. During neural induction, 
studies conducted in animal models have provided evidences that FGF proteins (FGFs) 
antagonize BMP signaling through the phosphorylation and inhibition of the BMP effector 
protein Smad1 and the direct repression of BMP transcription [182, 183] while 
concomitantly promoting the expression of neural markers acting in combination with 
BMP- and WNT-antagonists [184]. Furthermore, FGF signaling acts also independently 
of BMP and other signaling pathways to induce the expression of neuroepithelial 
markers and transcription factors required for neural fate specification [185]. Before the 
onset of neurogenesis, the basic fibroblast growth factor (bFGF or FGF2) and FGF8 
support the proliferative divisions of neuroepithelial cells [186, 187] and FGF10 
contributes to the initiation of neurogenesis by promoting the maturation of symmetrically 
dividing neuroepithelial cells into asymmetrically dividing radial glia cells [188]. Later in 
neurodevelopment, especially FGF2 acts in concert with other growth factors and 
signaling pathways as a potent mitogenic factor that critically regulates neural stem cells 
(NSCs) and neural progenitor cells (NPCs) proliferation and survival as indicated by 
gain- and loss-of-function studies performed both in vivo and in vitro [187, 189-196] and 
by its high levels of expression in the whole cortical ventricular and subventricular zones 
before and during all the timespan of neurogenesis [187, 197-199]. Later in 
neurodevelopment, FGF signaling is also involved in decreasing the pace of the 
generation of basal progenitors from apical radial glia cells [200]. In addition to its 
fundamental role in the regulation of neocortical progenitors proliferation and cell-cycle 
exit, FGF signaling is also critical for the correct acquisition of neocortical regional and 
cellular identities. The patterning function of FGF signaling starts during gastrulation 
when FGF signaling cooperates with other signaling pathways to determine the specific 
positional identities of neural progenitor cells along the antero-posterior axis. 
Specifically, the FGF pathway together with WNT and retinoic acid (RA) signaling directs 
the induction and patterning of the peripheral nervous system [201, 202] and the 
specification of posterior neural fates as demonstrated by the induced expression of 
different Hox and Cdx genes in chicken and mouse neural plate explants after exposure 
to FGF proteins [203]. After the initial anterior-posterior patterning of the neural plate 
during gastrulation, FGF8 and other FGF proteins initially expressed by the rostral 
signaling center continue to be expressed in the telencephalic primordium during and 
after the formation of neural tube [204]. Especially FGF8 has a crucial role in 
telencephalic development as it confers and maintains the telencephalic character of the 
anterior neural plate by positively and negatively regulating gene expression [205-208], 
by modulating the expression and activity of other signaling molecules including Wnts, 
BMPs, and Shh [186, 209] and by promoting the survival of telencephalic progenitors 
[206, 210, 211]. Once the dorsal and ventral subdivisions of the telencephalic vesicles 
have been established, FGF8 and other FGF proteins continue to play a central role in 
the development of the telencephalic midline [186, 212], in the further growth of the 
telencephalon and in the specification of the subdivision of the dorsal cerebral cortex into 
multiple functional areas by regulating the regional expression of multiple transcription 
factors [207, 213]. Also FGF2 continues to play a critical role in directing neocortical 
progenitors specification that is concentration-dependent, as low concentrations of this 
growth factor do not affect the neuronal commitment of progenitors while the exposure to 
higher concentrations in combination with other extrinsic signals promotes 
oligodendrogliogenesis and astrogliogenesis [191, 214-216]. Later in neurodevelopment 
FGF signaling is also required for neuronal migration with a prominent role exerted by 
FGF18 [217], for the translocation of astroglial cells from the ventricular zone to the 
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surface of the cortex [218] and for the control of axon growth, navigation, branching and 
target recognition with FGF proteins acting as target-derived signals. 
 
As other pathways, also the various intracellular FGF signaling cascades are activated 
by the binding of a member of the secreted fibroblast growth factor (FGF) signaling 
proteins to one of its corresponding FGF tyrosine kinase receptors. The human fibroblast 
growth factor (FGF) family comprises twenty two genes that encode secreted signaling 
proteins (FGFs), eighteen of which activate the signaling cascade by binding to FGF 
tyrosine kinase receptors. The secreted signaling FGF proteins can be classified into 
seven subfamilies based on their biochemical function, sequence similarities and 
evolutionary relationships, including five subfamilies of paracrine FGFs (also known as 
canonical FGFs), one subfamily of endocrine FGFs and one subfamily of intracellular 
FGFs [219, 220]. Canonical secreted FGF proteins are tightly bound to heparin/heparan 
sulfate (HS) proteoglycans (HSPGs) that enable to limit their diffusion through the 
extracellular matrix (ECM), serve as cofactors to regulate the specificity and affinity for 
cell surface signaling tyrosine kinase FGF receptors (FGFRs) and protect FGF proteins 
from degradation [221]. FGF proteins belonging to the paracrine subfamilies bind to one 
of the four cell surface tyrosine kinase FGF receptors (FGFRs) using heparin/HS 
proteoglycans as cofactors and interacting with the chaperone heat shock protein 90 
(HSP90) [222, 223]. Binging of the FGF ligand induce receptor dimerization and trans-
autophosphorylation of the kinase domain [224]. Activated FGF receptors phosphorylate 
distinct adaptor proteins that in turn start one of the four major intracellular FGF signaling 
cascades, comprising PI3K-AKT, RAS-MAPK, PLCγ, and STAT pathways [220, 221, 
224-226]. The regulatory mechanisms of all four FGF molecular signaling cascades are 
based on many molecules that are themselves regulated by FGFs through positive or 
negative feedback loops [180, 220]. Activation of RAS-MAPK and PI3K-AKT pathways is 
initiated by phosphorylation of the adapter protein fibroblast growth factor receptor 
substrate 2a (FRS2a) that is constitutively associated with the juxtamembrane region of 
the FGF receptor. Phosphorylated FRS2α binds the membrane anchored adaptor 
protein growth factor receptor-bound 2 (GRB2) and the tyrosine phosphatase SHP2 
[227, 228]. GRB2 subsequently activates the PI3K-AKT pathway and the RAS-MAPK 
pathway through the recruitment to the signaling complex of the GRB2 associated 
binding protein 1 (GAB1) [229] and the guanine nucleotide exchange factor protein son 
of sevenless (SOS) [227], respectively. The PI3K-AKT pathway has the downstream 
effect of positively and negatively modulating the activity of target molecules that 
regulate gene transcription through their phosphorylation by the serine/threonine-specific 
protein kinase AKT but there is still little evidence for the role of this signaling pathway in 
neural development in vivo downstream of FGF receptors [180]. Most notably ATK 
inhibits the activity of transcription factors as the forkhead box class transcription factor 
FOXO1 and cytosolic proteins as tuberous sclerosis complex 2 (TSC2) that results in the 
activation of other protein complexes as mTOR complex 1 [230]. Also the RAS-MAPK 
pathway positively regulates the expression of several target genes through the 
phosphorylation by the mitogen-activated protein kinase (MAPK) including members of 
the E26 transformation-specific (ETS) family of transcription factors as Etv4 (Pea3) and 
Etv5 (Erm), AP1, GATA proteins, c-myc, and CREB [231, 232] while it also activates 
negative regulators of the FGF signaling pathways such as SHP2, CBL, SPRY, SEF, 
MPK3 and DUSP6 [220, 233]. The MAPK/Erk pathway is particularly important in 
mediating the proliferative activity of neural stem cells (NES) and neocortical progenitors 
(NPCs), in orchestrating the acquisition of specific regional and cellular identities [233] 
and it also involved in regulating neuronal migration and differentiation [180].  
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Figure 7: Schematic representation of the FGF signaling pathway. Illustrated are the 
four intracellular signaling pathways activated by the binding of a canonical secreted 
FGF protein to its corresponding receptor (FGFR), PLCγ pathway, STAT pathway, PI3-
AKT pathway and MAPK pathway. Adapted from Ornitz D.M. and Itoh N. [220]. 
On the other hand, activation of PLCγ and STAT pathways begins with the 
phosphorylation by activated tyrosine kinase FGF receptors of member of the signal 
transducer and activator of transcription (STAT) protein family and membrane-
associated enzyme phospholipase C g (PLCγ), respectively.  
 
Specific tyrosine kinase sites of the FGF receptor phosphorylate selectively STAT1, 3, 
and 5 that translocate via an importin a/b ternary complex to the nucleus [234] where 
they activate gene transcription by binding to a consensus DNA-recognition motif known 
as gamma-activated sites (GAS) found in the promoter region of their target genes [235]. 
Instead, phosphorylation of PLCγ leads to the production of inositol triphosphate (IP3) 
and diacylglycerol (DAG) through the hydrolysis of phosphatidylinositol 4,5-bisphosphate 
[236]. IP3 and DAG have in turn the effects of inducing calcium ion release from 
intracellular stores thus increasing intracellular calcium ion levels and activating 
calcium/calmodulin dependent protein kinase enzymes as protein kinase C (PKC), 
respectively [236, 237], that have the downstream effect of stimulating neurite outgrowth 
[238]. The activation of PLCγ pathway is further modulated by the adaptor protein 
GRB14 that inhibits tyrosine phosphorylation of FGF receptors at multiple sites thus 
preventing PLCγ phosphorylation [239].  
 
The epidermal growth factor (EGF) signaling is implicated in the self-renewal of 
neural stem cells (NSCs) and in the proliferation of neocortical progenitors as 
demonstrated by the elevated concentration of EGF ligands in the embryonic neocortex 
[240] accompanied by high levels of expression of EGF receptors in these cell types 
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[241, 242].  
Figure 8: Schematic representation of the EGF signaling pathway. Activation of an 
Erb tyrosine kinase receptor after ligand binding results in the formation of homodimeric 
or heterodimeric receptor complexes and the consequent phosphorylation of specific 
tyrosine residues located on their intracellular domains. Phosphorylation of EGF 
receptors may start the same four intracellular signaling cascades activated in the FGF 
signaling, i.e. the PLCγ, STAT, PI3K-AKT and RAS-MAPK pathway, resulting in the 
regulation of gene transcription. Adapted from Scaltriti M. and Baselga J. [243]. 
 
To promote the proliferation and survival of neural stem cells (NSCs) and neocortical 
progenitors, EGF signaling acts in combination with FGF2 as indicated by several in vitro 
studies [187, 244-249] with FGF2 enhancing the responsiveness of neural progenitors to 
EGF, a mechanisms that might account for the synergistic activities of these two factors 
[250, 251]. As FGF2, also EGF influences neocortical progenitors fate decisions by 
supporting the maintenance of a multipotent state while concomitantly blocking neuronal 
and oligodendroglial differentiation [252, 253]. At later stages of neurogenesis, EGF 
signaling also contributes to the orchestration of neuronal migration [254] and to the 
determination of  neocortical progenitors lineage choice and cellular identity [252, 255].  
The signaling cascades triggered by the activation of the epidermal growth factor 
receptor (EGFR) or another of the three members belonging to the Erb family of receptor 
tyrosine kinases (erbB2/HER-2, erbB3/HER-3, and erbB4/HER-4) after binding of EGF, 
comprise the PI3K-AKT, RAS-MAPK, PLCγ, and STAT pathways [243, 256, 257], that 
are the same signaling cascades of the FGF signaling pathway [220, 221, 224-226]. As 
in the case of FGF signaling, all these four pathways have the downstream effect of 
regulating gene transcription through different molecular mechanisms. 
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Retinoic acid (RA) is mainly involved in patterning and neuronal differentiation 
during central nervous system development. As a patterning factor, it contributes to the 
regionalization along both the anteroposterior (AP) and dorsoventral axes (DV) of the 
neural plate and neural tube. Concerning the formation of the anteroposterior axis of the 
neural plate, retionic acid (RA) in combination with WNT and fibroblast growth factor 
(FGF) signaling pathways, is specifically responsible for the organization of the posterior 
regions, comprising the hindbrain and the anterior spinal cord [203, 258-261], as first 
indicated by studies performed in a quail model that provided evidences of absence of 
the posterior hindbrain and abnormalities in the anterior spinal cord in the absence of 
retinoic acid signaling [261-263]. These evidences were further confirmed by the 
discovery that retinoic acid is synthesized in the posterior mesoderm and that the 
retinoic acid catabolizing enzyme CYP26C1 is highly expressed in the anterior 
mesoderm [264]. Regarding its role in the dorsoventral patterning of the developing 
neural tube, retinoic acid is generated by the newly formed somites and it acts mainly in 
the specification the dorsoventral axis of the spinal cord regulating the acquisition of 
interneuron, sensory neurons and motor neuron identities and their development [265-
267]. In addition to its patterning function, retinoid signaling plays also a role in the 
maintenance of neural stem cells and neural progenitors proliferation [268-270]. 
Additional researches conducted in murine and human in vitro models demonstrated that 
retinoic acid is involved the differentiation of several types of neurons and glia [271, 
272]. From studies conducted in animal models it is also known that retinoid signaling is 
critically involved in vivo in the regulation of motor neurons differentiation [258, 259, 
273], in the specification of motor neurons subtypes [274-276] and in their axon and 
neurite outgrowth [261, 277] by regulating the expression of hundreds of genes 
comprising transcription factors, enzymes, extracellular and structural proteins, cell-
surface glycoproteins and receptors, growth factors, neurotransmitters and neuropeptide 
hormones [278]. Also in the adult, retinoid signaling has a role in the maintenance of 
motor neurons differentiated state, nerve regeneration and it is involved in neural 
plasticity [258, 259].  
 
The molecular mechanisms regulating the synthesis of retinoic acid (RA) and retinoid 
signaling cascade are based on retinol, also known as vitamin A, that functions as both a 
transport form and a precursor form of retinoids [258, 279]. Retinol can not be 
synthesized endogenously in animals and it should be derived from the diet in the form 
of carotenoids and retinyl esters [258, 279]. These dietary components are stored as 
retinyl esters through modifications to the terminal polar end group of the molecule and 
serve as retinol storage supplies. Esterification of the long-chain acyl groups of retinyl 
esters converts them to retinol [258, 279]. To exert its transport function from the storage 
sites to the cells that require retinoids, retinol is released into the bloodstream and 
circulates bound to retinol-binding protein 4 (RBP4). The retinol-RBP4 complex is 
internalized into the target cells through the interaction of RBP4 with the polyprotic 
transmembrane receptor “stimulated by retinoic acid 6” (STRA6) [280].  
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Figure 9: Schematic representation of the molecular pathways involved in the 
generation, catabolism and signal transduction of retinoic acid (RA). Extracellular 
retinol binds to the retinol-binding protein 4 (RBP4) and the complex is internalized into 
the cells through the interaction of RBP4 with the polyprotic transmembrane receptor 
“stimulated by retinoic acid 6” (STRA6). Cytoplasmic retinol forms a complex with retinol-
binding protein 1 (RBP1) and is metabolized in a two step process. First dehydrogenase 
10 (RDH10) metabolizes retinol to retinaldehyde (Ral) and subsequently retinaldehyde 
(Ral) is metabolized to retinoic acid (RA) by retinaldehyde dehydrogenases (RALDHs). 
The newly synthesized retinoic acid (RA) can be released from the cytoplasm and serve 
as stimulus for other cells (paracrine signalling) or can directly translocate to the nucleus 
of the same cell where it has been produced (autocrine signaling) by forming a complex 
with the cellular retinoic-acid-binding protein 1 or 2 (CRABP1 or CRABP2). In the 
nucleus, retinoic acid (RA) binds to a transcription complex which comprise a pair of 
ligand-activated nuclear transcription factors belonging to two distinct classes, retinoic 
acid receptors (RARs) and retinoid X receptors (RXRs). The transcriptionally active 
complex regulates gene expression through the recognition of consensus sequences 
known as RA-response elements (RAREs) present in the control elements of RA-
responsive genes or through other mechanisms still not fully understood. Retinoic acid 
(RA) catabolism is mediated by different members of the cytochrome P450 family 26 
(CYP26) class of enzymes. Adapted from Maden M. (2007) [258]. 
 
In the cytoplasm, retinol binds to the retinol-binding protein 1 (RBP1) and is metabolized 
to retinoic acid (RA) in a two-step process. First, dehydrogenase 10 (RDH10) converts 
retinol to retinaldehyde (Ral) and subsequently retinaldehyde (Ral) is metabolized to 
retinoic acid (RA) by retinaldehyde dehydrogenases (RALDHs) [281]. Once retinoic acid 
(RA) has been synthesized, it enters the nucleus assisted by the cellular retinoic-acid-
binding protein 1 or 2 (CRABP1 or CRABP2) [282] and influences the transcription of 
target genes by binding to a heterodimeric transcription complex comprising a pair of two 
different ligand-activated nuclear transcription factors, the RA receptors (RARs) and the 
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retinoid X receptors (RXRs) [258, 259]. In humans there are three RA receptors (RARα, 
RARβ and RARγ) and three retinoid X receptors (RXRα, RXRβ and RXRγ), all 
presenting several isoforms. In addition to ligand binding, phosphorylation of these 
receptors and recruitment of a wide variety of co-activators or co-repressors is required 
for the induction or repression of gene transcription [283]. Activated heterodimeric RAR-
RXR complexes regulate gene transcription through the recognition of consensus 
sequences known as RA-response elements (RAREs) present in the control elements of 
RA-responsive genes and through other mechanisms still unidentified [283, 284]. 
 
Early in development the canonical Wnt signaling controls the anterior-posterior 
axis formation of the neural tube through a concentration gradient characterized by 
higher concentrations in the posterior areas and lower concentrations in the anterior 
regions [285-287]. Therefore, inhibition of the canonical Wnt signaling is required for the 
induction of the forebrain as demonstrated in studies conducted in animal models [288-
290] and human in vitro neural differentiation protocols [287]. Later, during the first 
stages of cortical development, canonical Wnt signaling supports neocortical progenitors 
(NPCs) proliferation, as demonstrated by gain-of-function and loss-of-function 
experiments in which the over-expression of a stabilized form of β-catenin resulted in the 
over-proliferation of neocortical progenitors [291, 292] while the conditional deletion of β-
catenin leaded to the depletion of progenitor cells [292, 293]. Additional studies 
performed in mouse mutants have confirmed that specific Wnt genes are involved in the 
expansion of specific subtypes of telencephalic progenitors [294]. Concomitant to its 
action of stimulating the mitogenic activity of neural progenitors, Wnt signaling is also 
critically involved in the dorsoventral patterning of the neural tube as it contributes to cell 
fate specification by exerting the combined actions of promoting a dorsal telencephalic 
(i.e. cortical) identity while suppressing ventral telencephalic (i.e. subcortical) fates [293, 
295].  
Wnt signals are pleiotropic and exert multiple functions during neural induction and 
patterning of the forbrain. From a molecular perspective, the Wnt signaling network is 
extremely complex and three main signal transduction cascades can be broadly 
distinguished, the β-catenin dependent canonical Wnt pathway and two noncanonical β-
catenin independent pathways, including the noncanonical planar cell polarity (PCP) 
pathway (PCP) and the noncanonical Wnt/calcium pathway.  The three main Wnt 
signaling pathways differ with respect to the molecular cascades activated upon binding 
of the ligand to its corresponding receptor and for the biological function they exert.  
Concerning their biological function, the canonical Wnt signaling pathway mainly 
regulates stem cell proliferation and self-renewal, neural cell fate specification and body 
axis formation by modulating gene transcription [296-298] and it is the Wnt singaling 
cascade primarily activated during induction and patterning of the forbrain. On the other 
hand, the noncanonical Wnt planar cell polarity (PCP) pathway is primarily involved in 
controlling remodeling of the cytoscheleton, coordinated cell migration, tissue polarity 
and axon guidance [296, 299, 300]. Finally, the noncanonical Wnt/calcium pathway 
regulates intracellular calcium levels and contributes to the regulation of cell migration 
and axon guidance while also acting in combination with the noncanonical Wnt planar 
cell polarity (PCP) pathway in instructing tissue polarity [296, 299, 301]. All the three Wnt 
signaling pathways are activated by the binding of a Wnt protein to one of its 
corresponding receptors. Wnt ligands (Wnts) are cysteine-rich secreted glycoproteins 
encoded in humans by 19 genes [302] and their corresponding human Wnt receptors 
and co-receptors belong to a diversified population comprising more than 15 different 
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members, including Frizzled G protein-coupled receptors [303], low-density lipoprotein 
receptor-related protein 6 (LRP6) [304] and the closely related LRP5 [304], receptor Tyr 
kinase-like orphan receptor (ROR) [305], protein Tyr kinase 7 (PTK7) [306], receptor Tyr 
kinase (RYK) [306], muscle skeletal receptor Tyr kinase (MUSK) [306] and members of 
the proteoglycan families [302]. On the basis of which receptor and signaling cascade is 
activated within the canonical and non-canonical Wnt signaling pathways in different 
cellular contexts, they can be further dissected into various distinct sub-branches [299, 
302, 307, 308]. In the canonical Wnt signaling pathway, the signaling cascade is 
activated by the concomitant binding of a Wnt glycoprotein to two cell surface proteins, a 
member of the Frizzled (FZD) family of serpentine G protein-coupled receptors and the 
low-density-lipoprotein receptor related protein 6 (LRP6) or the closely related LRP5 that 
act as co-receptors, resulting in the formation of the Wnt-FZD-LRP6/5 trimeric complex. 
The activated Frizzled receptor recruits to the plasma membrane the cytoplasmic 
phosphoprotein Dishevelled (Dvl) [309] which in turn recruits Axin [310-312], a key 
component of the multi-protein β-catenin destruction complex, including also the 
adenomatous polyposis coli gene product (APC), casein kinase Ia (CK Ia) and glycogen 
synthase kinase 3 (GSK3) that are two kinases with a prominent role in the 
phosphorylation of LRP6 or LRP5 [312-314]. Engagement of the multi-protein β-catenin 
destruction complex to the plasma membrane prevents cytosolic β-catenin 
phosphorylation by the sequential action of casein kinase 1 (CK1) and glycogen 
synthase kinase 3 (GSK3) and the consequent targeting of β-catenin for degradation in 
proteosomes via ubiquitination after having been recognized by the E3 ubiquitin ligase 
subunit β-Trcp [310, 315, 316]. Unphosphorylated β-catenin is then able to translocate to 
the nucleus where it forms a transcriptional active complex with members of the T cell 
factor/lymphoid enhancer factor (TCF/LEF) family of transcription factors and regulates 
the transcription of its target genes [310]. Also in the planar cell polarity (PCP) signaling 
pathway, the binding of a Wnt protein to its cognate Frizzled receptor and co-receptor 
results in the recruitment to the plasma membrane of the cytoplasmic phosphoprotein 
Dishevelled (Dvl) through the activated Frizzled receptor. Dishevelled (Dvl) in turn 
activates both the small GTPases Ras-related C3 botulinum toxin substrate 1 (RAC1) 
and Ras homolog gene family member A (RHOA) which in turn activate RHO kinase 
(ROCK) and JUN-N-terminal kinase (JNK), respectively. Activated RHO kinase (ROCK) 
leads to the actin polymerization and microtubule stabilization while activated JNK 
translocates to the nucleus to regulate gene transcription. Instead in the WNT/calcium 
pathway, WNT proteins trigger the Frizzled-mediated activation of heterotrimeric G 
proteins resulting in the activation of phospholipase C (PLC) which in turn stimulates 
diacylglycerol and inositol-1,4,5-trisphosphate (Ins(1,4,5)P3) production. Ins(1,4,5)P3 
stimulates calcium release from intracellular stores and the activation of effectors such 
as calcium- and calmodulin-dependent kinase II (CAMKII), calcineurin and protein 
kinase C (PKC) which activate the transcriptional regulator nuclear factor associated 
with T cells (NFAT) that in turn translocates to the nucleus to regulate gene transcription.  
In addition to these three main Wnt signaling pathways, there are additional non-
canonical Wnt signaling cascades triggered by the binding of WNT proteins to their 
corresponding Frizzled receptors and specific co-receptors that result in tissue-specific 
downstream events. 
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Figure 10: Simplified schematic illustrating the three main WNT signaling 
pathways, the planar cell polarity (PCP) pathway, the β-catenin dependent pathway and 
the WNT/calcium pathway. After binding of a Wnt ligand to its cognate transmembrane 
receptor and co-receptor present on the cell surface, th cytoplasmic phosphoprotein 
Dishevelled (Dvl) is recruited to the plasma membrane and in turn activates different 
signaling cascades. Planar Cell Polarity (PCP) pathway: In this signaling cascade, 
Dishevelled (Dvl) activates the small GTPases RAC1 and RHOA, which in turn activate 
RHO kinase (ROCK) and JUN-N-terminal kinase (JNK), respectively, resulting in 
polymerization of actin and stabilization of the microtubules. β-catenin dependent 
pathway: In this pathway Dishevelled (Dvl) recruits to the plasma membrane and 
inactivates the β-catenin destruction complex comprising glycogen synthase kinase 3 
(GSK3), casein kinase I a (CKIa), Axin and adenomatosis polyposis coli (APC) by 
binding Axin. The inactivation of the β-catenin destruction complex leads to the 
accumulation of β-catenin in the cytoplasm and its translocation to the nucleus, where it 
activates the transcription of target genes. WNT/calcium pathway: In this signaling 
cascade, Dishevelled (Dvl) phosphorylates calmodulin-dependent kinase II (CAMKII), 
protein kinase C (PKC) and calcineurin. Calmodulin-dependent kinase II (CAMKII) 
translocates to the nucleus where it negatively regulates β-catenin dependent gene 
transcription. Protein kinase C (PKC) promotes actin polymerization and calcineurin 
activates the nuclear factor of activated T cells (NFAT) that regulates the transcription of 
genes controlling cell fate and cell migration. Adapted from Niehrs C. [307]. 
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Sonic Hedgehog (Shh) signaling controls important developmental processes 
including the growth, patterning and morphogenesis of many different regions within the 
body plans of humans and other mammals and with respect to the central nervous 
system (CNS) it has a prominent role in the dorsoventral patterning of the neural tube, 
neural stem cells proliferation and neurons and glial cell survival. Concerning its role in 
the dorsoventral axis formation of the neural tube, Shh secreted from the notochord and 
later from the floorplate directs cell fate choices in a dose-dependent manner by 
inducing and maintaining the expression of key transcription factors that define ventral 
neural tube structures along all the anteroposterior axis of the neural tube [317-322]. As 
Shh acts as a ventralizing factor, it does not play a role in the patterning and acquisition 
of neocortical excitatory pyramidal projection neurons identities but it is the critical 
instructing factor in establishing the formation of the medial and lateral ganglionic 
eminences that will give rise to the wide variety of neocortical inhibitory interneurons 
[318, 320, 323, 324]. In addition to controlling cell fate choices, Shh promotes the 
proliferation and inhibits the differentiation of neural stem cells [325, 326] and neocortical 
progenitor cells (NPCs) [327, 328]. 
 
In the canonical Shh pathway, activation of Shh signal requires binding of Shh to the 12-
span transmembrane receptor Patched (PTCH-1 or PTCH-2). The canonical receptor 
Patched inhibits downstream signaling through the physical interaction with the GPCR-
like 7-span transmembrane protein Smoothened (SMO) that prevents Smoothened high 
expression and activity. Shh binding to Patched-1, and possibly Patched-2, results in the 
derepression of Smoothened (SMO) with its consequent accumulation on the cell 
surface membrane and phosphorylation of its cytoplasmic tail that results in the 
activation of the Shh downstream signalling cascade [329, 330]. In the absence of 
Smoothened activation, the cytoplasmic protein Suppressor of Fused (SUFU) directly 
binds and sequestrates in the cytoplasm members of the glioma-associated oncogene 
homolog (GLI) family of zinc finger transcription factors that are the terminal 
transcriptional effectors of Shh pathway. In vertebrates, the GLI family of zinc finger 
transcription factors comprises three members, GLI1, GLI2, and GLI3. Cytoplasmic 
sequestration of GLI transcription factors by SUFU promotes the processing and 
degradation of GLI proteins therefore resulting in the inhibition of the Shh signaling 
cascade [331, 332]. Instead, in response to activation of Shh canonical signaling 
pathway, GLI proteins are differentially phopshorylated and processed into 
transcriptional activators that translocate to the nucleus where they actively regulate 
gene transcription inducing the expression of Shh target genes. In addition to the 
classical Shh signaling cascade, there are also non-canonical pathways related to Shh 
signaling based either on the activation of signaling from PTCH1/SMO but independent 
of GLI transcription factors or on the activation of GLI transcription factors independent 
of Shh ligand or PTCH1/SMO [330, 332]. 
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Figure 11: Simplified schematic illustrating Sonic hedgehog signaling pathway. 
Binding of a member of the Hedgehog (Hh) family of proteins, including Sonic hedgehog 
(Shh), to its cognate 12-span transmembrane receptor Patched (PTCH1 or PTCH2) 
enables the derepression of the GPCR-like 7-span transmembrane protein Smoothened 
(SMO). Activation of Smoothened (SMO) results downstream in the activation of the 
cytoplasmic protein Suppressor of Fused (SUFU) that in turn enables the differential 
phosphorylation of GLI proteins and their processing into transcriptional activators that 
translocate to the nucleus where they actively regulate gene transcription. Adapted from 
Meng et al. (2015) [333]. 
1.6 Transcriptional programs orchestrating neocortical development 
 
The signaling pathways essential for the proper control of all the different phases of 
neurogenesis ultimately regulate the transcription of target genes by acting in 
combination with transcription factors, histone-modifying enzymes and chromatin-
remodelling complexes. In the context of corticogenesis, their coordinated transcriptional 
regulatory effect exerted in conjunction with other molecular mechanisms contributes to 
direct neocortical progenitors (NPCs) cell-fate restriction and to establish the distinct 
laminar identities of neocortical pyramidal projection neurons [334-336]. The specific 
transcriptional programs and molecular mechanisms underlying neocortical pyramidal 
projection neurons sequential generation and regulating the acquisition of different 
neuronal subtypes identities have not yet been fully discovered and are currently an 
active area of research [62, 114, 337-341]. Although, many progresses have already 
been made in the identification of key transcription factors that are selectively expressed 
in transient cellular compartments present at different stages of embryonic and fetal 
neocortical development and characteristic of distinct neocortical layers. First evidences 
of the cellular compartment- or layer-specific expression of distinct transcription factors 
were gained from studies performed in murine models [163, 342-346] and these findings 
have been found to be highly conserved across mammals [347]. Combined with the 
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identification of transcription factors characterized by region- and cell type-specific 
expression, additional gain and loss of function studies of murine mutants have started 
to identify the precise roles of specific transcription factors in the determination of 
neocortical progenitor cells (NPCs) regional and cellular identities and their functions in 
regulating the progressive cell fate potential restriction from NPCs to postmitotic neurons 
[30, 337, 339, 341, 348, 349]. Moreover, there are evidences that specific transcription 
factors act also as postmitotic regulatory controls necessary to establish the precise 
neuronal subtype identities of newly born neurons and to further direct the postmitotic 
refinement and maintenance of postmitotic neurons cell-type specification [148, 151, 
350-352]. Along with their role in directing the specification of cell-type identities, the 
activation of specific transcriptional programs and the resulting expression of particular 
transcription factors determine also the distinctive cellular features of different neuronal 
subtypes, including their morphology, electrophysiological properties and axonal 
connectivity [346, 353, 354]. Therefore, neuronal subtype-specific transcription factors 
can be used as molecular markers to identify different neuronal classes [30, 344] or they 
can be manipulated through genetic engineering technologies to study the mechanisms 
of neocortical pyramidal neurons subtype-specific development and function [346, 353, 
355, 356]. 
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Chapter 2: Pluripotent stem cells 
2.1 Pluripotent stem cells 
 
Stem cells are characterized by the properties of self-renewal, that is the ability to 
undergo mitosis while maintaining the same undifferentiated state of the mother cell, and 
their differentiation potential or potency, that is the capacity to differentiate into a range 
of more specialized cell types. According to their differentiation potential, stem cells can 
be classified as totipotent, pluripotent, multipotent, oligopotent and unipotent. In the 
spectrum of cell potency, totipotent stem cells represent the cells with the greatest 
differentiation potential as they are able to generate all the embryonic and 
extraembryonic tissues and to give rise to an entire organism. In the mammalian 
developing embryo, the zygote derived from that fusion of an oocyte and a sperm cell 
and the early embryonic blastomeres up to at least the 4-cell stage embryo are totipotent 
stem cells [357]. As embryonic development proceeds to the 8-cell stage and beyond, 
blastomeres gradually lose their totipotency and become pluripotent stem cells. Contrary 
to totipotent stem cells, pluripotent stem cells are able to differentiate into cells of the 
germ line and into any cell type belonging to or derived from all the three germ layers of 
the developing embryo but they have lost the capacity to generate extraembryonic 
tissues as the umbilical cord, the placenta and the amniotic membrane. As embryonic 
development further proceeds, stem cells maintain their ability to self-renew but their 
differentiation potential becomes restricted to the generation of cell types belonging to a 
specific lineage. Therefore, the differentiation products of multipotent stem cells are a 
closely related family of cells, as is the case of neural stem cells (NSC) that are able to 
differentiate into neurons, astrocytes and oligodendrocytes [358, 359]. Characterized by 
a further restriction of potency are oligopotent stem cells that, as the name suggests, are 
able to differentiate into only a few tissue-specific cell types as lymphoid or myeloid stem 
cells. At the most restricted end of the potency spectrum, there are unipotent stem cells 
that have the ability to produce only cells of their own type, but maintain the property of 
self-renewal that is required to be defined as stem cells. Examples include muscle stem 
cells and epidermal stem cells that are thought to be able to generate only skeletal 
muscle cells and keratinocytes respectively. 
 
Special attention has been gained by pluripotent stem cells (PSCs) given their potential 
to differentiate into cells types belonging to the three germ layers and all their 
derivatives. To generate PSCs adapted to in vitro culture conditions and to maintain 
them indefinitely as stable cell lines in an undifferentiated state, different approaches 
have been followed. Based on their derivation method, PSCs can be classified as 
embryonic stem cells (ESCs) and induced pluripotent stem cells (iPSCs).  
 
Embryonic stem cells (ESCs) are derived from the inner cell mass of blastocyst stage 
embryos. The first embryonic stem cells were isolated from mouse embryos in 1981 by 
Evans M. and Kaufman M. [360] and Matin G.R. [361] independently, using different 
experimental approaches. The stage at which embryos were explanted, the number of 
cells explanted and the culture conditions in which embryonic cells were grown after 
explantation were essential factors that determined the success in isolating and 
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maintaining ESCs indefinitely in culture as stable cell lines. In the following years, 
derivation techniques and cell culture conditions have been adapted to generate ESCs 
also from other species, including non-human primates in 1995 [362] and humans in 
1998 [363]. 
 
A completely different approach for generating PSCs is based on reprogramming fully 
differentiated somatic cells back to a pluripotent state by ectopically expressing a small 
set of key transcription factors. PSCs obtained using this procedure were named 
induced pluripotent stem cells (iPSCs) to distinguish them from PSCs of embryonic 
origin. Mouse adult fibroblasts were successfully converted into PSCs for the first time 
by Takahashi and Yamanaka in 2006 [364]. In the following years, the set of 
transcription factors used to achieve cell line conversion and the culture conditions 
adopted were adjusted to extend the reprogramming approach to other species, 
including humans [365-367].  
 
Critical to the successful generation of PSCs using both generation methods are the 
culture conditions in which cells are grown and propagated. In fact, both ESCs and 
iPSCs without regard to the species of origin would spontaneously differentiate into cell 
types of all the three germ layers if the cell culture medium does not contain species-
specific factors that support the pluripotent state. The PSCs natural tendency to 
differentiate into mixed cell types belonging to the three germ layers and all their 
derivatives follows an order that recapitulates in vitro the steps of early embryonic 
development [368-370]. Furthermore, it has been discovered that PSCs differentiation 
potential can be directed to produce specific cell types by exposing them and their 
progeny to precise molecular cues that trigger the same signaling pathways activated 
during in vivo prenatal development. These findings resulted in the blossoming of many 
2D and 3D differentiation protocols for the generation of a myriad of specific cell types 
[371-374], including neocortical progenitors and neurons [176, 177, 375-378].  
 
Thanks to their ability to differentiate into virtually any cell type under defined culture 
conditions, PSCs have attracted a lot interest. Currently, ESCs, iPSCs and their 
differentiation products find applications in both basic and clinical research. In basic 
research, PSCs have transformed the field of developmental biology providing an 
extremely powerful in vitro tool to investigate the molecular mechanisms underlying the 
pluripotent state and orchestrating developmental processes in health and disease. 
Furthermore, PSCs are also applied more broadly as disease models of pathologies that 
do not have a developmental origin and find applications in translational researches 
aimed at identifying therapeutic targets as well as in drug discovery, drug testing and 
drug repositioning studies. Another attractive potential application of PSCs is in 
regenerative medicine as specific cell types derived from PSCs can be used in cell 
replacement therapies [379]. Given all the fields in which PSCs are applied, 
technological advances in cell culture techniques and differentiation protocols are 
progressing at a fast pace.                                                                                                                                                
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2.2 Induced pluripotent stem cells 
  
The generation of pluripotent stem cells (PSCs) starting from somatic cells was first 
achieved in 2006 by Takahashi and Yamanaka that were able to reprogram back into a 
pluripotent state mouse embryonic and adult fibroblasts [364]. These pluripotent stem 
cells (PSCs) generated by reprogramming fully differentiated somatic cells back to a 
pluripotent state were named induced pluripotent stem cells (iPSCs). The hypothesis at 
the basis of the generation of induced pluripotent stem cells (iPSCs) was that somatic 
cells can be reprogrammed back to a pluripotent state by ectopically expressing a small 
set of key transcription factors. This hypothesis stemmed from the convergence of three 
major research lines comprising the reprogramming by somatic cell nuclear transfer 
(SCNT), the discovery of master regulator transcription factors and the studies 
conducted with embryonic stem cells (ESCs). Until 1962, it was thought that cellular 
differentiation was a unidirectional process and that somatic cells were irreversibly 
committed to their cell fate and not able to be reprogrammed to a pluripotent state. John 
Gurdon research was able to disprove this view by experimentally proving that the 
nucleus taken from a differentiated frog intestinal epithelial cell and transplanted into an 
enucleated oocyte is capable of generating a fully functional tadpole [380]. Thus, this 
experiment demonstrated that oocytes contain factors that are able to reprogram a 
somatic nucleus and that the nucleus of a somatic cell retains the same genetic 
information, as early embryonic cells, required for the development of an entire 
organism. The procedure of transplanting the nucleus of a somatic cell into an 
enucleated oocyte is known as somatic cell nuclear transfer (SCNT). Following the path 
opened by the pioneering Gurdon experiment, SCNT has been applied for intraspecies 
and interspecies cloning of animals as demonstrated by the famous experiment 
performed by Wilmut research team of cloning Dolly the sheep [381] and by the 
subsequent cloning of other mammals [382-384]. In addition to somatic cell nuclear 
transfer (SCNT), somatic cells are able to be reprogrammed back to a pluripotent state 
also through the fusion with embryonic stem cells (ESCs) [385, 386]. The second stream 
of research that contributed to set the basis for the idea of reprogramming somatic cells 
through the delivery of a selected combination of transcription factors came from the 
realization that there are certain transcription factors able to determine and induce 
specific lineage identities.  The first evidences were collected in 1987 when the ectopic 
expression of the Drosophila transcription factor Antennapedia was demonstrated to 
induce the formation of legs instead of antennae [387] and the forced expression of the 
mammalian transcription factor MyoD was proved to convert fibroblasts into myocytes 
[388]. The third area that contributed to create the conditions for the emergence of the 
iPSCs technology is the research conducted on embryonic stem cells (ESCs) that 
provided the necessary background knowledge about pluripotent stem cells culture 
conditions [363, 389]. The combination of the evidences gained from somatic nuclear 
transfer (SCNT) and the discovery of master regulator transcription factors able to 
determine and specify precise cell lineage identities led to hypothesize that “it is a 
combination of multiple factors in oocytes or ESCs that reprogram somatic cells back 
into the embryonic state and to design experiments to identify that combination” [390]. 
Moreover, the knowledge gained from ESCs culture conditions was essential to be able 
to generate and maintain induced pluripotent stem cells (iPSCs). To test the feasibility of 
changing the cell identity of fully differentiated somatic cells and reprogram them back to 
pluripotent state, Yamanaka group started to concomitantly deliver into somatic cells by 
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retroviral transduction a set of 24 genes known to be highly and selectively expressed in 
embryonic stem cells (ESCs) and to be critically involved in the maintenance of the 
pluripotent state. Successful induction of the pluripotent state was detected by 
transducing with the reprogramming factors embryonic fibroblasts derived from a 
transgenic mice in which the βgeo cassette, that confers resistance to the antibiotic 
geneticin (G418), has been inserted into a Fbx15, a gene not essential for pluripotency 
maintenance but highly expressed in mouse embryonic stem cells. Embryonic fibroblasts 
derived from the Fbx15βgeo/βgeo mice and transduced with the reprogramming factors were 
grown in the same culture conditions applied for culturing embryonic stem cells (ESCs) 
with the addition of antibiotic G418, so that only somatic G418-resistant cells 
successfully induced to a pluripotent state were able to survive being positively selected. 
Subsequently, by the process of elimination the initial set of 24 reprogramming genes 
was narrowed down to only 4 genes that were sufficient to effectively induce 
pluripotency when ectopically expressed into somatic cells. The original minimal set of 
reprogramming transcription factors identified by Yamanaka’s group consisted of Oct4, 
Sox2, Klf4 and c-Myc (OSKM). One year later, in 2007 concomitantly Yamanaka 
research team [365, 366] and Thomson’s group [367] were able to extend the 
reprogramming approach to generate iPSCs also from human somatic cells. The 
induction strategies adopted by the two groups differed with respect to the set of 
reprogramming genes of choice and the gene delivery method utilized for the 
reprogramming. Yamanaka research team was able to successfully induce adult human 
dermal fibroblasts into iPSCs by using the same set of transcription factors previously 
adopted for the reprogramming of mouse somatic cells and by optimizing the retroviral 
transduction method and the cell culture conditions, adapting them to human cells [365, 
366]. On the other hand, Thomson’s group employed a slightly different set of 
reprogramming genes comprising the transcription factors Oct4, Sox2 and Nanog 
combined with the RNA-binding protein Lin28 and adopted lentiviruses as gene delivery 
system [367]. The homeodomain transcription factor Oct4 (octamer-binding transcription 
factor 4 also known as POU5F1) belonging to the POU family [391, 392], the 
transcription factor Sox2 (sex determining region Y-box 2) belonging to the Sry-related 
HMG box family [393] and the homeobox transcription factor Nanog [394-396] have 
essential roles in early development as they form the core regulatory network at the 
basis of the pluripotent state.  These three transcription factors upregulate the 
expression of other genes characteristic of the pluripotent state while concomitantly 
suppressing the expression of genes that promote differentiation and therefore their 
expression is crucial for the maintenance of self-renewal and pluripotency [397-401]. 
The other two reprogramming factors selected by Yamanaka’s group, Klf4 and c-Myc, 
are two tumor-related genes. Klf4 (Kruppel-like factor 4) is a member of the Klf family of 
transcription factors and it is known to be involved in the regulation of cell proliferation, 
differentiation and apoptosis [402]. Concerning the pluripotent state, Klf4 contributes to 
the long-term maintenance of pluripotent stem cells [403] and to the activation of Nanog 
and other pluripotent stem cells specific genes through the direct repression of p53 
[404], as it has been experimentally demonstrated that the p53 protein suppresses 
Nanog and other  pluripotent stem cells specific genes [405]. c-Myc (myelocytomatosis 
oncogene) is an oncogene that belongs to the Myc family of transcription factors and it 
codes for a nuclear phosphoprotein. As Klf4, also c-Myc has multiple functions and it is 
critically involved in controlling cell cycle progression, cell growth, cell differentiation, 
cellular transformation and apoptosis [406-408]. In the context of reprogramming fully 
differentiated somatic cells back into a pluripotent state, c-Myc protein activates the 
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transcription of many target genes promoting transformation and proliferation by binding 
enhancer box sequences (E-boxes) and by recruiting histone acetyltransferase (HAT) 
complexes [409-412]. The association with histone acetyltransferase (HAT) complexes 
may promote global histone acetylation, therefore enabling the binding of Oct3/4 and 
Sox2 to their specific target sites [364, 410]. Furthermore, c-Myc also directly controls 
DNA replication [413]. Instead, the fourth factor selected to induce pluripotency by 
Thomson’s group in combination with Oct3/4, Sox2 and Nanog, is Lin28. Lin28 is a gene 
that codes for an RNA-binding protein critically involved in regulating the self-renewal of 
mammalian pluripotent stem cells [414, 415]. Lin28 proteins are highly expressed in the 
inner cell mass (ICM) and epiblast [416] where they repress let-7 microRNAs preventing 
premature differentiation [417, 418] and concomitantly influence mRNA translation [414]. 
In the context of reprogramming, both Nanog and Lin28 are non-essential factors that 
enable to increase the reprogramming efficiency in human cells [367] with Lin28 
specifically contributing to enhance the reprogramming efficiency by promoting an 
increased number of cell divisions and an accelerated cell division rate [419]. 
 
These first reprogramming protocols demonstrated the feasibility of inducing fully 
differentiated somatic cells of different species into a pluripotent state following a robust 
and simple reprogramming procedure based on the forced expression of a small set of 
transcription factors. However, these first reprogramming protocols were characterized 
by very low efficiencies, just around 0.1% of mouse fibroblasts [364] and approximately 
0.1%-0.01% of human fibroblasts [365-367, 420] were successfully reprogrammed into 
iPSCs. In addition to the low efficiency of iPSCs generation, there were also safety 
concerns regarding the overexpression of the cocktail of reprogramming factors using 
integrating vectors as retroviruses or integrating lentiviruses, including incomplete 
reprogramming, immunogenicity, epigenetic changes, genetic mutations, gene insertions 
and the risk that using gene delivery vectors that stably integrate into the genome may 
activate or inactivate host genes resulting in tumors formation [421]. In a quest to 
improve reprogramming efficiency and the quality of iPSCs induction while avoiding the 
hazards due to the stable integration of transgenes into the genome of iPSCs, many 
researches have focused on the development of new methods for the generation of 
integration-free iPSCs. These new reprogramming methods can be broadly classified on 
the basis of the three different strategies adopted to generate transgene-free iPSCs that 
include the excision of the reprogramming factors, the use of alternative forms of gene 
delivery vectors enabling to avoid integration altogether and the direct delivery of 
reprogramming factors. The excision of the reprogramming factors has been achieved 
either using Cre-recombinase excisable lentiviruses [422] or the piggyBac transposon 
system  [423, 424]. Another strategy pursued has been the use of alternative forms of 
gene delivery vectors that enable to avoid the integration of the reprogramming factors 
altogether. Toward this aim, several alternative viral and non-viral delivery systems have 
been explored, comprising non-integrating viruses as adenovirus [425], DNA expression 
vectors [426], RNA virus as Sendai virus [427], plasmid episomal vectors [428, 429] and  
minicircle DNA [430]. A third approach that has been developed consists in the direct 
transfection or delivery of the reprogramming factors. In this area of research, 
synthesized mRNA of the reprogramming factors modified to overcome innate antiviral 
responses have been directly transfected into somatic cells [431] or reprogramming 
proteins have been directly delivered to generate induced pluripotent stem cells (iPSCs) 
[432, 433]. In addition, reprogramming by using exclusively chemical compounds has 
been reported for mouse [434] but not human iPSCs induction up to now [435].  
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Combined with the exploration of various gene delivery vectors enabling to avoid the 
integration of exogenous transgenes into the generated iPSCs, several combinations of 
reprogramming factors and various adjustments to the cell culture conditions have been 
tested and adopted to expand the spectrum of the starting somatic cell types induced 
into a pluripotent state [436-441] and to optimize the reprogramming procedure for each 
different species [364, 365, 367, 442-446]. In fact, even if the reprogramming procedure 
is robust and simple and many different fully differentiated somatic cell types from a wide 
variety of species can be reprogrammed to a pluripotent state by the forced ectopic 
expression of the classical cocktail of reprogramming factors (OSKM), optimized 
combinations of reprogramming factors and adjustments of the culture conditions 
significantly increase the reprogramming efficiency of each gene delivery method 
applied to a specific somatic cell type of a definite species [447]. The main milestones 
achieved in the field are summarized in the timeline reported below. 
 
Figure 11: Main milestones in iPSCs technology. Timeline summarizing the main 
milestones achieved in iPSCs technology in the first decade since their initial derivation. 
Adapted from Chari S and Mao S. [448]. 
 
To validate that the generated induced pluripotent stem cells (iPSCs) are indeed 
pluripotent stem cells (PSCs), a wide set of quality controls aimed at confirming both the 
functional properties and the molecular identity of iPSCs are routinely performed [449]. 
These screenings include the evaluation of iPSCs colony morphology, their growth in 
culture for several passages, the expression of key pluripotency markers characteristic 
also of embryonic stem cells (ESCs), the monitoring of alkaline phosphatase (AP) 
expression and activity, the functional assessment of their differentiation potential to 
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generate cells belonging to all the three germ layers either in vivo or in vitro and the 
ability to contribute to the generation of chimera.  
 
The first qualitative assessment of the pluripotent identity of newly generated iPSCs is 
the evaluation of colony morphology that should be round shaped and densely packed 
with cells characterized by a high nucleus to cytoplasm ratio presenting large nucleoli 
and a scant cytoplasm, similarly to embryonic stem cells (ESCs). Then, selected iPSCs 
clones are grown in culture for several passages to assess their ability to self-renew. To 
confirm that candidate iPSCs display the molecular hallmarks characteristic of the 
pluripotent state, the expression of key pluripotency markers is monitored at protein and 
transcriptional level. Routinely monitored pluripotency markers include transcription 
factors that form the core regulatory network at the basis of the pluripotent state and 
surface membrane antigens. Alkaline phosphatase (AP) expression and activity, that are 
upregulated in pluripotent stem cells (PSCs), are also generally examined. Moreover, to 
better assess the specific molecular state of the newly generated iPSCs also their global 
DNA methylation levels may be evaluated. The gold standard to verify the differentiation 
potential of candidate iPSCs and their ability to generate cells belonging to all the three 
germ layers is the in vivo teratoma formation assay. This assay consists in the 
subcutaneous injection of candidate iPSCs into immunodeficient mice resulting one to 
two months after transplantation in the formation of teratomas, that are tumors 
containing a mixed variety of tissues belonging to all the three germ layers. The 
pluripotency of candidate iPSCs can also be assessed in vitro by performing the 
embryoid bodies (EBs) formation assay which consists in culturing iPSCs before as 
floating aggregates and subsequently replating them as a monolayer culture while using 
throughout the protocol a medium that enables spontaneous cell differentiation. Another 
key assay to validate the pluripotency of newly derived iPSCs is the generation of 
chimera. In this assay, candidate iPSCs are injected into the blastocysts of an animal 
belonging to the same or a different species and it is monitored both the ability of iPSCs 
to contribute to the generation of chimera and their transmission to the offspring. This 
assay is routinely not applicable to human iPS cell lines in compliance with ethical stem 
cell research guidelines. It is worth noting that it is not necessary to perform all the 
assays summarized above to validate the pluripotency of candidate iPSCs due to 
redundancy and cost limits. Therefore, only a selected combination of these assays is 
usually performed for routinely screening and validating newly generated iPS cell lines. 
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Figure 12: Schematic summarizing the control assays to validate the pluripotency 
of candidate pluripotent stem cells (PSCs). Checklist summarizing the experimental 
controls to assess the function and the state of candidate PSCs. Evaluation of PSCs 
based on their functional operational definition consists of in vitro and in vivo assays 
aimed to assess the differentiation potential and self-renewal capacity of the cells under 
screening. The functional evaluation of PSCs is combined with tests aimed to confirm 
that candidate PSCs match the molecular definition of the pluripotent state which is 
assessed at the transcriptional, epigenetic and protein expression level. A third level of 
analysis aimed to evaluate the reproducibility of the generated PSCs would be advisable 
but is not always possible to achieve due to cost limits. In this schematic, the blue boxes 
indicate in vivo differentiation assays that can not be performed on human pluripotent 
stem cells in compliance with ethical stem cell research guidelines, while the red box 
marks the uncertain relevance of X chromosome reactivation as a criterion for assessing 
human ground state pluripotent stem cells, due to the lack of knowledge about the status 
of the X chromosome in human naive pluripotency. Adapted from De Los Angeles et al. 
[449]. 
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2.3 Pluripotent stem cells as a tool to investigate human neocortical 
development in health and disease 
 
Studies of human neurodevelopment are crucial to understand the regulatory 
mechanisms that give rise to the peculiar structure and functions of the human brain and 
to investigate the molecular basis of many neurological and psychiatric disorders that 
have a developmental origin [450-454]. Currently, the experimental tools available for 
studying neocortical development include post-mortem brain tissues, animal model 
systems and different types of in vitro cellular and tissue platforms.  
 
Post-mortem brain tissues are definitely the most physiological model system presently 
available to investigate human neurodevelopment. Epigenetic, transcriptional and 
protein synthesis investigations of these samples constitute the primary source of 
information about the molecular programs regulating human neocortical development 
and are essential to define the gold standard cell-specific signatures to which are 
ultimately compared data obtained from animal model systems and in vitro cell culture 
platforms, to assess their validity and relevance. Though, neocortical development 
researches based on human post-mortem brain tissues face several obstacles, including 
the difficulty in the procurement of high-quality post-mortem tissues that results in a 
limited number of samples available and the lack of experimental control on the 
developmental stage of the samples obtained that consequently translates into a 
constrained and suboptimal coverage of the different human neurodevelopmental 
periods investigated [15, 455]. A further limitation is posed by the impossibility to conduct 
experimental manipulations on post-mortem brain tissues which confines this 
experimental tool to more descriptive studies. 
 
Many of these limitations can be overcome by conducting research using animal model 
systems that represent a powerful tool to investigate the molecular mechanisms, cellular 
functions and circuit dynamics of the neocortex, as they allow experimental 
manipulations and the achievement of high spatial and temporal resolution [62, 108, 
111, 456]. Given these advantages, studies performed in animal model systems have 
provided fundamental insights into many human neurodevelopmental processes and 
cortical functions [4, 15, 29, 30, 336]. However, the use of animal model systems in 
neuroscience research is to some extent limited by the accessibility to the relevant 
biological targets for measurements and observation, the restricted throughput and 
sometimes the presence of confounding variables due to the complexity of the system. 
Most importantly, it has to be taken into consideration that vertebrate and invertebrate 
animal models are limited in precisely mimic the cellular complexity distinctive of the 
human brain [36, 75, 457-460] and in recapitulating certain characteristic features of 
human neurodevelopment and physiology due to the evolutionary distance between 
humans and these model organisms [4, 47, 461]. 
 
A third major category of model systems available to investigate human neocortical 
development consists of a wide variety of human ex vivo and in vitro tissue and cellular 
platforms [462]. These platforms comprise organotypic brain slices [463], primary 
cultures of neocortical progenitors and neurons [464], direct conversion of fully 
differentiated somatic cells into specific subtypes of neurons without passing through the 
pluripotent state, a process known as transdifferentiation or lineage reprogramming 
[465], and 2D or 3D cell culture platforms based on the differentiation of pluripotent stem 
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cells (PSCs) into neocortical progenitors [176, 177, 466] and distinct subtypes of 
neurons [375, 376, 467]. In this context, human PSCs-based technologies have 
attracted a lot of attention as their differentiation potential can be directed to generate 
with high efficiency the neural cell types of interest through the exposure to small 
molecules that trigger the same signaling pathways activated during human in vivo 
neurodevelopment. Human PSCs in vitro differentiation preserves the order of 
sequential generation of the different neocortical cell types, with deep-layer neurons 
developing first followed by the maturation of upper-layer neurons [375, 468]. The 
competence to recapitulate in a dish the main in vivo neurodevelopmental events and 
the ability to enable to reach an unprecedented spatial and temporal precision in the 
selection and analysis of specific developmental stages, makes human PSCs-based 
differentiation platforms the model system of choice to study the spatio-temporal 
transcriptional programs orchestrating neocortical development [468] and their disruption 
in disease [377, 378, 469-471]. In fact, the spatial and temporal resolution in 
investigating specific developmental stages offered by PSCs-based platforms is 
impossible to achieve using other model systems such as human brain tissues, animal 
models and other cell culture platforms like transdifferentiation protocols that are also 
able to generate the desired neural cell type populations with high efficiency but do not 
mimic the cell fate specification developmental trajectories. This unique advantage as a 
tool to model neocortical neurogenesis has fostered the development of many 2D and 
3D human PSCs-based culture systems. 2D PSCs-based differentiation protocols do not 
recapitulate the complex neocortical cytoarchitecture, lack cell-matrix interactions and do 
not fully mimic all the physiological cell-cell interactions characteristic of intact human 
brains but their intrinsic simplicity offers several advantages shared also with other in 
vitro 2D cell culture systems, as human primary neuronal cultures and human neurons 
generated through lineage reprogramming. All these three 2D cell culture platforms 
enable experimental accessibility to measure and investigate the cellular and molecular 
targets of interest, allow a precise control of the extracellular environment that results in 
more homogenous cultures and they can be easily experimentally manipulated [462, 
472]. Overall, these advantages make 2D PSCs-based differentiation protocols an highly 
reliable and reproducible in vitro model system to study neocortical development. 
Additional researches, aimed to bridge the gap between the cellular and tissue/organ 
level of structural organization and to mimic more closely in vitro the cytoarchitectonic 
complexity of the developing human brain, have been recently devoted to develop 
several 3D cell culture systems [462, 473, 474].  Currently, 3D cell culture systems 
include cortical spheroids [475] and cerebral organoids that can be either region-specific 
[378, 476] or able to reproduce various brain developmental regions [377]. Cortical 
spheroids and even more cerebral organoids recapitulate in vitro many biological 
features of the in vivo developing human brain as cell-matrix interactions, proper cell-cell 
connection patterns and the spatial organization of different tissue-specific cell types but 
they still lack the ability to reproduce the overall spatial organ level organization [477]. 
Furthermore, the increased complexity and faithfulness in mimicking the developing 
human brain of these 3D in vitro model systems is currently accompanied by an 
increased difficulty in accessing and measuring the biological targets of interest and by a 
reduced experimental control over the differentiation process that results in an enhanced 
heterogeneity and diminished reproducibility of the differentiation products. To overcome 
these hurdles and to optimize these in vitro technologies, many studies are focusing on 
applying tissue engineering approaches to 3D culture systems [473]. These approaches 
include attempts of integrating these platforms with 3D bio-printing methods [478] 
following the preliminary successes for other organs [479-481] and research plans to 
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provide organoids with systems mimicking the vascular network [462, 473, 482-485] and 
with scaffolds or beads that release patterning molecules to improve and standardize 
their spatial organization [486, 487]. The convergence of tissue engineering with 2D and 
3D stem cells-based cultures has opened an active area of research that is already 
producing new technologies generally refereed to as organs on-a-chip [473, 488].  
 
In addition to be an essential tool to investigate human neocortical development, 2D and 
3D PSCs-based differentiation protocols become also a powerful tool for modeling 
neurodevelopmental disorders when applied to iPSCs, as iPSCs fully recapitulate the 
genetic background of diseased individuals and therefore they allow to bridge the gap 
between the genetic lesions and the clinical data by providing a model system to 
investigate in vitro pathophysiological mechanisms [469]. iPSCs conservation of the 
patient-specific genetic makeup not only allows to identify the molecular pathways 
underlying neurodevelopmental disorders and analyze the disease-related cellular 
phenotypes but enables also to distinguish important differences in disease states 
specific to individual patients, therefore increasing the degree of resolution in 
understanding shared and unique disease mechanisms. This property renders iPSCs 
also attractive to the pharmaceutical industry as their integration into drug discovery 
pipelines may be critical in the evaluation of potential side effects arising in humans but 
undetected in animal models [489, 490] and offers the promise to move toward 
developing patient-specific therapies, a field also known as personalized or precision 
medicine [491, 492]. 
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Chapter 3: Genetic basis of neurodevelopmental 
disorders  
3.1 Genetic architecture of neurodevelopmental disorders 
 
Neurodevelopmental disorders comprise a wide variety of syndromes characterized by 
impaired development and growth of the central nervous system (CNS) that have a 
prenatal, infancy or early childhood origin. Their onset is generally in the first years of life 
even if certain pathologies such as schizophrenia emerge later, in adolescence and 
early adulthood. Their initial diagnosis is mainly based on clinical symptoms and for 
certain conditions it is also aided by the presentation of distinctive facial features. The 
etiology of many neurodevelopmental disorders is still unclear despite their high 
incidence (at least 13-15% in the US, according to [493] and NSCH data) as the majority 
of these pathologies involve complex traits and for only a minority of these disorders a 
defined causative genetic mutation could be identified. Though, the high heritability of 
complex neurodevelopmental disorders established by twin [494, 495] and family [496, 
497] correlation studies and the identification of rare Mendelian syndromes that meet the 
same diagnostic criteria [498-501] have highlighted the importance of the genetic 
component as being causative or a predisposing risk factor acting in combination with 
environmental components. Consequently, these evidences have fostered the research 
in identifying the genetic architecture of complex polygenic neurodevelopmental 
disorders such as autism spectrum disorders (ASD), attention deficit hyperactivity 
disorder (ADHD), schizophrenia and intellectual disability (ID) and this is currently an 
active area of investigation [453, 502-504]. Thanks also to technological advances in 
genetics and genomics, several studies have already enabled the description of various 
mutations that lead to rare Mendelian syndromes [498-501] and have revealed many 
variants correlated to complex neurodevelopmental disorders [503, 505-509].  
 
 
 
 
Figure 13: Estimates of the genetic and environmental contributions to several 
neurodevelopmental disorders. Histograms representing the relative percentages of 
the additive genetic variance (G) and environmental factors, subdivided into shared 
environment (E) and non-shared environment (NE) variances, predisposing to different 
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neuropsychiatric disorders, including neurodevelopmental disorders. Data were obtained 
from twin, family and population studies. Adapted from Gandal M.J. et al. [503]. 
 
The identified causal genetic variants and genetic risk factors associated to 
neurodevelopmental disorders can take different forms and be classified according to 
the type of genetic mutation, ranging from genomic structural variations affecting the 
chromosome structure to alterations in the nucleic acid sequence. Genomic structural 
variations associated to neurodevelopmental disorders include copy number variations 
(CNVs), in which genomic regions larger than 1 kilo base pairs are duplicated or deleted 
resulting in altered gene dosage characterized respectively by triploidy or haploid 
number of copies of the genetic elements encoded in the affected genomic loci [510, 
511], and other forms of small chromosomal rearrangements (<50 kb) as inversions and 
translocations [503, 509]. Also alterations in the nucleotide composition have been 
linked to neurodevelopmental disorders pathogenesis in the form of trinucleotide 
repeats, insertions and deletions of bases known as indels or single base pair changes 
that can be further classified on the basis of their occurrence as single nucleotide 
polymorphisms (SNPs), when the single nucleotide change is present to some 
noticeable degree within a population (> 1%), or single nucleotide variations (SNVs) if 
the single nucleotide modification is either rare (< 1%) or common [512-514]. The 
genetic variants associated to neurodevelopmental disorders can also be classified on 
the basis of their origin as new germline mutations, also known as de novo mutations or 
their inheritance pattern, according to their frequency within a population as rare or 
common and depending on their effect size that reflects the degree of biological 
causality.  
Genome wide association studies (GWAS) performed on large cohorts of healthy 
controls and individuals affected by complex neurodevelopmental disorders have 
identified that there is an inverse relationship between mutation frequency and effect 
size. For common alleles  (allele frequency > 0.5%) the link to biological causality is 
more blurred and their effect size is reduced (odds ratio < 1.3) with respect to selected 
high-impact rare variants that are able to produce larger effects size (odds ratio typically 
2-60) and more evident phenotypic mutations [503, 515]. This inverse relationship 
between mutation frequency and effect size is also followed by neurodevelopmental 
disorders characterized by a simple genetic architecture in which disease liability can be 
ascribed to one or few genes, as in the case of rare Mendelian syndromes and specific 
rare de novo mutations. This trend can by explained by the negative selection of high-
impact mutations producing large effect size due to the reduced reproductive fitness of 
their phenotypes. Consequently, high-impact genetic variations usually occur de novo 
and are generally rare. This observation has lead to question the relative contributions to 
disease liability that can be ascribed to common and rare variants respectively and to 
investigate their penetrance. To this regard, two different models emphasizing the role of 
either common or rare mutations have been proposed. The common disease common 
variant (CDCV) model hypothesize that genetic susceptibility to complex 
neurodevelopmental disorders is ascribable to several high-frequency variants that 
confer moderate risk taken alone but are responsible for a large percentage of genetic 
predisposition in aggregate. On the other hand, the common disease rare variant 
(CDRV) model highlights the contributions of rare variants to disease susceptibility. 
Many CNVs and genome wide association studies (GWAS) aimed at testing the CDCV 
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and CDRV hypothesis have been performed [516-522], though their results remain 
inconclusive toward providing a defined answer to this debate and new perspectives and 
investigation approaches are emerging [503, 511, 523].  
The identification of specific genotypes linked to neurodevelopmental disorders 
phenotypes is only a first objective of the field. Other major aims include the discovery of 
the molecular mechanisms underlying disease etiology, the identification of the specific 
disease-related abnormalities occurring at cellular, neuroanatomical and physiological 
level and building a framework that connects these different levels of biological 
investigation between each other and to the peculiar cognitive and behavioral 
impairments related to specific clinical phenotypes. In this larger perspective, two 
different approaches are followed. On one hand, the research focus is still directed 
toward the identification of single genotype-phenotype correlations. By following a 
bottom-up strategy and increasing the specificity of the genetic target under 
investigation, this single genotype approach potentially enables to better dissect the 
underlying molecular mechanisms as well as to identify cellular alterations and to draw 
genotype-phenotype associations [524, 525]. On the other hand, a more holistic 
approach based on integrative methods combined with systems biology is adopted to 
identify convergent pathways and common cellular targets disrupted in the pathological 
states [503, 504, 511, 523, 526]. The first results obtained using this strategy have 
started to highlight shared or disease-specific biological processes altered in several 
neurodevelopmental disorders and suggest that common inherited and rare de novo 
variants affect different pathways [507, 527-532]. 
3.2 Copy number variations contribution to neurodevelopmental 
disorders liability 
 
In this research context aimed at understanding the etiology and multiple-level defects 
implicated in neurodevelopmental disorders and at discovering therapeutic targets 
building on this knowledge, the study of copy number variations (CNVs) has provided 
initial evidences of the relevant role played by rare mutations in disease liability and risk 
predisposition [533, 534]. The first recognitions that CNVs underlie specific 
neurodevelopmental disorders emerged from laboratory tests performed on individuals 
presenting clinical symptoms meeting well-defined diagnostic criteria. Laboratory tests 
enabled to identify the specific genomic regions deleted or duplicated in the affected 
subjects and therefore allowed to link definite genotypes to precise clinical syndromes, 
also known as genomic disorders, like Williams syndrome, Smith-Magenis syndrome 
and DiGeorge syndrome [535-537]. These genomic disorders are characterized by high 
penetrance and low incidence reflecting the rare occurrence rate of the underlying CNVs 
that generally arise as de novo mutations since they are under negative selection. The 
importance of CNVs in the etiology of genomic disorders characterized by a simple 
genetic architecture highlighted by these initial findings lead to investigate the 
contribution of CNVs also to complex polygenic neurodevelopmental disorders. 
Genome-wide studies of CNVs association with complex neurodevelopmental disorders 
took mainly three study design forms, including family-based analyses aimed at 
identifying spontaneous disease-related CNVs that occurred de novo in the proband, 
population level studies also trying to assess the overall contribution of rare CNVs to 
disease risk through the comparison of affected patients to healthy controls and 
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researches focused on delineating the association of specific genomic regions or genes 
to multiple disorders in a comprehensive way [538]. These studies discovered a large 
number of additional CNVs related to specific syndromes [539, 540]. Furthermore, they 
identified many recurrent CNVs that are associated with different degrees of penetrance 
to one or more complex neurodevelopmental disorder, as developmental delay [541], 
intellectual disability [542], autism spectrum disorder [518], attention deficit hyperactivity 
disorder [543] and schizophrenia [544]. Therefore, even if specific CNVs are rare and 
generally arise as de novo mutations, according to current estimates at least 15% of 
human neurodevelopmental disorders have been ascribed to rare CNVs that produce 
selective gene dosage imbalances [534]. The percentage of CNVs contribution to 
disease liability increases if taking into account even other CNVs mildly related to 
complex neurodevelopmental disorders. 
 
A general trend that emerged from these studies is that clinical phenotypes are more 
frequently associated with deletions than with duplications. This observation might be 
explained by taking into consideration the mechanisms that produce the structural 
variation. Deletions may result from interchromosomal, interchromatid and 
intrachromatide nonallelic homologous recombination (NAHR) while duplications are 
mediated only by interchromosomal and interchromatid non-allelic homologous 
recombination (NAHR) [545, 546]. Therefore, deletions are more likely to occur than 
duplications. Furthermore, in addition to induce haploinsufficiency, deletions uncover 
recessive alleles of the CNV region consequently increasing the probability of the 
manifestation of disease-related phenotypes [534, 547]. Another observation worth 
noting is the high level of phenotypic variability highlighted by investigations of the 
contribution of specific CNVs to both genomic disorders characterized by simple genetic 
architectures and complex neurodevelopmental disorders. The clinical phenotypes vary 
widely even in neurodevelopmental disorders that have a simple genetic basis involving 
a specific CNV [536]. This phenotypic variability seems even increased when examining 
CNVs association to complex neurodevelopmental disorders. The degree of association 
of a precise CNV to a specific complex neurodevelopmental disorder is generally partial, 
meaning that the presence of the CNV only sometimes results in a specific 
neuropsychiatric phenotype and it is also frequent that the same CNV is associated with 
multiple neurodevelopmental disorders [538, 548-551]. Moreover, CNV alleles 
associated to neuropsychiatric disorders of developmental origin can also be expressed 
at a low frequency in the healthy population [550].  
 
The high phenotypic variability of CNVs genotypes and the current lack of an integrative 
explanatory framework for this observed variability highlights that the contributions of 
specific CNVs and CNVs as a genetic variant group to human neurodevelopmental 
disorders liability are still mostly unexplored. Further advancement of this field is 
necessary given the high degree of neurodevelopmental disorders liability ascribable to 
CNVs [534]. Therefore, research focus is at present directed toward constructing this 
framework and better defining the genotype-phenotype relationship by discovering the 
pathways and molecular mechanisms disrupted in disease as well as by identifying the 
resulting cellular, physiological and neuroanatomical abnormalities produced by specific 
alterations in gene dosage at the level of both single genes present in the CNV and all 
the genes contained in the CNV combined. Studies taking into consideration also 
specific genetic backgrounds are pursued as well, given that the high phenotypic 
variability of CNVs genotypes might be at least partly ascribed to the modulatory effects 
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exerted by epigenetic regulation and the expression of other common and rare alleles 
[538, 552]. 
3.3 Copy number variation at the 7q11.23 locus 
 
Copy number variation of the Williams-Beuren syndrome chromosome region (WBSCR), 
located on the long arm (q) of chromosome 7 at position 11.23 (7q.11.23 locus), is of 
special interest as the two disorders resulting from the deletion (Williams syndrome, WS) 
and duplication (7q.11.23 duplication syndrome, 7q11DUP) of this region exhibit 
cognitive and behavioral phenotypes marked by both similar features and symmetrically 
opposite traits [553-557]. The relatively simple and defined genetic basis underlying 
these disorders combined with the specificity of the observed opposite cognitive and 
behavioral phenotypic alterations make the study of the 7q11.23 locus particularly 
attractive to investigate the genetic basis of precise aspects of human cognition. 
Furthermore, the association of 7q11.23 duplication to complex neurodevelopmental 
disorders such as autism spectrum disorder and schizophrenia while 7q11.23 deletion 
produces a well-characterized syndrome without clear overlapping to complex 
neurodevelopmental disorders, render the study of this locus also extremely interesting 
to identify the molecular mechanisms unique to each disorder, common to both 
syndromes and shared with other complex neurodevelopmental disorders. 
The Williams-Beuren syndrome chromosome region (WBSCR) spans 1.5 to 1.8 million 
base pairs (Mb) comprising 26 to 28 genes (Figure 14, panel A). Rearrangements of this 
region occur as it is flanked by blocks of low copy repeat sequences containing genes 
and pseudogenes that share high sequence homology, known as duplicons. Therefore, 
due to its peculiar genetic architecture, WBSCR is prone to frequent structural 
rearrangements resulting in CNV of this locus. In fact, the spatial closeness and the high 
level of sequence homology between duplicons make WBSCR vulnerable to 
misalignments of duplicons during meiosis and subsequent unequal crossing over 
resulting in abnormal recombinant products, where the WBSCR is either deleted or 
duplicated (Figure 14, panel C) through a mutational mechanism know as nonallelic 
homologous recombination (NAHR).  
CNV of the 7q11.23 locus is sporadic and can occur spontaneously during meiosis on 
either paternally or maternally inherited chromosome 7. The length of the deletion or 
duplication depends on which duplicons are involved in the rearrangement. Generally, 
the low copy repeats sequences involved in the rearrangement are the medial and 
centromeric duplicons (specifically, blocks B indicated in Figure 14). Their nonallelic 
homologous recombination results in the typical deletion or duplication of 1.5 Mb in the 
WBSCR encompassing 26 to 28 genes that occurs in the majority of patients. Less 
frequently, duplicons misalignment gives rise to a larger deletion or duplication of 1.8 Mb 
comprising 28 genes [558-560]. 
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Figure 14: Schematic representation of the Williams-Beuren syndrome 
chromosome region and rearrangements mechanisms leading to 7q11.23 CNVs. In 
panel A is reported a schematic of the Williams-Beuren syndrome chromosome region 
(WBSCR) highlighting the genes contained in it and the low copy repeat sequences 
flaking the region. In panel B and C are represented the normal and misaligned pairing 
of duplicons during meiosis that results after crossing over in normal recombinant 
products or in deletions and duplications of WBSCR, respectively. Adapted from Pober 
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B.R. [536].  
It is also possible that shorter or larger atypical deletions or duplications of the WBSCR 
arise. The effects of these atypical duplications have not yet been fully investigated while 
more extreme phenotypes accompanied by moderate to severe intellectual disability 
have been observed in individuals with deletions longer than 1.8 Mb [561]. On the other 
hand, deletions of the WBSCR shorter than 1.5 Mb have been associated with variable 
phenotypes [562-564]. The more pronounced phenotypic changes related to 7q11.23 
CNV size are observed in WS with respect to 7q11DUP follow the general trend 
observed in many CNV studies where clinical phenotypes have been more frequently 
detected in cases of deletions rather than duplications. 
3.4 Williams syndrome 
 
Williams syndrome (WS) is a multisystem disorder caused by the deletion of the 
Williams Beuren syndrome chromosome region (WBSCR). Prevalence is estimated to 
range from 1:7500 to 1:20000 based on different sources [565, 566]. WS patients 
display peculiar phenotypes characterized by distinctive facial features, intellectual 
disability accompanied by psychiatric and psychopathological conditions, cardiovascular 
disorders, connective tissue abnormalities and endocrine system impairments. 
Cardiovascular abnormalities include supravalvular aortic stenosis (SVAS) present in the 
majority of patients and stenosis of other large and medium arteries that are due to the 
elastin (ELN) gene dosage imbalance, hypertension and myxomatous degeneration of 
aortic or mitral-valve leaflets [567, 568]. Several endocrine abnormalities are also found 
in WS patients including hypothyroidism, hypercalcemia and hypercalciuria [569, 570]. 
 
WS mean IQ of 50-60 indicates the presence of mild to moderate intellectual disability 
but WS affected individuals with normal IQs are also present [553-555]. The 
characteristic pattern of cognitive abilities displayed by WS patients reveals strengths in 
interpersonal and social skills, facial recognition, auditory memory, language 
performance and language-related skills above than expected for their IQ [553, 556]. 
These strengths are accompanied by marked weaknesses in visuospatial construction, 
visuomotor skills and significantly impaired performance in writing, mathematics and 
drawing [554, 557, 571]. This distinctive cognitive pattern is combined with unique 
personality traits characterized by excessive friendliness, over engaging behaviors even 
with strangers, lack of social inhibition and high levels of empathy [553, 572-574]. Other 
common behavioral problems in WS are reduced adaptive behavior than expected for IQ 
and difficulty with emotional regulation [575, 576]. WS is also frequently accompanied by 
several psychiatric and psychopathological conditions including anxiety disorders [577], 
specific phobias [578], attention deficit disorder [579], perseveration, restricted interests 
and repetitive behaviors [580].  
 
The unique cognitive and behavioral profile that characterizes WS individuals has been 
associated with a peculiar pattern of cellular and neuroanatomical abnormalities. 
Histological analyses have highlighted differences in the global and regional neuronal 
organization as well as decreased neuronal size, increased packing density and 
coarseness abnormalities distinctive of WS brains compared to controls [581]. 
Anatomical examination of the central nervous system has identified a significant 
reduction in whole brain volume (11-13%) [582, 583] and several morphological 
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abnormalities in the cerebral cortex, amygdala, hippocampus, cerebellum, basal ganglia, 
brainstem and corpus callosum of WS patients. In WS affected individuals, the overall 
volume of the amygdala is increased [584] and the hippocampus has normal size but 
exhibit subtle shape alterations and it is characterized by an impaired metabolism [585]. 
It is reported that the cerebellum has normal or increased size, depending on the studies 
[582, 586] and at a closer inspection it reveals a distinctive increase of the neocerebellar 
vermal lobus area [582] while basal ganglia and brainstem display a significant reduction 
in size [587-589]. The volume of the corpus callosum is significantly reduced especially 
in the caudal part and in the splenium and its shape is more convex compared to 
controls [590]. Diffusion tensor imaging (DTI) studies have revealed that several major 
white matter tracts are compromised displaying abnormal volumes, density and integrity 
[591, 592]. Specifically, the right superior longitudinal fasciculus, the left fronto-occipital 
fasciculus, the caudate and the cingulum show compromised integrity as indicated by 
the increased values of fractional anisotropy, that is a measure of microstructural 
integrity, whereas the corticospinal tract shows decreased values [593]. Of outstanding 
interest is the more pronounced integrity defect revealed in the superior longitudinal 
fasciculus (SLF) of the right hemisphere that is associated with the dorsal stream, a 
pathway involved in visuospatial construction [593, 594]. This defect might be related to 
the visuospatial impairment characteristic of WS. Overall, lesions of these white matter 
tracts may constitute one of the anatomical substrates underlying the cognitive and 
behavioral abnormalities characteristic of WS.  
The cerebral cortex of WS individuals is also characterized by multiple structural defects, 
including reduced volume and increased gyrification in specific regions, increased 
cortical complexity of specific areas and sulci abnormalities, as revealed by magnetic 
resonance imaging (MRI) studies. Loss of volume affects especially the occipital and 
superior parietal cerebral cortex while the volume of frontal lobes cortex is relatively 
preserved [583, 587, 595]. Cortical surface analyses have revealed decreased sulcal 
depth in the intraparietal and orbitofrontal sulci and a reduction in the extent of the 
central sulcus [596] along with a specific increased gyrification of the right parietal, right 
occipital and left frontal regions [597-599]. Several spatially extended cortical regions 
distinguished by an increased complexity and thickness have been identified [597], 
including delimited zones of right hemisphere perisylvian and inferior temporal 
cortex [598]. Furthermore, multiple sulcal abnormalities have been detected as a 
reduced sulcal depth in the intraparietal and orbitofrontal sulci and a reduction in the 
extent of the central sulcus [600]. 
In addition to the cellular and neuroanatomical abnormalities, functional MRI (fMRI) 
researches have revealed differences in neural activation between individuals affected 
by WS and healthy controls during tasks involving response inhibition [601], visuospatial 
construction [602] and auditory processing [603]. Abnormal amygdala activation in 
response to processing of social, emotional and fearful stimuli might be considered the 
neural correlate of the abnormal social cognition and emotional dysregulation distinctive 
of WS [572, 604, 605]. 
Part I: Introduction 
 47 
 
3.5 7q11.23 duplication syndrome 
 
7q11.23 duplication syndrome (7q11DUP) is a multisystem disorder caused by the 
duplication of WBSCR. Prevalence is unknown and it is estimated to range from 1:7500 
to 1:20000 based on prevalence estimates of WS [606, 607]. Compared to WS, 
7q11DUP generally exhibit milder and highly variable phenotypes characterized by 
minor facial features, neurological problems, psychiatric conditions, cardiovascular 
disorders, motor speech disorders such as dysarthria and dyspraxia and additional 
phonologic problems [608]. Other frequent impairments observed in a subset of patients 
include joint laxity, genitourinary tract abnormalities and gastrointestinal problems 
comprising chronic constipation and feeding difficulties as well as chronic otitis, 
diastema, strabismus and hearing loss [606, 608]. It is worth noting that facial features 
presented by 7qDUP individuals are opposite with respect to the distinctive facies of WS 
patients. 
 
Among the impairments observed in 7q11DUP, neurological problems and psychiatric 
conditions have special relevance as they are the predominant phenotypic trait and they 
are observed to some extent in the majority of patients. Neurological problems include 
developmental coordination disorder, involuntary movements, balance problems, 
hypotonia, high pain tolerance, hydrocephalus and seizures [606, 608-610]. The median 
IQ of 7q11DUP is in the low average but it can range widely from severe mental 
retardation to normal and above average scores, so intellectual disability is diagnosed 
just in a subset of patients [611]. The pattern of cognitive abilities presented by 
7q11DUP affected individuals reveals preserved weaknesses and strengths in specific 
abilities. Spatial abilities and nonverbal reasoning are preserved at all ages while a 
decrease in verbal abilities over lifetime has been detected, especially affecting 
expressive language, accompanied by weak reading and mathematics performance that 
are at the bottom of the average or low average range [611, 612]. This pattern of 
cognitive abilities display some symmetrically opposite strengths and weaknesses 
compared to WS where language skills are preserved but visuospatial abilities are 
severely impaired. In contrast some weaknesses, as below average performance in 
mathematics, are shared by both disorders. In the majority of 7q11DUP patients 
adaptive behavior is limited as in WS and maladaptive behavior scores range from high 
to normal [611]. 7q11DUP is also frequently accompanied by several psychiatric and 
psychopathological conditions, including anxiety disorders, attention deficit hyperactivity 
disorder (ADHD), social and specific phobias, that are conditions also associated with 
WS [611]. In addition, 7q11DUP patients frequently display also disruptive behavior 
disorder (DBD), oppositional defiant disorder (ODD) and social phobias [611]. 
Furthermore, 7qDUP has also been associated with autism spectrum disorders [518, 
608, 611, 613] and schizophrenia [560]. 
 
The identification of the neural correlates underlying the cognitive and behavioral profiles 
characterizing this syndrome is under study. As 7q11.23 duplication syndrome was 
identified later since it is characterized by milder phenotypes and occurs less frequently 
than WS, the number of studies documenting the cellular, anatomical and physiological 
alterations distinctive of this disorder are reduced and further researches are necessary 
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to better delineate them. Up to now, anatomical examination of the central nervous 
system has identified a significant increase in total brain volume [614]  and several 
morphological abnormalities in the cerebral cortex, amygdala, hippocampus, cerebellum, 
basal ganglia and corpus callosum [608]. The increase in total brain volume observed in 
7q11.23 duplication is frequently accompanied by a dilatation of the lateral ventricles, a 
condition known as ventriculomegaly, and it is in contrast with the decreased whole brain 
volume observed in WS patients [582, 583, 610]. Amygdala and hippocampus volumes 
are smaller compared to WS and 7q.11.23 duplication patients display cerebellar vermis 
hypoplasia [608] while WS affected individuals have a cerebellum of normal or increased 
size compared to controls [586]. Furthermore, putamen and caudate volumes are larger 
in 7q11.23 duplication with respect to both WS and controls [608]. In some patients the 
volume of the corpus callosum is reduced [608] as in WS and the white matter seems 
decreased, immature, underdeveloped and shows hyperintensities [608, 610], a sign of 
white matter lesion, but further studies are necessary to confirm and refine these 
findings. The cerebral cortex in some cases of 7q11.23 duplication is also characterized 
by multiple structural defects [606], including increased thickness, simplified gyral 
pattern and cortical dysplasia of the left temporal lobe [609, 610]. This anatomical defect 
is particularly interesting as it might explain the language impairments usually associated 
with this syndrome. 
 
In addition to cellular and neuroanatomical abnormalities, few preliminary functional MRI 
(fMRI) studies have started to assess the neural activation profiles peculiar to 7q11.23 
duplication syndrome highlighting a dysfunction of the limbic system characterized by 
hypofunctional amygdala, cingulum and orbital frontal cortex [614].  
3.6 Analysis of the genotype-phenotype correlation in Williams 
syndrome and 7q11.23 duplication syndrome 
 
Many researches aimed to unravel the link between 7q11.23 CNV genotypes and clinical 
phenotypes and the relationship of specific genes contained within the WBSCR to their 
cellular and neuroanatomical correlates have already been performed [470, 608-610, 
615-621]. Study designs vary widely including: 1) functional and neuroanatomical 
examinations of individuals affected by 7q11.23 CNV, 2) behavioral, neuroanatomical 
and cellular studies using animal models systems engineered for specific genes 
contained in the WBSCR, 3) transcriptional analyses and cell morphology 
characterizations of iPSCs-derived neurons generated from affected individuals or 
engineered through CRISPR/Cas9 genome editing technology. 
 
The results obtained from functional and neuroanatomical examinations of individuals 
affected by 7q11.23 CNVs constitute the majority of the current clinical knowledge of 
these disorders and studies of individuals affected by atypical WBSCR deletion started 
to provide some insights into the contribution of specific genes to the neurocognitive 
profile that characterizes WS [615, 616]. 
 
Several mouse models harboring either the complete [617], partial [618] or only a single 
gene [619, 620, 622, 623] deletion and single gene duplication [624] of WBSCR have 
been generated and characterized. The mouse model with complete deletion of WBSCR 
recapitulates the main cognitive, behavioral and physical defects observed in individuals 
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affected by WS [617]. Partial deletion and single gene knock-in and knockout mouse 
models mimic specific aspects of WS and 7q11DUP and therefore helped to define the 
contribution of single genes to the clinical phenotype [618-620, 622, 623]. Among the 
genes contained in WBSCR investigated up to now, it was found that Gtf2i, Gtf2ird1 and 
Limk1 are related to neurological and cognitive phenotypes, confirming the findings 
obtained from studies of atypical WS cases [615, 616]. 
 
Few studies have also started to explore the effects of 7q11.23 dosage imbalance on the 
transcriptome of iPSCs generated from affected individuals [470] and iPSCs-derived 
neurons [470, 621]. Transcriptional profiling of iPSCs generated from WS and 7q11DUP 
patients revealed deregulation of disease-relevant pathways already in the pluripotent 
state [470]. Specific subsets of disease-relevant transcriptional deregulations already 
present in the pluripotent state resulted amplified upon iPSCs differentiation toward 
different lineages, including neocortical progenitors (NPCs) [470]. Gene ontology (GO) 
enrichment analysis of Williams syndrome iPSCs-derived NPCs and neocortical neurons 
identified deregulated disease-relevant biological processes, including ‘cell maturation’, 
‘cell adhesion’, ‘axon guidance’ categories, along with downregulation of the canonical 
Wnt signaling pathway [621]. Furthermore, the comparison between the transcriptional 
profiles of WS, 7q11DUP and healthy controls iPSCs and iPSCs-derived neuronal cells 
began to identify symmetrically opposite gene expression signatures that may be 
ascribed to the gene dosage imbalance along with some candidate genes responsible 
for specific disease-related traits [470]. These insightful studies have just started to 
identify the impact of 7q11.23 dosage imbalance on the overall transcriptome of some 
neocortical cell types. Further researches are necessary to better compare the 
transcriptional profiles of WS and 7q11DUP, to expand the neocortical cell types 
examined and to gain insights into the molecular mechanisms underlying these 
syndromes that are of interest for both basic research and to discover therapeutic 
targets, as currently therapeutic options are mainly restricted to behavioral interventions 
and symptomatic treatments. 
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Chapter 4: Induced pluripotent stem cells as a model 
system to investigate human neocortical development 
and neurodevelopmental disorders 
4.1 Derivation of human induced pluripotent stem cell lines  
 
In this study 13 human induced pluripotent stem cells (iPSCs) lines have been 
generated from a cohort comprising six controls, four individuals affected by typical 
Williams-Beuren syndrome (WS) and three individuals affected by 7q11.23 duplication 
syndrome (7q11DUP). Among the healthy subjects chosen as controls, two are 
unaffected relatives of individuals presenting with typical Williams-Beuren syndrome and 
the other four are unrelated individuals. The four iPSCs control lines derived from 
unrelated individuals have been used in the first phase of this study to perform a 
comprehensive transcriptional, cellular and physiological characterization of the in vitro 
neocortical differentiation protocol. Having established the reliability and quality of our 
protocol, this differentiation strategy was later adopted as a model system to investigate 
how 7q11.23 gene-dosage imbalances impact neocortical neurons development by 
applying it also to iPSCs lines derived from WS patients, 7q11DUP individuals and the 
additional healthy controls. General information concerning the iPSCs lines generated in 
this research and their applications are reported in Table 1.  
 
Condition Sample ID Sex iPSCs clones 
Brain 
matched Application 
Williams syndrome 
(WS) 
WS 361 F iPSC#8 no disease modeling 
WS 728 M iPSC#13 no disease modeling 
WS 1574 M iPSC#27 yes disease modeling 
WS 5437 M iPSC#36 yes disease modeling 
Controls 
WS 361-1* F iPSC#20 no disease modeling 
WS 728-1* F iPSC#2 no disease modeling 
HSB 286 M iPSC#7 yes protocol validation iPSC#20 
HSB 292 M iPSC#7 yes protocol validation iPSC#38 
HSB 311 F iPSC#1 yes protocol validation disease modeling iPSC#36 
HSB 314 M iPSC#43 yes protocol validation iPSC#47 
7q11.23 duplication 
syndrome (7qDUP) 
7q11DUP 242 F iPSC#11 no disease modeling 
7q11DUP 314 M iPSC#6 no disease modeling 
7q11DUP 809 M iPSC#12 no disease modeling 
 
Table 1: Summary table reporting information about the 13 human iPSCs lines 
included in this study. 
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The availability of brain tissues matched to the four unrelated control iPSCs lines were 
particularly valuable as their transcriptional analysis and comparison to iPSCs-derived 
neocortical neurons offered the possibility to better assess the quality of the neural 
differentiation protocol to which all iPSCs were subjected. 
 
To induce pluripotency, a non-integrating reprogramming method based on the 
transfection of episomal plasmid vectors slightly modified from Okita et al. [429, 625] has 
been chosen. In this protocol reprogramming has been achieved through nucleofection 
of four episomal plasmids encoding respectively human OCT3/4 and short harpin RNA 
against p53, human SOX2 and KLF4, human L-MYC and LIN28, EGFP. Transcription 
factors OCT3/4 and SOX2 are master regulators of the transcriptional network 
responsible of controlling and maintaining the pluripotent state [398, 399]. These two 
transcription factors belong to the original reprogramming cocktail employed in the 
Yamanaka experiment [364], along with the transcription factor KLF4 known for 
contributing to the long-term maintenance of the pluripotent state [403]. To improve the 
reprogramming efficiency in human iPSCs generation, the fourth classical transcription 
factor delivered to induce pluripotency, the oncogene c-Myc, has been substituted by 
another member of the Myc family of transcription factors, L-Myc [626]. Always having in 
mind to further enhance the reprogramming efficiency in human cells, the RNA-binding 
protein LIN28 was added to the reprogramming cocktail [367] and the tumor suppressor 
protein p53 was silenced through short hairpin RNA targeting [626]. Along with the 
plasmids containing the set of reprogramming factors of choice, an episomal vector 
encoding the enhanced green fluorescent protein (EGFP) was cotransfected into 
somatic cells to monitor its fluorescence signal as a means of reprogramming quality 
control. More specifically, EGFP fluorescence was at first monitored during the early 
phases of the reprogramming to evaluate nucleofection efficiency and in the following 
weeks, before colonies picking, it was monitored to check the progression of 
pluripotency induction.  
 
 
Figure 15: Schematic of the reprogramming protocol. In this schematic 
representation are highlighted the main events and phenotypic changes that occur 
during the episomal vector-based reprogramming protocol along with specifics of the 
culture conditions and representative pictures of the main reprogramming stages.  
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At the moment of colony picking, along with colonies morphology the absence of 
fluorescence expression was taken as an indicator that the iPSCs colonies selected for 
further expansion no longer retained the episomal plasmids. Reprogramming 
experiments were continued only if at least 20% of the nucleofected cells were EGFP-
positive 4-6 days post-transfection. The fluorescence signal reached a pick 
approximately 2 weeks after nucleofection and started to decrease thereafter, indicating 
the progressive reduced persistence of episonal plasmids in transfected cells and finally 
their complete absence as expected from this non-integrating gene delivery system. By 
the time iPSCs colonies were ready to be manually picked, one of the parameters on 
which clonal selection was based was the non-detectability of the fluorescence signal 
through eye inspection in the colony of choice. 
 
All reprogramming experiments performed in this study started from primary human 
fibroblasts cultures that were derived from skin or meninges biopsies through manual 
dissection and were subsequently cultured in fibroblasts medium (see Materials and 
Methods). After expansion, fibroblasts were nucleofected with the four episomal 
plasmids described above. Transfected cells were cultured until confluent for 
approximately 2 weeks and then replated at a lower density to avoid overconfluence and 
to enable clonal generation of iPSCs colonies. During these first stages of the 
reprogramming, transfected cells were cultured on matrigel-coated plates [627] in 
Essential 6 medium [628], a commercial chemically defined and xeno-free medium 
produced according to cGMP requirements and optimized to support the reprogramming 
of somatic cells. To optimize the reprogramming of human cells, Essential 6 medium 
was supplemented with basic fibroblast growth factor (bFGF) in combination with sodium 
butyrate to improve the reprogramming efficiency and hydrocortisone to stimulate 
transfected fibroblasts proliferation. Hydrocortisone was administrated until cell density 
reached 50% of confluence and sodium butyrate was withdrawn from the medium 2-4 
days after replating while bFGF was consistently supplied at the same concentration. 
Under these culture conditions, iPSCs colonies intermingled with fibroblasts started to 
appear approximately 20 days after transfection and in the following 5-10 days promising 
individual iPSCs colonies were selected and manually picked for further clonal 
expansion. Clone selection was based on the lack of expression of EGFP fluorescence 
signal in the colony and on the visual evaluation of colony and cell morphology. Tightly 
packed colonies with round defined borders and composed of cells with a high nucleus-
to-cytoplasm ratio were selected for further clonal expansion. Manually picked colonies 
were seeded on matrigel-coated plates and cultured in Essential 8 Flex medium [628-
630] for long-term maintenance and cryopreservation. Also Essential 8 Flex medium is a 
commercial chemically defined, xeno-free and serum-free medium that differs from the 
reprogramming medium for the addition of TGFβ1 and for the substitution of key 
unstable heat-sensitive components with optimized analogs that have an extended 
activity, thus removing the requirement of changing the medium daily. Routine 
passaging of iPSCs colonies has been performed using EDTA when cells reached 
approximately 85% confluence [631]. EDTA-based splitting enables to routinely passage 
iPSCs colonies as small aggregates. As this passaging method is E-cadherin 
dependent, it just relies on chemically loosening direct cell-cell and cell-substrate 
adhesion without the necessity of enzyme neutralization, centrifugation or drug 
administration and therefore it allows to maximize cell survival. Furthermore, as EDTA 
treatment harvests iPSCs colonies faster than more differentiated cells, it also enables 
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differential dissociation and intrinsically sustains the purity of the culture, thus reducing 
the opportunities for contamination since manual cleaning is rarely required.   
4.2 Pluripotency validation of human induced pluripotent stem cell 
lines  
 
Before starting the quality controls aimed at validating pluripotency, iPSCs clones were 
cultured until at least passage 5 after manual picking. The rationale behind this choice 
was to allow enough time for eliminating plasmid persistence from iPSCs clones while 
starting to assess their pluripotency at low passages to both minimize the potential onset 
of chromosomal abnormalities due to long-term culture and to optimize time and costs. 
The first screening step has been inspecting several clones for each human iPSCs line 
for integration of exogenous reprogramming factors and positively selecting only 
transgene-free clones for further analysis (Figure 16 B-C). To assess whether episomal 
plasmids were integrated into the genome of individual iPSCs clones, their DNA was 
extracted and PCR was performed using a primer pair designed on the EBNA-1 
sequence derived from Epstein-Barr virus that is present in all four nucleofected 
plasmids (Figure 16A). Then, karyotype analysis was performed to rule out the presence 
of chromosomal abnormalities and it enabled to confirm that all selected iPSCs clones 
had a normal karyotype (Figure 17 F,M,T). To confirm that iPSCs clones met the 
standard criteria to assess pluripotency, the expression of a panel of selected classical 
nuclear and surface pluripotency markers was checked through immunofluorescence. All 
iPSCs colonies examined were found positive for the transcription factors critically 
involved in the maintenance of the pluripotent state OCT4, SOX2, Nanog as well as for 
the mambrane antigens selectively expressed on the surface of pluripotent stem cells 
TRA-1-60 and the stage-specific embryonic antigen-4 (SSEA-4) (Figure 17: A-E Williams 
syndrome, H-L healthy controls, O-S 7q-microduplication syndrome). The combined 
expression of these markers was a first evidence that all human iPSCs clones generated 
are indeed pluripotent. Furthermore, to test the differentiation potential of selected iPSCs 
clones in vivo, teratoma formation assay was performed. Briefly, iPSCs cells were 
injected subcutaneously into immunodeficient SCID mice and after approximately 2 
months all mice developed detectable tumors. Histological examination through 
hematoxylin and eosin staining confirmed that the extracted tumors were teratomas and 
contained tissues of all the three germ layers (Figure 18 G,N,U). The combination of the 
results obtained from this panel of assays enabled to determine that all selected iPSCs 
clones are pluripotent (Figure 17). Further prove of the differentiation potential of 
selected iPSCs clones into all the three primary germ layers also in vitro came from the 
analysis of the products of embryoid bodies formation assay that was performed on a 
subset of iPSCs clones generated from control lines (Figure 18). In this standard 
pluripotency test, iPSCs were cultured in suspension as three-dimensional aggregates 
for one week in a basic differentiation medium containing fetal bovine serum (FBS) and 
subsequently replated and grown in the same medium as a monolayer culture for two-
three additional weeks prior to fixation and immunofluorescence staining for key markers 
of the three germ layers.  
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Figure 16: Assessment that the episomal plasmids are non-integrated into the 
genome of the generated iPSCs lines. A. Plasmid maps of the four episomal vectors 
adopted to generate iPSCs. Underlined in red is the EBNA-1 region common to all 
vectors onto which the primers employed in the PCR were designed on. B-C. PCR 
results of the integration check demonstrating that the selected human iPSCs clones are 
transgene-free. Untransfected fibroblasts and water have been used as negative 
controls while cell samples collected during the early stages of the reprogramming 
protocol and the four reprogramming episomal plasmids have been employed as 
positive controls. In B are reported the results for the four human iPSCs lines derived 
from unrelated individuals that were adopted to extensively characterize the neocortical 
differentiation protocol while in C are reported the results for the nine human iPSCs lines 
generated from a cohort including individuals affected by typical Williams-Beuren 
syndrome (WS 361, WS 728, WS 1574, WS 5437), unaffected healthy relatives (WS 
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361-1, WS 728-1) and 7q11.23 duplication syndrome patients (7q11DUP 242, 7q11DUP 
314, 7q11DUP 809). 
 
Figure 17: Human iPSCs lines characterization. Representative images of the 
pluripotency validation controls performed on human iPSCs lines derived from Williams 
syndrome affected individuals (top panel: A-G), healthy controls (middle panel: H-N) and 
7q-microduplication patients (bottom panel: O-U). A-E, H-L, O-S. Representative 
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immunofluorescence stainings for the nuclear pluripotency markers OCT4, Nanog, 
SOX2 and for the surface markers SSEA-4 and TRA-1-60. Selected clones of all the 
human iPSCs lines examined presented a strong expression of all these markers. Scale 
bar: 100 µm. F,M,T. Representative karyotype analysis results indicating a normal 
karyotype in all the selected iPSCs clones. G,N,U. Representative hematoxylin and 
eosin stainings of iPSC-derived teratomas demonstating the presence of tissues 
belonging to the three germ layers, ectoderm (G’, N’, U’), mesoderm (G’’, N’’, U’’), and 
endoderm (G’’’, N’’’, U’’’) in all the selected iPSCs clones. Scale bar: 100 µm. 
 
Expression of two key cytoskeletal proteins including the type VI intermediate filament 
(IF) protein Nestin that is a maker of neural stem cells and neural progenitors and the 
microtubule protein β–III tubulin that is a marker of early postmitotic neurons confirmed 
that all human iPSCs lines tested were able to differentiate into ectodermal cells. 
Mesoderm differentiation potential was assessed monitoring the expression of the 
ckytoskeletal protein alpha smooth muscle actin (αSMA), a marker of myofibroblasts. 
Finally, evidence that the generated human iPSCs were able to form also endodermal 
tissues came from the positivity for both the plasma protein alpha-fetoprotein (AFP) and 
the transcription factor hepatocyte nuclear factor 3-beta (HNF3β, encoded by the FOXA2 
gene) that are expressed in the developing liver.  
 
 
Figure 18: Embryoid bodies formation assay. Embryoid bodies (EBs) formation assay 
was applied to a subset of iPSCs clones derived from   to assess the differentiation 
potential of the generated human iPSCs also in vitro. Immunocytochemical stainings of 
differentiated embryoid bodies with antibodies selectively marking cells derived from the 
three germ layers. A-B. Nestin and β-III tubulin expression demonstrates differentiation 
toward ectodermal fates. C. αSMA positivity indicates mesodermal differentiation. D-E. 
The expression alpha fetoprotein (AFP) and FOXA2 confirmed the presence of 
endodermal cells. Scale bar: 50 µm. 
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Chapter 5.Extensive characterization of a pluripotent 
stem cells based differentiation protocol for 
the in vitro generation of authentic human 
neocortical neurons 
5.1 Pluripotent stem cells based directed neocortical differentiation 
protocol  
 
In this study we applied a pluripotent stem cells (PSCs) based directed neocortical 
differentiation protocol that recapitulates in vitro the main in vivo neurodevelopmental 
events. The feeder-free differentiation protocol adopted comprise two phases, a first 
neural induction phase at the end of which PSCs become telencephalic neuroepithelial 
cells followed by a prolonged terminal differentiation phase that allows patterned 
neuroepithelial cells to acquire full maturation. The small molecules based strategy 
employed integrates several previously published neural induction [176] and neocortical 
differentiation protocols [375, 376] in a new synthesis to generate the major subtypes of 
human neocortical progenitors cells and neurons with high efficiency and in less 
proportions glial cells. All the stages of the differentiation protocol are performed in 
adherent monolayer culture conditions and using chemically defined media. Neural 
induction was achieved by adopting a dual SMAD inhibition strategy combined with Wnt 
signaling inhibition. Dual inhibition of SMAD signaling to induce neural conversion was 
first employed by Studer’s group [176] and since then it has become a milestone small 
molecules-based strategy to convert PSCs into neuroepithelial cells with high efficiency 
in just 11 days. The rational behind the dual SMAD inhibition strategy is based on the 
knowledge that ectodermal cells have an autonomous tendency to acquire neural 
identities when the transforming growth factor-β (TGF-β) signaling pathway is not 
activated [165-171, 466, 630]. Therefore, neural conversion was achieved exploiting the 
synergistic action of two small molecules that act on different branches of the 
transforming growth factor-β (TGF-β) signaling pathway by competing with TGF-β 
ligands for binding to their cognate receptors [176]. Specifically, the small molecule LDN-
193189 is used as an inhibitor of bone morphogenetic protein (BMP) type I receptors 
ALK2 and ALK3, that in their active form are responsible for the recruitment and 
subsequent phosphorylation of SMAD1, SMAD5 and SMAD8 [173, 632, 633]. Inhibition 
of BMP-mediated TGF-β signaling prevents differentiation toward trophectoderm and 
ectodermal fates [176]. Moreover, inhibition of TGF-β/Activin/NODAL pathway is 
achieved through SB-431542 administration. SB-431542 is a small molecule that 
selectively inhibits bone morphogenetic protein (BMP) type I receptors ALK4, ALK5 and 
ALK7 [633-635]. In their active form these type I receptors recruit and activate SMAD2 
and SMAD3 through phosphorylation [172, 173]. Inhibition of the TGF-β/Activin/NODAL 
pathway promotes the exit from the pluripotent state by reducing Nanog expression 
levels [636] and suppresses differentiation toward the mesodermal lineage [176]. To 
increase the generation efficiency of neuroepithelial cells patterned toward telencephalic 
fates [287] and further promote the disruption of the pluripotent state [637], iPSCs were 
also exposed to Wnt signaling inhibition, that was accomplished by administrating 
XAV939 during the neural induction phase. This chemical compound inhibits Wnt/β-
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catenin-mediated transcription by repressing tankyrase 1 [638]. The combined exposure 
to these three chemical compounds results in a highly efficient generation of 
telencephalic neuroepithelial cells competent to form neural rosettes, that are two 
dimensional in vitro radial arrangements of columnar cells mimicking in vitro the 
developing neural tube. This highly homogenous cell population is then replated at the 
end of the neural induction phase and grown in a neuronal medium only supplemented 
with brain derived neurotrophic factor (BDNF) until all the major cell types populations of 
neocortical neurons are generated and have achieved functional maturity. Interestingly, 
the differentiation protocol mimics in vitro the sequential generation of human neocortical 
pyramidal neurons, with deep layer neurons being generated first followed by the 
appearance and maturation of upper layer neurons. Therefore, at the end of 
differentiation protocol after 80 days of in vitro differentiation, both mature deep layer 
and upper layer pyramidal neurons are produced accompanied by inhibitory 
interneurons and minor populations of glial cells. This protracted time of in vitro 
differentiation closely recapitulates the timespan of human cortical neurogenesis that is 
thought to last for approximately 100 days [115].  
 
Figure 19: Schematic of the neocortical differentiation protocol adopted in this 
study. The main cell types emerging during in vitro neurogenesis are represented. The 
media and substrates used in each differentiation phase are reported below along with 
representative pictures and specifics of the informative cell fate and cell-stage specific 
markers monitored through immunocytochemistry at each time point to confirm the 
generation of the expected cell types. The differentiation protocol applied in this study 
integrates several previously published neocortical differentiation protocols [176, 375, 
376] in an optimized synthesis. 
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This differentiation paradigm has been applied in the first part of this study to four 
different human induced pluripotent stem cells (iPSCs) lines to assess its reproducibility 
and ability to generate authentic human neocortical progenitors cells and neurons in vitro 
with high efficiency. In the second phase of this study, this differentiation strategy has 
been applied to iPSCs lines generated from patients affected by either deletion or 
duplication of the Williams-Beuren syndrome chromosome region (WBSCR) located on 
the long arm (q) of chromosome 7 at position 11.23 (7q.11.23 locus) and additional 
family-matched control lines to model in vitro these two human neurodevelopmental 
disorders.  
5.2 Integrative analysis of iPSCs-derived neuronal populations 
obtained at different in vitro neurodevelopmental stages 
 
Given the importance to rely on a solid and highly reproducible differentiation protocol 
that generates authentic neocortical neurons in vitro with high efficiency before applying 
it as model system to investigate the molecular mechanisms underlying the two 
syndromes resulting from 7q11.23 CNVs, we decided to perform a comprehensive 
characterization of the in vitro neurodevelopmental process. This extensive analysis has 
been performed on four control human induced pluripotent stem cells (iPSCs) lines.  
 
Neocortical neurons have been generated from two separate clones of each iPSCs line 
to better evaluate the reproducibility of the differentiation paradigm and to finely 
discriminate the degree of variability due to inter-line and intra-line differences. General 
information about iPSCs lines and clones are reported in Table 2. On these eight human 
iPSCs clones we performed an integrative analysis of the iPSCs-derived neuronal 
populations obtained at four different time points of in vitro neurogenesis, when specific 
cell types are expected to appear during the differentiation paradigm: 
i)  day 0, pluripotent stem cells,   
ii)  day 10-14, neuroepithelial cells,   
iii)  day 36-42, neocortical progenitor cells intermingled with deep layer (cortical layers 
V/VI) pyramidal neurons and inhibitory interneurons,   
iv)  day 80-83, deep and upper layer (cortical layers II/III) pyramidal neurons and 
inhibitory interneurons accompanied by neocortical progenitor cells and minor 
populations of glial cells.   
 
The transcriptional dynamics regulating in vitro neocortical differentiation have been 
investigated by performing RNA-sequencing (RNA-seq) at both population and single-
cell level. In order to assess how well our in vitro iPSCs-based system was able to 
reproduce the essential features of in vivo neurodevelopment and to determine to which 
in vivo neurodevelopmental period were related the different in vitro differentiation 
stages, population level transcriptional data obtained from iPSCs-derived neuronal cells 
collected at different time points have been compared to the transcriptional profiles of 
donor-matched and unmatched brains included in the reference brain’s transcriptome 
atlas BrainSpan, generated in our laboratory. The presence of specific cell types was 
also validated by monitoring the expression of a panel of informative cell fate and cell-
stage specific markers through immunocytochemistry. Moreover, the functional maturity 
of iPSCs-derived neocortical neurons obtained at the end of the differentiation protocol 
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was determined by monitoring their firing properties and spontaneous synaptic activity 
as well as their passive properties through whole-cell patch clamp recordings. Overall, 
this integrative panel of analyses enabled an in-depth characterization of the 
transcriptional, cellular and physiological signatures of the neuronal populations obtained 
at different in vitro differentiation stages, fully validating the reproducibility of the 
optimized neocortical differentiation protocol of choice and its efficiency and reliability in 
generating all the major subtypes of neocortical progenitors cells, pyramidal neurons and 
inhibitory interneurons with high efficiency.  
5.2.1 Transcriptional analysis of human induced pluripotent stem 
cells-derived neuronal cells 
 
RNA-sequencing was performed on a total of 35 cell samples collected at four different 
time points of in vitro neocortical differentiation and on 4 additional matched brain 
specimens. Single or replicate differentiations were conducted on two distinct clones for 
each of the four distinct human iPSCs lines and one specific area of each matched brain 
was selected for sequencing. Details providing general information of the samples are 
reported in Table 2. Total RNA was extracted using RNeasy Plus Mini kit and 500 ng of 
each sample were employed to prepare cDNA libraries with Illumina TruSeq 
Stranded Total RNA LT Sample Prep Kit. cDNA libraries were provided to the Yale 
Center for Genomic Analysis where paired-end RNA sequencing was performed on 
Illumina Hi Seq2000 to an average depth of 100M reads per sample. Raw sequencing 
data were first processed with FastQC to have an initial assessment of data quality and 
identified low quality reads were filtered out before proceeding to sequence alignment 
against GRCh38/hg38, using the Spliced Transcripts Alignment to a Reference (STAR) 
software [639]. RSEQtools, SAMtools and UCSC applications were employed to convert 
sequence alignment data in BAM format to MRF format and to complete a wide variety 
of tasks including quantification of expression values, identification of transcriptional 
active regions, manipulation of gene annotation sets, visualization of the mapped reads 
and generation of signal tracks. Subsequent data processing with conditional quantile 
normalization (CQN) and ComBat packages in R enabled to correct for gene length, 
gene GC content, sequencing site and batch effects.  
 
Sample 
ID Sex Age iPSCs clone 
Number of 
replicate 
differentiations 
Matched 
brain 
HSB 286 M 20 pcw 
iPS#7 2 Parietal CX iPS#20 1 
HSB 292 M 13 pcw 
iPS#7 1 Parietal CX iPS#38 1 
HSB 311 F 8 pcw iPS#1 1 Dorsal telencephalon iPS#36 1 
HSB 314 M 8 pcw iPS#43 1 Dorsal telencephalon iPS#47 1 
 
Table 2: Summary table reporting the information about the 35 cell samples 
comprising iPSCs and iPSCs-derived neuronal cells along with the specifications 
of the respective four matched-brains used for RNA-sequencing. 
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To examine the contribution of different variables to the global transcriptional dynamics 
orchestrating in vitro neocortical differentiation, we performed principal component 
analysis (PCA) including data from iPSCs, their neural derivatives and selected 
informative human prenatal brain tissue specimens comprised in the reference brain’s 
transcriptome atlas BrainSpan, generated in the laboratory (www.brainspan.org). 
Principal component analysis (PCA) is a data reduction technique that enables to 
determine the variables having the biggest effect on variability in data. In our case PCA 
shows that samples cluster mainly on the basis of their in vitro differentiation stage 
(Figure 20). 
 
 
Figure 20: Principal component analysis (PCA) of iPSCs and iPSCs-derived 
neuronal cells samples. PCA demonstrates that cell samples cluster on the basis of 
their in vitro developmental stage and enables to assess to which in vivo 
neurodevelopmental period are related the different in vitro differentiation stages. The 
percentage of data variability accounted for by each principal component is reported in 
parenthesis.  
 
This finding has been further confirmed by covariate analysis on the principal 
components (PCs) which indicates that the differentiation stage contributed more to the 
global differences in gene expression than any other sample-dependent and 
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sequencing-dependent tested variable (Figure 21). The sample-dependent variables 
examined included sex, age, differentiation stage while the sequencing-dependent 
variables investigated comprised flow cell, read length, raw reads, uniq percent, uniq 
reads, rRNA and tRNA counts. 
 
 
 
 
Figure 21: Heatmap of the covariate analysis performed on the principal 
components (PC) related to sample-dependent and sequencing-dependent 
variables. In parenthesis are reported the percentages of data variability accounted for 
by each principal component. 
 
PCA results also highlighted that at all the time points analyzed the contributions to data 
variability due to inter-line and intra-line differences are comparable. This finding 
indicates that the differences detected between samples can be ascribed to the intrinsic 
biological variability of how each single iPSCs clone responds to the differentiation 
paradigm rather than to a diversity between different iPSCs lines. More specifically, 
considering each in vitro differentiation time point separately, samples collected at day 0 
and at day 10-14 form more compact clusters while samples collected at day 36-42 and 
day 80-83 are less clustered together and intermingled in some cases (Figure 20). This 
observation can be explained by the different differentiations rates at which in vitro 
neurons are maturing. The more advanced along the differentiation timeline is the time 
point analyzed, the more apparent becomes the intrinsic biological variability of how 
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distinct iPSCs clones respond to the differentiation protocol, with some iPSCs clones 
being able to differentiate more prematurely than others.  
 
The inclusion in the analysis of also human prenatal brain tissue specimens enabled to 
assess how well the transcriptional profiles of our iPSCs-derived neuronal cells reflected 
those of neurons obtained from human brain samples and to infer to which in vivo 
neurodevelopmental period were related the different in vitro differentiation stages. As 
clearly shown in the PCA plot and further confirmed by correlation analysis, iPSCs-
derived neuronal cells generated at all the different time points clustered closely and had 
a high correlation with human prenatal brain-derived neurons (Figure 20, Figure 22). 
Specifically, iPSCs-derived neuronal cells obtained at the end of the neural induction 
phase show a high correlation with human embryonic forebrain samples (4 pcw, 
Carnegie stage 12) while iPSCs-derived neurons generated at intermediate stages of 
the differentiation protocol are highly correlated with human early fetal dorsal 
telencephalon specimens (8 pcw) (Figure 22). In agreement with the progression of in 
vitro neurogenesis, iPSCs-derived neocortical neurons obtained at the end of the 
differentiation paradigm show the highest correlation with human early mid fetal parietal 
cortex tissues (13 pcw and 16-17 pcw) (Figure 22). 
 
Figure 22: Correlation analysis of the transcriptomes of human iPSCs, iPSCs-
derived neuronal cells and human brain tissue samples. This analysis reveals the 
correlation between the different in vitro differentiation stages and in vivo 
neurodevelopmental periods. The numbers of donor-matched and additional BrainSpan 
brain tissue specimens included in the analysis are reported in the top legend. 
 
To better investigate the transcriptional changes occurring along in vitro neocortical 
development, we performed differential gene expression analysis. This analysis 
identified a total number of 28094 differentially expressed genes (DEGs) between the 
four different in vitro differentiation stages investigated. The specific number of DEGs 
detected performing pairwise comparisons between the four selected time points are 
summarized in Table 3.  
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Table 3: Table summarizing the number of differentially expressed genes (DEGs). 
DEGs were identified by performing pairwise comparisons between the four different 
time points of in vitro differentiation investigated and always comparing more 
differentiated in vitro stages to less differentiated ones. In light blue squares are 
indicated the total number of DEGs while in red and in green are reported the total 
numbers of upregulated and downregulated DEGs respectively. Upregulated and 
downregulated DEGs denote the genes that have increased or decreased expression 
with respect to the most differentiated in vitro stage of each comparison. 
 
GO enrichment analysis performed on the identified DEGs enabled to gain the first 
insights about in vitro neocortical differentiation progression and the cell types generated 
at different time points of in vitro neurogenesis. Top-ranking biological process 
categories for the 2409 genes upregulated at the end of the neural induction phase with 
respect to the pluripotent state included “nervous system development” (GO:0007399), 
“neural stem cell population maintenance” (GO:0097150), “Notch signaling pathway” 
(GO:0007219), “regulation of cell-cell adhesion” (GO:0022407) and “central nervous 
system development” (GO:0007417), indicating the correct conversion of iPSCs into 
neuroepithelial stem cells after 10-14 days of in vitro differentiation. Progressing along in 
vitro development, the most enriched biological process categories for the 1640 DEGs 
identified through the comparison of intermediate in vitro time points to earlier 
differentiation stages comprised again terms related to “nervous system development” 
(GO:0007399) and “central nervous system development” (GO:0007417) which confirm 
the neural lineage commitment of differentiating cells as well as terms related to “neuron 
migration” (GO:0001764),“axonogenesis” (GO:0007409), “axon guidance” 
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(GO:0007411), “chemical synaptic transmission” (GO:0007268), “neurotransmitter 
secretion” (GO:0007269), “regulation of glutamatergic synaptic transmission” 
(GO:0051966), “glutamate secretion” (GO:0014047) and “calcium ion-regulated 
exocytosis of neurotransmitter“ (GO:0048791)  indicating the successful generation of 
functional pyramidal neurons starting from intermediate differentiation time points. 
Moreover, GO enrichment analysis performed on the 659 upregulated DEGs at the end 
of the in vitro paradigm with respect to intermediate differentiation stages highlighted as 
enriched categories many of those already identified in the previous comparison 
between the in vitro differentiation temporal windows of 36-42 days and 10-14 days 
confirming the further maturation of iPSCs-derived neocortical neurons. The acquisition 
of more functionally developed neuronal phenotypes with respect to previously 
examined time points was corroborated by the enrichment in many biological process 
categories related to ion transmembrane transport (GO:0006813, GO:0034220, 
GO:0035725, GO:1902476, GO:0071805, GO:0010107) and synaptic transmission 
(GO:0007215, GO:0048791) combined with cellular component terms associated to 
voltage-gated ion channels (GO:1901387, GO:1905152, GO:0008076, GO:1901387,  
GO:0032414) and synapses formation (GO:0014069, GO:0042734, GO:0030666, 
GO:0008021, GO:0045211, GO:0048786). GO enrichment analysis of DEGs detected in 
the other pairwise comparisons across the different differentiation time points also 
identified many categories indicating the successful generation of neocortical neurons 
starting from intermediate differentiation stages that further reached morphological and 
functional maturity by the end of the in vitro protocol.  
 
As many of the DEGs identified through pairwise comparisons are overlapping, we also 
examined their distribution to better determine how they were specifically related to in 
vitro neurodevelopmental dynamics. We first explored the distribution of DEGs 
comparing the three representative differentiation time points to the pluripotent state 
(day 0) (Figure 23 A-A’). Then, we also investigated DEGs distribution between different 
in vitro differentiation time points, always comparing more differentiated in vitro stages to 
less differentiated ones (Figure 23 B-B’). GO enrichment analysis and KEGG pathway 
analysis were performed also on all the distinct gene lists generated by exploring DEGs 
distributions across the different time points. Top-ranking GO biological process 
categories upregulated in the pluripotent state included many terms related to cell cycle 
and mitosis (GO:0000083, GO:0006260, GO:0000278, GO:0007080, GO:0051726, 
GO:0000070) indicating the active proliferation of iPSCs. In agreement with the 
expected generation of neuroepithelial cells at the end of the neural induction phase, the 
most enriched GO categories detected for genes upregulated in samples collected at 10-
14 days of in vitro differentiation included terms related to Notch signaling 
(GO:0007219), cell fate commitment (GO:0045165) and specifically telencephalon 
development (GO:0021537) combined with terms indicating the negative regulation of 
alternative cell lineage identities (GO:0042664, GO:2000691, GO:0032331, 
GO:1903444, GO:1904761).  Among GO categories most enriched for DEGs 
upregulated at intermediate differentiation stages, we detected terms associated to 
positive regulation of cell migration (GO: 0030335, GO:0001764), cell differentiation and 
acquisition of neuronal identities (GO:0030154, GO:0030182, GO:0045666, 
GO:0007268, GO:0007411) in addition to terms related to central nervous system 
development (GO:0007417, GO:0007420, GO:0009953, GO:0048663) suggesting the 
successful generation of postmitotic neocortical neurons after 36-42 days of in vitro 
differentiation. Moreover, GO enrichment analysis performed on DEGs upregulated at 
the end of the differentiation process identified several terms related to synapse 
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maturation and functioning (GO:0060074, GO:0090126, GO:0090127, GO:0007268, 
GO:0098916) as well as electrophysiological activity (GO:1904457, GO:2000463, 
GO:0060079, GO:0042391, GO:0051969) further indicating the presence in culture of 
functionally mature neurons.  
 
 
Figure 23: Number and distribution of DEGs among the different in vitro 
differentiation stages. A-A’. Distribution of upregulated and downregulated DEGs 
identified by comparing the three representative differentiation time points to the 
pluripotent state. B-B’. Distribution of upregulated and downregulated DEGs identified by 
comparing time points at which neuronal populations have been generated (day 36-42 
and day 80-83) to the end of the neural induction phase (day 10-14). 
 
We next examined the functional organization of the transcriptional changes underlying 
in vitro differentiation by performing weighted gene co-expression network analysis 
(WGCNA) [640]. WGCNA is a correlation network methodology that enables to describe 
the relationship between gene transcripts by constructing co-expression networks where 
each gene expression profile corresponds to a node and the edges represent the degree 
of correlation between different gene expression profiles calculated through pairwise 
comparisons. Gene transcripts that present similar expression patterns form clusters of 
highly interconnected genes known as co-expression modules. The gene transcripts that 
display the highest connectivity among a module are known as hub genes and the first 
principal component of each module is the module eigengene whose expression pattern 
is considered representative of the transcriptional profile of the module. In our study 
WGCNA identified 46 modules (Figure 24).  
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Figure 24: WGCNA cluster dendrogram on all 35 iPSCs and iPSCs-derived 
neuronal cells samples groups genes in 46 distinct modules. Module assignments 
are denoted in the bottom color bar.  
 
Inspection of modules eigengenes expression enabled to establish the potential relation 
of distinct modules to specific in vitro developmental stages and developmental 
trajectories. Remarkably, genes comprised in module 4 were highly expressed in the 
pluripotent state and their expression decreased with the progressive acquisition of 
neocortical identities (Figure 25). Members of module 7 were characterized by a peak of 
expression at the end of the neural induction phase (Figure 26) while genes composing 
module M14 were upregulated during intermediate differentiation stages displaying an 
enhanced expression in samples collected at day 10-14 and day 36-42 (Figure 27). 
Instead, module 2 genes displayed an increased expression throughout the 
differentiation paradigm reaching a peak at the end of the differentiation protocol (Figure 
28). Furthermore, genes constituting module 3 were upregulated beginning from day 36-
42 of differentiation when deep layer pyramidal neurons and inhibitory interneurons start 
to be generated in vitro (Figure 29) and module 24 genes were selectively upregulated 
at the end of the differentiation paradigm, when more mature iPSCs-derived neocortical 
pyramidal neurons belonging to both deep and upper layers and inhibitory interneurons 
are produced (Figure 30). To gain a better understanding of the functional relevance of 
these selected modules, we performed also on them GO enrichment analysis and KEGG 
pathway analysis.  
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In agreement with the peak of expression of module 4 eigengene in the pluripotent state 
and its progressively decreased expression at later neocortical differentiation stages, GO 
enrichment analysis revealed that top-ranking biological process and molecular function 
categories associated to this module were mainly related to mitosis, cell cycle and cell 
proliferation (Figure 25 C).  
 
 
 
Figure 25: Analysis of module 4 identified through WGCNA. A. Module 4 eigengene 
expression at the four in vitro differentiation time points analyzed. Eigengene expression 
for each sample is reported as dot and the line represents the developmental trajectory 
based on its mean expression values at each time point. B. Top enrichments for GO 
cellular component terms. C. Top enrichments for GO biological process categories.  
 
These findings were also confirmed by the inspection of enriched GO cellular 
components categories that were mainly related to the nucleus and chromosomes 
(Figure 25 B). KEGG pathway analysis further corroborated these results detecting 
pathways as cell cycle (KEGG: 04110), DNA replication (KEGG: 03030), oocyte meiosis 
(KEGG 04114), progesterone-mediated oocyte maturation (KEGG: 04914) and p53 
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signaling pathway (KEGG: 04115). Overall, the enrichment in GO categories and 
pathways related to mitosis, cell cycle and cell proliferation associated to this module 
reflects the active proliferation that distinguishes the pluripotent state which is 
increasingly reduced with the progressive acquisition of mature neuronal phenotypes 
along the in vitro differentiation paradigm. 
 
On the other hand, consistent with the peaked expression of its eigengene at the end of 
the neural induction phase (Figure 26 A), module 7 most enriched GO biological process 
terms were related to cell maturation, cell differentiation and the acquisition of 
telencephalic identities (Figure 26 C). Analysis of GO molecular function terms detected 
as top-ranking several categories related to sequence-specific DNA binding RNA 
polymerase II transcription factor activity, DNA binding and protein binding suggesting 
the occurrence of transcriptional modifications involved in cell fate specification. In 
agreement with this findings, the most enriched GO cellular component categories 
included terms related to the nucleus, intracellular part and cell membrane as expected 
given the rapid cell identity transition that neuroepithelial cells are undergoing at this 
early neocortical differentiation stage (Figure 26 B). 
 
Figure 26: Analysis of module 7 identified through WGCNA. A. Module 7 eigengene 
expression at the four in vitro differentiation time points analyzed. Eigengene expression 
Part II: Results 
 71 
for each sample is reported as dot and the line represents the developmental trajectory 
based on the mean expression values at each time point. B. Top enrichments for GO 
cellular component terms. C. Top enrichments for GO biological process categories.  
 
Less selectively than transcripts composing module 7, transcripts comprised in module 
14 displayed an increased expression at intermediated stages of in vitro differentiation 
as evident from the inspection of the developmental trajectory followed by this module’s 
eigengene (Figure 27 A). Enriched GO biological processes associated to this module 
comprised categories related to the regulation of neurogenesis, neural plate 
anterior/posterior regionalization, neural stem cell maintenance, maintenance of 
apical/basal cell polarity, cell-cell signaling and cell-cell adhesion (Figure 27 C). 
Moreover, the detection of enriched GO biological process terms related to mitosis and 
regulation of the cell cycle further denoted the presence of actively proliferating cells 
committed to the neural lineage (Figure 27 C).  
 
 
 
 
Figure 27: Analysis of module 14 identified through WGCNA. A. Module 14 
eigengene expression at the four in vitro differentiation time points analyzed. Eigengene 
expression for each sample is reported as dot and the line represents the developmental 
trajectory based on the mean expression values at each time point. B. Top enrichments 
for GO cellular component terms. C. Top enrichments for GO biological process 
categories.  
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The enrichment in molecular function terms associated to the regulation of transcription 
(GO: 0008134, GO: 0001191), chromatin modification (GO: 0003682) and DNA binding 
(GO: 0003677) further suggests that iPSCs-derived neuronal cells present in culture at 
these intermediate in vitro differentiation stages are actively transitioning to different 
cellular identities. Enriched GO cellular component terms including nucleus, 
chromosome and cytoplasm were also in agreement with the other GO analyses findings 
(Figure 27 B). The presence in culture of proliferating neural stem cells and neocortical 
progenitors was further corroborated by the enrichment for GO molecular function 
categories related to Notch binding (GO: 0005112) and the detection of Notch signaling 
pathway (KEGG: 04330) through KEGG pathway analysis. In addition to neocortical 
progenitor cells, the generation of neocortical neurons at intermediate stages of in vitro 
differentiation was indicated by the enrichment in many cellular component categories 
related to synaptogenesis (GO:0070044, GO:0042734, GO:0045202, GO:0045211, 
GO:0070032, GO:0014069, GO:0019717, GO:0032279), voltage gated-channels 
(GO:0001518, GO:0034704), axonal growth (GO:0030462, GO:0044295) and dendrite 
development (GO:0032839) (Figure 27 B) and further supported by the identification of 
axon guidance (KEGG:04360) through KEGG pathway analysis. Overall, these data are 
in agreement with the expected acquisition of neuroepithelial stem cells identities by the 
majority of cells present in culture at the end of the neural induction phase and with the 
generation of neocortical progenitor cells intermingled with deep layer pyramidal neurons 
and inhibitory interneurons in the temporal window comprised between 36 and 42 days 
of in vitro neurogenesis. 
 
Then, GO and KEGG pathway enrichment analyses were performed on transcripts 
belonging to modules 2, 3 and 24 to evaluate the transcriptional changes associated to 
the acquisition of postmitotic neocortical neurons identities, as these modules display 
respectively an increased expression throughout the differentiation paradigm (Figure 28 
A), starting from intermediated stages of in vitro differentiation (Figure 29 A) and 
selectively at the end of the differentiation protocol (Figure 30 A) as indicated by the 
developmental trajectories followed by their eigengenes.  
  
Module 2 most enriched GO biological process, cellular component and molecular 
function categories were mainly related to synaptogenesis and physiological maturation 
and comprised also terms indicating the acquisition of complex neuronal morphologies 
(Figure 28 B, C). The acquisition of functionally mature neuronal phenotypes was 
revealed by the enrichment in many GO cellular component terms related to voltage-
gated ion channels and synaptic components (Figure 28 B). These findings were 
corroborated by the considerable number of top-ranking GO molecular function 
categories associated to ion channel activity (GO: 0005216), voltage-gated ion channel 
activity (GO: 0005244, GO: 0005242, GO: 0015269), transmitter-gated ion channel 
activity (GO: 0022824) and glutamate receptor activity (GO:0008066) which suggest that 
iPSCs-derived neuronal cells progressively become functionally mature and express the 
necessary ion channels to generate action potentials (APs). In addition, the presence of 
many top-ranking GO biological process categories associated to synaptogenesis, 
synaptic transmission and the structural and functional development of the presynaptic 
and postsynaptic terminals (Figure 28 C) further confirmed that iPSCs-derived 
neocortical cells increasingly acquire physiological maturity with the progression of in 
vitro differentiation and are able to form functional networks. In minor proportions, GO 
biological process terms associated to axonogenesis and dendritic spine morphogenesis 
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(Figure 28 C) accompanied by top-ranking GO cellular component categories related to 
the axonal growth cone, dendrite cytoplasm and microtubules (Figure 28 B) and GO 
molecular function terms indicating cytoskeletal rearrangements (GO: 00030276, GO: 
0008017, GO: 0051010), suggested neuronal morphological development along our in 
vitro differentiation paradigm. 
 
 
 
Figure 28: Analysis of module 2 identified through WGCNA. A. Module 2 eigengene 
expression at the four in vitro differentiation time points analyzed. Eigengene expression 
for each sample is reported as dot and the line represents the developmental trajectory 
based on the mean expression values at each time point. B. Top enrichments for GO 
cellular component. C. Top enrichments for GO biological process categories.  
 
Enriched GO categories associated to module 3 were broadly overlapping to top-ranking 
GO terms previously identified analyzing module 2. Though, complementary to module 2 
major focus on synaptogenesis and physiological maturation, the majority of enriched 
GO biological process, molecular function and cellular component terms linked to 
module 3 indicated neocortical neurons development and the acquisition of complex 
neuronal morphologies with less categories related to the development of functional 
maturity (Figure 29 B, C). 
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Figure 29: Analysis of module 3 identified through WGCNA. A. Module 3 eigengene 
expression at the four in vitro differentiation time points analyzed. Eigengene expression 
for each sample is reported as dot and the line represents the developmental trajectory 
based on the mean expression values at each time point. B. Top enrichments for GO 
cellular component terms. C. Top enrichments for GO biological process categories.  
 
In agreement with its characteristic developmental trajectory that reaches a plateau 
starting from intermediate stages of in vitro neurogenesis (Figure 29 A), many top-
ranking GO biological process terms were related to neocortical neurons development 
as “embryonic morphogenesis”, “nervous system”, “central nervous system” and 
“forebrain development” (Figure 29 C). Moreover, enrichment in many GO biological 
process categories related to axonogenesis, cytoskeleton organization and dendritic 
spine development and morphogenesis, constitute evidences of the generation of 
neocortical neurons with distinct neuronal morphologies (Figure 29 C) starting from 
intermediate differentiation stages. These results are further supported by the 
enrichment in GO cellular component terms as “neurons spine”, “microtubule” and 
“cytoskeleton” (Figure 29 B). Interestingly, GO molecular function categories associated 
to this module are mainly related to histone and chromatin modifications and 
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transcription factor binding further suggesting cell fate specification in the terminal 
differentiation phase. 
 
In agreement with the peaked expression of its eigengene at the end of the 
differentiation paradigm (Figure 30 A), also module 24 most enriched GO biological 
process, cellular component and molecular function categories comprised several terms 
related to neuronal development, acquisition of complex and mature neuronal 
morphologies, synaptogenesis and voltage-gated ion channels expression and function 
(Figure 30 B, C).  
 
 
 
Figure 30: Analysis of module 24 identified through WGCNA. A. Module 24 
eigengene expression at the four in vitro differentiation time points analyzed. Eigengene 
expression for each sample is reported as dot and the line represents the developmental 
trajectory based on the mean expression values at each time point. B. Top enrichments 
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for GO cellular component terms. C. Top enrichments for GO biological process 
categories.  
 
Top-ranking GO biological process terms associated to this module as “nervous system 
development”, “neuron projection regeneration”, “neurons remodeling”, “positive 
regulation of developmental growth” and “embryonic development” (Figure 30 C) broadly 
indicate that in vitro neocortical neurogenesis continues throughout the differentiation 
paradigm culminating at its end as expected. Other more specific enriched GO cellular 
component categories as “dendritic spine” and “axolemma” (Figure 30 B) suggest the 
acquisition of mature postmitotic neuronal morphologies after 80 days of in vitro 
differentiation. Neuronal morphological development is also accompanied by the 
acquisition of functionally mature neuronal phenotypes as revealed by the enrichment in 
many GO cellular component terms related to synaptogenesis and voltage-gated ion 
channels also in this module (Figure 30 B). These findings are corroborated by the 
identified top-ranking GO molecular function categories comprising ion channel activity 
(GO: 0005216), voltage-gated ion channel activity (GO: 0005244, GO: 0005242, GO: 
0015269) and transmitter-gated ion channel activity (GO: 0022824) which further 
suggest that iPSCs-derived neocortical neurons obtained at the end of the in vitro 
differentiation paradigm express the necessary ion channels to generate action 
potentials (APs). In addition, enriched GO molecular function terms broadly related to 
receptor activity (GO:004872) and more specifically highlighting glutamatergic and 
GABAergic receptor activity (GO:0004890) combined with several top-ranking GO 
cellular component categories related to synapse maturation (Figure 30 B) and GO 
biological processes terms associated to neurotransmitter secretion and the regulation of 
synapse structure, activity and plasticity (Figure 30 C) suggest that by the end of the 
differentiation protocol the synaptic terminals of iPSCs-derived neocortical neurons are 
sufficiently mature to enable neurons communication with each other and consequently 
the formation functional networks. In agreement with results obtained from GO 
enrichment analysis, the physiological maturity reached by iPSCs-derived neocortical 
neurons after 80 days of in vitro differentiation was also suggested by the enrichment for 
pathways as neuroactive ligand-receptor interaction (KEGG:04080), glutamatergic 
synapse (KEGG:04724) and long-term potentiation (KEGG:04720) identified through 
KEGG pathway analysis. 
 
5.2.2 Transcriptional analysis of human induced pluripotent stem 
cells-derived neuronal cells at single cell level 
 
To identify the distinct neuronal populations obtained at different differentiation 
stages,and further characterize their transcriptional profiles at single cell resolution, 
we performed single-cell RNA-sequencing on a total number of 1632 human iPSCs-
derived neuronal cells. Neuronal cells were collected at the same three different in 
vitro differentiation stages previously investigated also through RNA-sequencing at 
population level (Table 4). Single cells were sequenced on Illumina HiSeq 2000 in 
single-read mode performing 100 cycles. Raw data were then processed with FastQC to 
have an initial assessment of data quality and mapped to the genome. In addition to 
FastQC, as part of the quality control (QC) criteria we checked the reads aligned to 
exonic, intronic and intergenic regions and removed cells with less than 30% aligned 
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reads to coding sequences in the human genome (Figure 31 A). Next, we checked the 
reads distribution across different chromosomes and discarded from further analysis 
cells with more than 10% unique reads mapped to mitochondrial chromosome (Figure 
31 B). We further checked gene coverage uniformity as it is considered an indicator of 
RNA degradation and chose those cells with fold change of average reads coverage 
within gene less than 2. The number of cells that passed our quality controls and were 
included in subsequent analyses are also reported in Table 4.  
 
 
Figure 31. Quality control criteria applied to remove low quality single cells from 
further analysis. A. Distribution of the coding sequences (cds) mapping ratio for all 
iPSCs-derived neuronal cells. Cells with less than 30% of aligned reads mapped to 
coding sequences (cds) were discarded from further analysis. B. Distribution of the 
mitochondrial chromosome (ChrM) mapping ratio for all iPSCs-derived neuronal cells. If 
more than 10% of all aligned reads were mapped to mitochondria chromosome (ChrM), 
the cell was removed from further analysis. Thresholds are reported as red dotted lines. 
 
Samples D10-14 D36-42 D80-D83 Total 
Human iPSCs derived neurons before QC 480 480 672 1632 
Human iPSCs derived neurons after QC 356 297 429 1082 
Table 4. Number of single cells sequenced for human iPSCs-derived neuronal 
cells generated at different stages of the in vitro neocortical differentiation 
protocol. 
 
To identify the full cohort of iPSCs-derived neuronal cells generated at different in vitro 
differentiation stages, we performed clustering analysis using pcaReduce package in R 
which adopts an agglomerative unsupervised clustering approach that integrates 
principal components analysis (PCA) and hierarchical clustering [641]. Our clustering 
analysis identified 21 transcriptionally distinct neuronal populations (Figure 32). The 
majority of cells displayed transcriptional profiles of a single type, with few evidences of 
intermediate cell types.  
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Figure 32: Visualization of single-cell clusters using t-SNE. Clustering analysis 
performed on 1082 iPSCs-derived neuronal cells collected at three informative in vitro 
differentiation stages identified 21 cell clusters. Individual points correspond to single 
cells and each point is colored according to cell cluster membership. Cell clusters were 
determined using pcaReduce package in R and t-SNE representation was used only for 
visualization.  
 
We assigned our 21 clusters to 6 main cellular identities by inspecting the expression of 
known markers which resulted in the identification of 4 neuroepithelial progenitors 
(NEPs) subtypes, 3 apical radial glial cells residing in the ventricular zone (vRGCs) 
subtypes, 2 outer radial glial cells (oRGCs) subtypes, 3 intermediate progenitor cells 
(IPCs) subtypes, 5 excitatory pyramidal neurons (Ex) subtypes and 5 inhibitor 
interneurons (Int) subtypes (Figure 33). As cell classes, NEPs and vRGCs were 
distinguished by an enhanced expression in known neural stem cells marker genes as 
NES, PAX6, SOX2, PROM1, GLI3, HES1, LRIG1, PALLD, FABP7, GJA1. This 
increased expression of neural stem cells genes was accompanied by a pronounced 
downregulation of genes associated to more mature neocortical progenitors and 
neuronal phenotypes as the pan-neuronal markers DCX, MAP2, SOX4, SOX11, STMN2 
and neuronal classes or neuronal subtypes specific genes as BCL11A, BCL11B, 
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MEF2C, GAD1,GAD2, SST and NPY (Figure 33). oRGCs were characterized by an 
increased expression of subtype-specific genes as LIFR, PTPRZ1, SLC1A3, TNC, 
FAM107A and other neural stem cells markers common also to NEPs and vRGCs as 
GLI3, PAX6, SOX2 or to IPCs as VIM (Figure 33). IPCs were identified by transcriptional 
signatures distinguished by the combined expression of transcripts highly expressed 
also in oRGCs as VIM and shared with other neuronal classes as DCX, SOX4, SOX11, 
BCL11A and STMN2 (Figure 33). Both excitatory pyramidal neurons and inhibitory 
interneurons were characterized by an increased expression in pan-neuronal markers as 
MAP2 accompanied by a decreased expression in neural stem cells markers as NES, 
PROM1, GLI3, GJA1 and oRGCs markers as LIFR, PTPRZ1 and SLC1A3. Further 
analyses aimed to assigning precise cellular identities to each specific excitatory and 
inhibitory neuronal subtype identified through our unsupervised clustering approach are 
currently ongoing. 
 
 
 
Figure 33: Subtype-specific gene expression profiling at single-cell resolution. 
Representative heatmap of some cell-type specific differentially expressed genes. 
Analysis of the gene expression signatures distinctive of each identified cell cluster 
allowed to assign our 21 clusters to 6 main cellular identities comprising neuroepithelial 
progenitors (NEPs), apical radial glial cells residing in the ventricular zone (vRGCs), 
outer radial glia (oRGCs), intermediate progenitor cells (IPCs), excitatory pyramidal 
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neurons (Ex) and inhibitory interneurons (Int). Further analysis aimed to assign even 
more precise cellular identities to each cell cluster are currently ongoing. In the first top 
color bar are denoted the differentiation stages at which each cell cluster was detected 
while in the second top bar are indicated the colors assigned to each cell cluster.  
 
To confirm that our differentiation protocol properly recapitulates in vitro human 
neocortical neurogenesis respecting the sequential generation of neocortical pyramidal 
neurons, we examined the neuronal populations generated at different differentiation 
stages. 
 
At the end of the neural induction phase we detected mainly NEPs and vRGCs with the 
only exception of one excitatory neuron (Figure 34 A).  
 
 
Figure 34: Clustering analysis of iPSCs-derived neuronal cells obtained at the end 
of the neural induction phase. A. Clustering analysis performed on iPSCs-derived 
neuronal cells after 10-14 days of in vitro differentiation identified 7 cell clusters. In the t-
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SNE plot used to visualize the results of the clustering analysis individual points 
correspond to single cells and each point is colored according to cell cluster 
membership. B. Percentages of neuroepithelial progenitros (NEPs) and apical radial glial 
cells residing in the ventricular zone (vRGCs). C. Percentages of the 4 different NEPs 
subtypes. D. Percentages of the 2 different vRGCs subtypes. The presence of NEPs 
and vRGCs confirms the correct neural lineage commitment and the onset of in vitro 
neurogenesis at this differentiation stage. 
 
Both NEPs and vRGCs were considerably present in culture (Figure 34 B) and formed 
two well-separated major clusters. Both cell types were further subdivided into cell 
subtypes that were also nearly equally represented (Figure 34 C, D). These findings 
indicated the correct neural lineage commitment in agreement with transcriptional data 
obtained from RNA-sequencing at population level. The presence of vRGCs further 
proves that in vitro neurogenesis has already started at this differentiation stage. 
Moreover, the identification of well-defined cell clusters assigned to two major cell 
identities indicates also the reproducibility of the initial phase of our differentiation 
strategy as neuronal cells obtained from all the 9 neocortical differentiations performed 
were combined in the clustering analysis.  
 
Analysis of the cell populations present in culture at intermediate differentiation stages 
revealed that mainly excitatory pyramidal neurons and inhibitory interneurons were 
generated starting from intermediate differentiation stages (Figure 35 A, B). Specifically, 
4 distinct subtypes of excitatory pyramidal neurons and 3 different subtypes of 
neocortical inhibitory interneurons were identified (Figure 35 A). Ex-3 and Ex-4 were the 
predominant excitatory neuronal subtypes generated (Figure 36 D) while Int-2 and Int-3 
were the prevailing neocortical inhibitory interneurons derived (Figure 35 E), as evident 
from the inspection of the percentages of each cell subtype relative to the total number 
of excitatory and inhibitory neurons respectively. In addition to neuronal populations, we 
detected also the presence of later-born neocortical progenitor cells (NPCs) populating 
in vivo the subventricular zone, including 3 distinct intermediate progenitor cells (IPCs) 
subtypes and 1 outer radial glial cells (oRGCs) cluster (Figure 35 A). IPC-2 was the main 
neocortical progenitor population present in culture at this differentiation stage (Figure 35 
C). Furthermore, it is worth noting the complete absence in our single cell dataset of 
NEPs and vRGCs starting from intermediate differentiation stages. These findings 
combined confirmed the correct differentiation progression and the successful 
generation of neocortical neurons after approximately 40 days of in vitro differentiation 
accompanied by later-born NPCs. 
 
Analysis of the iPSCs-derived neuronal populations obtained at the end of the 
differentiation protocol confirmed the presence in culture of excitatory pyramidal 
neurons, inhibitory interneurons and late-born neocortical progenitors also at this time 
point (Figure 36 A, B). A finer inspection of the cell subtypes belonging to these three 
major classes indicated that additional excitatory pyramidal neurons (Ex-1) and inhibitory 
interneurons subtypes (Int-1, Int-5) were generated after protracted in vitro differentiation 
with respect to earlier time points. Interestingly, these neuronal subtypes were the most 
prominent neuronal subtypes derived at the end of our differentiation paradigm in 
addition to subtype 5 excitatory pyramidal neurons that were generated also at 
intermediate differentiation stages but with low efficiency (Figure 36 C-D). The number of 
Ex-2 and Int-4 populations remained similar at both intermediate and final differentiation 
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stages (Figure 36 C, D; Figure 36 C, D). Consistently, at this time point the proportions 
of previously detected neuronal subtypes, including inhibitory interneurons subtypes Int-
2, Int-3 and excitatory pyramidal neurons Ex-4 were markedly reduced compared to 
previous differentiation stages, while excitatory pyramidal neurons Ex-3 were completely 
absent (Figure 36 C, D). Also at this differentiation stage, neocortical neurons were 
intermingled with all the later-born neocortical progenitors detected at intermediate 
differentiation stages and with an additional oRGCs subtype (oRGC-1). As for neuronal 
subtypes, also the proportions of neocortical progenitor cell subtypes detected at 
intermediate and final differentiation stages were different. IPC-1 and IPC-3 were 
prevailing at the end of the differentiation paradigm while IPC-2 that were predominant at 
intermediate differentiation stages resulted considerably decreased (Figure 35 E, Figure 
36 E). The presence in culture of additional excitatory and inhibitory neocortical neurons 
subtypes and previously detected neuronal classes still combined with late-born 
neocortical neurons progenitors further proves the generation of a more complete set of 
neocortical neuronal populations by the end of our differentiation paradigm (Figure 36). 
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Figure 35: Clustering analysis of iPSCs-derived neuronal cells obtained at 
intermediate differentiation stages. A. Clustering analysis performed on iPSCs-
derived neuronal cells after 36-42 days of in vitro differentiation identified 11 cell 
clusters. In the t-SNE plot used to visualize the results of the clustering analysis 
individual points correspond to single cells and each point is colored according to cell 
cluster membership. B. Percentages of the three main cell types identified through our 
clustering analysis in this temporal window, i.e. neocortical progenitor cells (NPCs), 
excitatory pyramidal neurons (Ex) and inhibitory interneurons (Int). C. Percentages of the 
4 different NPCs subtypes. D. Percentages of the 4 distinct pyramidal neurons subtypes. 
E. Percentages of the 3 different inhibitory interneurons subtypes. 
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Figure 36: Clustering analysis of iPSCs-derived neuronal cells obtained at the end 
of the differentiation protocol. A. Clustering analysis performed on iPSCs-derived 
neuronal cells after 80-83 days of in vitro differentiation identified 14 cell clusters. In the 
t-SNE plot used to visualize the results of the clustering analysis individual points 
correspond to single cells and each point is colored according to cell cluster 
membership. B. Percentages of the three main cell types identified through our 
clustering analysis in this temporal window, i.e. neocortical progenitor cells (NPCs), 
excitatory pyramidal neurons (Ex) and inhibitory interneurons (Int). C. Percentages of the 
5 different NPCs subtypes. D. Percentages of the 4 distinct pyramidal neurons subtypes. 
E. Percentages of the 5 different inhibitory interneurons subtypes. 
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5.2.3 Immunocytochemical validation of neuronal cell types identities 
 
The transcriptional results were confirmed by monitoring the expression of a panel of 
informative cell fate and cell-stage specific markers through immunocytochemistry. At 
day 12 that corresponds to the end of the neural induction phase, the majority of cells 
derived from all the eight different iPSCs clones examined had acquired a 
neuroepithelial identity as demonstrated by the widespread positivity for several nuclear 
and cytoskeletal early neuroectodermal markers including the transcription factors 
PAX6, SOX1, OTX2 [642] and the type VI intermediate filament protein Nestin (Figure 
37 A-D’). Furthermore, the cell fate commitment to telencephalic identities was 
confirmed by the positivity of the majority of cells for the transcription factor forkhead box 
protein G1 (FOXG1) (Figure 37 E-E’). 
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Figure 37: iPSCs-derived neuronal cells acquire telencephalic identities at the end 
of the neural induction phase. Immunocytochemical analysis for a selected panel of 
neuroepithelial and telencephalic markers confirms the transcriptional results indicating 
the successful conversion of iPSCs into neuroepithelial cells after 12 days of in vitro 
neocortical differentiation. A-D’. Representative pictures indicating that the majority of 
cells in culture are positive for the neuroecotdermal markers PAX6, SOX1, OTX2 and 
Nestin E-E’. FOXG1 widespread positivity confirms their telencephalic commitment. 
Furthermore, as visibile in stainings for SOX1 (B-B’), Nestin (D-D’) and FOXG1 (E-E’) 
neural rosettes structures, that are two-dimensional radial arrangements of columnar 
cells mimicking in vitro the developing neural tube, are beginning to form. Scale bar: 100 
µm. 
 
At intermediate in vitro neurodevelopmental time points comprised in the temporal 
window between day 36 and day 42 of differentiation, we assessed that iPSCs-derived 
neuronal cells had become either neocortical intermediate progenitor cells or had 
already acquired postmitotic neurons identities as suggested by the analysis of their 
transcriptional profiles. In order to assess the presence in culture of neocortical 
progenitor cells, we monitored the expression of the transcription factor T-box brain 
protein 2 (TBR2) which is selectively upregulated after the transition from radial glia to 
intermediate progenitor and subsequently downregulated in the transition from 
intermediate progenitor to postmitotic neuron [643]. In conjunction with TBR2 we also 
monitored the expression of the cytoskeletal protein Nestin that is expressed by mitotic 
neuronal cells. To validate the transcriptional signatures that indicate excitatory 
pyramidal neurons generation at these time points, we evaluated the expression of the 
cytoskeletal protein microtubule-associated protein 2 (MAP2) which is a postmitotic pan-
neuronal marker and of the vesicular glutamate transporter 1 (VGLUT1) that is a protein 
mainly expressed on the membrane of synaptic vesicles involved in glutamate transport. 
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Figure 38: Neocortical progenitor cells and deep layer postmitotic pyramidal 
neurons are present in culture after 40 days of in vitro differentiation. A. Positivity 
for TBR2 and Nestin indicates the presence in culture of neocortical progenitor cells. B. 
Excitatory pyramidal neurons identity is confirmed by VGLUT1 positivity combined with 
MAP2 expression. C. Positivity for SOX1 and βIII-tubulin further confirms the generation 
of immature neurons. D-F. The deep layer laminar identity of the postmitotic neurons 
generated at intermediate stages of in vitro differentiation has been validated by 
monitoring the expression of the layer specific transcription factors TBR1 and CTIP2. D. 
Representative image of TBR1 and CTIP2 costaining, indicating that the expression of 
these two transcription factors is mainly segregated. E. TBR1 and βIII-tubulin positivity 
confirms the generation of layer 6 corticothalamic projection neurons. F. CTIP2 and 
MAP2 positivity substantiates the presence in culture of layer 5 subcortical projection 
neurons. Scale bar: 100 µm. 
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We assessed the expression of the SRY-Box 1 transcription factor (SOX1) also at this 
later time points as in addition to maintain the progenitor cell state during the early 
stages of neocortical differentiation its expression is preserved during later stages of 
neurogenesis when its function switches to promote neural lineage differentiation [644]. 
In this context SOX1 expression was monitored in conjunction with βIII-tubulin that is a 
microtubule element expressed by both immature and postmitotic neurons to be able to 
detect also the presence of neuronal populations that are not yet postmitotic and 
consequently are not labeled by MAP2 staining. In order to further validate the laminar 
identity of the glutamatergic neurons generated in this intermediate differentiation time 
window, we inspected the expression of two deep layer specific transcription factors, 
TBR1 and CTIP2 that were used as markers of layer 6 [645] and layer 5 [350] neurons 
respectively. Our stainings validated the presence of all the above mentioned markers 
confirming the generation at intermediate in vitro differentiation stages of neocortical 
progenitor cells combined with TBR1-positive layer 6 corticothalamic projection neurons 
and CTIP2-positive layer 5 subcortical projection neurons in agreement with 
transcriptional data (Figure 38). 
 
At the end of the differentiation protocol the highly efficient generation of pyramidal 
neurons populating both deep and upper neocortical layers and inhibitory interneurons 
was confirmed by monitoring the expression of pan-neuronal and neuronal subtype- or 
layer-specific markers. As pan-neuronal markers we employed the cytoskeletal proteins 
already used in the immunocytochemical analysis performed at intermediate 
differentiation time points, including βIII-tubulin to detect the generation of both immature 
and postmitotic neurons and MAP2 to selectively assess the presence of postmitotic 
neurons. In addition we investigated the expression of the type IV intermediate filament 
neurofilament light (NF-L) that forms heteropolymers composing the axoskeleton. In 
order to confirm the generation of excitatory pyramidal neurons after 80 days of in vitro 
differentiation, we continued to monitor the expression of VGLUT1 in conjunction with 
MAP2 (Figure 39 A). To validate the presence in culture of inhibitory interneurons we 
performed stainings for the inhibitory neurotransmitter γ-aminobutyric acid (GABA) in 
conjuction with MAP2 (Figure 39 B). The generation of minor populations of glial cells 
was verified by the positivity for the cytoskeletal intermediate filament protein glial 
fibrillary acidic protein (GFAP) (Figure 39 B). To further assess the presence of 
pyramidal neurons belonging to both deep and upper neocortical layers, in addition to 
evaluating the expression of the transcription factors TBR1 and CTIP2 as markers of 
layer 6 and layer 5 neurons respectively, we performed stainings for the transcription 
factors cut like homeobox 1 (CUX1) which is expressed by layer 2-4 neurons [646] and 
SATB homeobox 2 (SATB2) that indicates the presence of mainly upper layers callosal 
projection neurons [356]. Positivity for all these markers indicated the efficient generation 
of pyramidal projection neurons belonging to both deep and upper neocortical layers and 
inhibitory interneurons accompanied by small proportions of glial cells by the end of the 
differentiation protocol (Figure 39).  
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Figure 39: Both deep and upper layer neocortical pyramidal neurons accompanied 
by inhibitory interneurons are generated with high efficiency at the end of the 
differentiation protocol. A. The widespread positivity for VGLUT1 and MAP2 confirms 
the successful generation of iPSCs-derived excitatory pyramidal neurons. B. The 
presence of cells positive for the inhibitory neurotransmitter GABA in conjunction with 
MAP2 substantiates the derivation of inhibitory interneurons. Furthermore, GFAP 
expression indicates that also minor populations of glial cells are derived. C. The 
expression of the layer specific transcription factor TBR1 combined with neurofilament 
light (NF-L) confirms the generation of layer 6 corticothalamic projection neurons. D. 
Positivity for CTIP2 and MAP2 indicates the presence in culture of layer 5 subcortical 
projection neurons. E. Expression of CUX1 and βIII-tubulin (TUJ1) demonstrates the 
successful generation of upper layer neurons. F. SATB2 and MAP2 positivity denotes 
that also callosal projection neurons are generated with high efficiency at the end of the 
differentiation protocol. Scale bar: 100 µm.  
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In addition to confirm the successful derivation of neocortical neurons, inspection of the 
cytoskeletal markers reveals that iPSCs-derived neurons had acquired full morphological 
maturity after 80 days of in vitro differentiation. Stainings for  βIII-tubulin (TUJ1) and 
MAP2 highlighted neurons forming highly interconnected dendritic trees and axons 
projecting to distant targets (Figure 39 A,B,D-F) also organized in extended axon 
bundles as apparent from neurofilament light staining (Figure 39 C). Both the presence 
of the major neocortical neurons subtypes obtained at the end of in vitro directed 
neurogenesis detected through immunofluorescence analysis and their morphological 
maturity enabled to confirm the transcriptional signatures identified through RNA-
sequecing performed at both population and single-cell level. 
5.2.4 Functional properties of iPSCs-derived neocortical neurons 
 
An essential property that characterizes fully differentiated neurons is their physiological 
maturity. GO enrichment analysis performed on DEGs that have an increased 
expression at the end of the in vitro differentiation paradigm and selected WGCNA 
modules characterized by an increased expression throughout the differentiation 
paradigm revealed an enrichment in biological process categories related to voltage-
gated sodium channel activity, positive regulation of action potential, synaptic 
transmission and neurotransmitter secretion (Figure 40 A) as well as in cellular 
component terms associated to voltage-gated ion channels and synaptogenesis (Figure 
40 B).  
 
Figure 40: Top-ranking GO categories enriched at the end of the differentiation 
protocol suggesting the physiological maturity of iPSCs-derived neocortical 
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neurons. A. Top most-specific enrichments for GO biological process categories 
detected at the end of the in vitro differentiation paradigm. B. Top-ranking enrichments 
for cellular component terms. 
 
The increased expression of transcripts coding for voltage-dependent ion channels 
identified at the end of the differentiation protocol suggests that iPSCs-derived 
neocortical neurons might be able to generate action potentials and sustain repetitive 
firing. Furthermore, the progressive enriched expression of synaptic transmission and 
neurotransmitter secretion categories suggests that the neocortical neurons generated in 
vitro are able to communicate with each other and form functional networks. 
 
To directly evaluate the functional maturity of iPSCs-derived neocortical neurons 
generated at the end of the in vitro differentiation protocol, their electrophysiological 
properties have been investigated through whole-cell patch-clamp recordings performed 
both in current- and voltage-clamp mode. All analyses have been conducted in 
collaboration with Francesca Talpo. At first the percentage of physiologically mature 
neurons has been determined. The ability of neurons to initiate at least one action 
potential (AP) in response to the injection of progressively increasing steps of 
depolarizing currents has been assumed as a marker of functional maturation. The 
analysis revealed that the majority of cultured neocortical neurons are functionally 
mature (Figure 41 A). Then, the passive properties of both functionally mature (n=23) 
and immature (n=12) neurons have been examined, including the membrane 
capacitance (Cm), the input resistance (Rin) and the resting membrane potential (Vr) 
(Figure 41 B,C,D). In this context, the membrane capacitance is related to the size of 
cell, the input resistance is inversely proportional to the number of channels expressed 
by the cell while the value of the resting membrane potential can be considered an 
indicator of the relative proportions of the different ion channels expressed by the cell as 
it is determined by the concentration gradients of ions across the plasma membrane and 
by the membrane permeability to each type of ion. Physiologically mature iPSCs-derived 
neocortical neurons are characterized by a significant increase in their membrane 
capacitance ( Cm = 32.9 ± 3.4 pF) compared to physiologically immature neurons (Cm = 
15.2 ± 1.7 pF). The significantly increased membrane capacitance of neurons able to 
generate APs compared to immature cells indicates enlarged soma that is a distinctive 
trait of fully developed postmitotic neurons. The significantly decreased input resistance 
of fully differentiated iPSCs-derived neocortical neurons (Rin= 0.6 ± 0.09 GΩ) reflects the 
enhanced expression of ion channels in their plasma membrane with respect to more 
immature neuronal cells (Rin= 1.8 ± 0.7 GΩ). Moreover, the significantly more 
hyperpolarized resting membrane potential of mature iPSCs-derived neocortical neurons 
(Vr = -48.2 ± 1.3 mV) compared to more immature neuronal cells (Vr = -43.6 ± 1.8 mV) 
suggests that during in vitro differentiation iPSCs-derived neurons progressively acquire 
an ion-channels expression profile similar to that presented by fully developed postnatal 
neurons.  
 
To gain more insights into the level of functional maturation reached by iPSCs-derived 
neurons, their passive properties have been compared to the limited reference literature 
values available obtained from primary cultures of human fetal neocortical neurons [647] 
and human fetal [648] and postnatal [649] brain slices. 
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Figure 41: Passive properties of physiologically immature and mature iPSCs-
derived neocortical neurons. A. Total percentage of cells able and unable to fire action 
potentials when excited with suprathreshold depolarizing steps of current (n = 35). Cells 
unable to fire action potentials were considered still undifferentiated and immature (n = 
12) while neurons able to initiate at least one action potential in response to depolarizing 
stimuli were considered physiologically mature (n = 23) and further analyzed. B-D. Bar 
plots representing the passive properties recorded from both immature and functionally 
mature iPSCs-derived neurons indicating that the membrane capacitance, input 
resistance and resting membrane potential are significantly different between iPSC-–
derived immature ad mature neocortical neurons (Cm: p = 0.0009; Rin: p = 0.03 ; Vr: p = 
0.04 ). Data are expressed as mean ± SEM and compared using unpaired t-test, * p < 
0.05, ** p < 0.005. 
 
The passive properties of physiologically mature iPSCs-derived neurons resulted to be 
similar to those acquired from reference human fetal neocortical primary cultures derived 
from 7 to 9 postconceptional weeks (pcw) brain tissues and cultured for more than 20 
days in vitro (DIV) prior to perform electrophysiological recordings (Cm = 36.3 ± 2.7 pF; 
Rin = 0.9 ± 0.1 GΩ; Vr= −46.3 ± 2.8 mV) [647]. Furthermore, physiologically mature 
iPSCs-derived neurons are characterized by a resting membrane potential similar to that 
recorded from the cortical plate (CP) of human fetal brain slices at 16 to 22 gestational 
weeks (Vr = -49.8 ± 1.3 mV) [648] but still significantly more depolarized with respect to 
the resting membrane potential distinctive of postnatal neurons (Vr = -75.7 ± 1.2 mV) 
[649]. Overall, the comparison of the passive properties characterizing in vitro generated 
neocortical neurons with reference literature values indicates that iPSCs-derived 
neurons present passive properties values similar to human neocortical fetal primary 
cultures. Moreover, it seems that iPSCs-derived neurons are characterized by passive 
properties also similar to human fetal neurons recorded from brain slices but still not 
reach the full functional maturity that identifies human postnatal neurons in brain slices. 
Given the differences of in vitro culture environment between cell culture and brain 
slices, the results obtained from these last comparisons should be interpreted just as a 
further indication of the level of functional development of iPSCs-derived neocortical 
neurons.  
 
Then, the firing properties of iPSCs-derived neocortical neurons have been investigated 
in further detail. As the ability to generate APs and organizing them into specific firing 
patterns is mainly related to the activation of voltage-dependent inward Na+ currents and 
outward K+ currents, the total inward and outward ion currents that flow through the 
membrane at different potentials have been recorded from both physiologically mature 
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and immature neurons. Transient inward Na+ current mediated by voltage-gate sodium 
channels is characterized by a fast kinetics while outward K+ current due to voltage-
gated delayed rectifier potassium channels is marked by slow activation kinetics. Inward 
sodium currents and outward potassium currents are well expressed by mature iPSCs–
derived neurons (Figure 42 A; n=23), while they are almost absent in immature neurons 
(n=12) as expected. In accordance, quantification of the maximum sodium current 
density measured at -20mV shows a significant difference between mature neurons (-
77.0 ± 12.8 pA/pF) and immature neurons (-3.2 ± 0.6 pA/pF). The total absence of 
voltage-dependent inward currents in immature neurons indicates that their inability to 
generate APs is due to the lack of expression of voltage-gated channels.  
 
To better assess the level of functional development of mature iPSCs-derived 
neocortical neurons (n = 23), they have been classified into three categories on the 
basis of the spike amplitude and the number of spikes they were able to elicit when 
excited with suprathreshold depolarizing steps of current (Figure 42 D): i) iPSCs-derived 
mature neurons only able to generate spikes that did not reached the overshoot 
threshold of 0 mV were classified as cells able to initiate abortive spikes, ii) neurons 
competent to give rise to only a single spike that surpassed the overshoot threshold of 0 
mV were classified as single spike neurons, iii) cells able to fire trains of APs were 
categorized as repetitive firing neurons. More than 80% of mature iPSCs-derived 
neurons were able to elicit at least one action potential that reaches the overshoot and 
the majority of them was competent to generate trains of action potentials (56.5%, n = 
13/23) organized into characteristic repetitive firing patterns (Figure 42 B).  
 
Figure 42: Firing properties of iPSCs-derived mature neocortical neurons after 80 
or more days of in vitro differentiation. A. Sample traces of total inward and outward 
currents generated in response to a series of depolarizing voltage steps. B. Sample 
trace of repetitive firing behavior in response to steps of current injection. C. 
Representative trace of spontaneous action potentials. All neurons able to generate at 
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least one AP when stimulated with a suprathreshold depolarizing steps of current were 
also able to generate spontaneous APs (n=8).  D. Percentages of cells subdivided 
according to their firing properties elicited in response to steps of current injections 
(n=23; abortive spike 17%, n=4; single spike 26%, n=6; repetitive firing 57%, n=13).  
 
Also the percentages of neurons classified according to their firing properties have been 
compared to literature values from primary cultures of human fetal neocortical neurons 
[647] and human fetal [648] and postnatal [649] brain slices, using the same references 
previously employed in the passive properties comparison. In human neocortical primary 
cultures derived from 7 to 9 postconceptional weeks (pcw) old fetal tissues recorded 
after having grown at least 20 days in vitro, 81% of neurons (n = 22/27) were able to 
generated single APs and 14.8% of cells (n = 4/27) displayed repetitive firing. Only 
approximately one-third of the cells (n = 33/107) were able to initiate APs in recordings 
made from the cortical plate (CP) of 16 to 22 gestational weeks (gw) brain slices, where 
15.9% of the neurons were able to initiate at least an abortive AP (n = 17/107) and 14.9 
% of the cells were competent to elicit a single AP (n = 16/107). Additionally, 14.3% of 
CP cells at 20 and 22 gw (n = 8/56) produced repetitive firing of APs while all postnatal 
neurons recorded from human brain slices were able to generate a large number of APs 
(100%, n = 82). The comparison of these reference values with our recordings indicates 
that mature iPSC-derived neurons are less synchronized in their functional development 
compared to primary neocortical cultures derived from 7 to 9 pcw tissues, as indicated 
by the percentages of neurons competent to fire at least one AP (iPSCs-derived mature 
neurons = 82.6%; primary cultures = 96.3%), but mature iPSCs-derived neurons seem 
even more physiologically evolved with respect to primary cultures as suggested by the 
increased number of neurons able to sustain repetitive firing (iPSCs-derived mature 
neurons = 56.5%, primary cultures = 14.8%). Mature iPSCs-derived neurons seem also 
more physiologically developed than CP neurons up to 22 gw (single AP: iPSCs-derived 
neurons = 26.1%, CP neurons = 14.9 %; repetitive firing: iPSCs-derived neurons = 
56.5%, CP neurons = 14.3%) according to brain slice recordings [648] but have not yet 
acquired the full functional maturity of postnatal neurons (repetitive firing = 100%) [649]. 
In addition to monitoring the firing properties elicited in response to injections of 
suprathreshold depolarizing steps of current, also the ability to generate spontaneous 
APs has been evaluated in a random subgroup of neurons included in the previous 
analysis (n = 8), excluding cells that were able to initiate only an abortive spike. 
Monitoring the ability to generate spontaneous APs, revealed that all neurons able to 
generate at least one AP when stimulated with a suprathreshold depolarizing steps of 
current were also able to generate spontaneous APs, a finding that further suggests their 
physiological maturity (Figure 42 C). Finally, the characteristics of the APs in the form of 
spike amplitude and spike duration have been analyzed to assess the morphology of the 
generated APs and compare it to literature reference values.  
In iPSCs-derived neocortical neurons, spontaneous APs and APs generated in response 
to injections of suprathreshold steps of currents were characterized by similar values 
and consequently data were combined and treated as only one dataset (Table 5). The 
APs generated by iPSC-derived neocortical neurons are characterized by significantly 
lower spikes amplitudes and significantly higher spike durations compared to gold-
standard reference values obtained from human postnatal neocortical neurons brain 
slices [649], as assessed through one sample t-test. This finding indicates that in vitro 
derived neocortical neurons are physiologically active but the morphology of their APs is 
still immature, an expected finding in agreement with all the other electrophysiological 
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measurements performed and the transcriptional profiles obtained from iPSCs-derived 
neocortical neurons.  
 
APs parameters iPSC-derived neocortical neurons Postnatal neocortical neurons 
Spike amplitude 65.3 ± 4.1 mV (n = 23) 94.3 ± 1.5 mV (n = 43) 
Spike duration 3.40 ± 0.36 ms (n = 23) 2.1 ± 0.08 (n = 25) 
 
Table 5: Parameters characterizing the action potentials (APs) generated by 
iPSCs-derived neocortical neurons and postnatal neocortical neurons. In 
parenthesis are reported the number of cells analyzed. Mean values of APs spike 
amplitude and duration of postnatal neocortical neurons were obtained from [649].  
 
To further assess the functional maturity of our iPSCs-derived neurons generated after 
80 days of in vitro differentiation, both the excitatory and inhibitory spontaneous activity 
in the form of spontaneous excitatory postsynaptic currents (sEPSCs) and spontaneous 
inhibitory postsynaptic currents (sIPSCs) have been investigated (Figure 43 A, B). 
Synaptic spontaneous events are due to the combined effects of both the spontaneous 
stochastic release of synaptic vesicles and the release induced by spontaneous action 
potentials. Therefore, monitoring the spontaneous activity provides information about the 
ability of the recorded postsynaptic neurons to express functional receptors, the 
competence of presynaptic neurons to generate action potentials and the extent of 
connectivity between different cells, overall enabling to evaluate the functional maturity 
of the cultured neurons and the comprehensive development of the neuronal network. 
The majority of mature neurons presented sEPSCs (69%) and a substantial subgroup of 
these neurons presented also sIPSCs (38%) (Figure 43 C) confirming the generation of 
a functional network of pyramidal neurons and inhibitory interneurons at the end of the 
differentiation paradigm in agreement with transcriptional data (Figure 43 D). 
 
 
Figure 43: Spontaneous synaptic activity of iPSCs-derived mature neocortical 
neurons. After 80 or more days of in vitro differentiation also the spontaneous synaptic 
activity of iPSCs-dervied neocortical neurons has been monitored (n=16). A-B. Sample 
traces of inhibitory (sIPSCs) and excitatory spontaneous postsynaptic currents 
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(sEPSCs) acquired in voltage-clamp mode, performing the recordings at 0 mV and -70 
mV respectively. The inhibitory or excitatory nature of the events was confirmed by 
applying at the end of the recordings the AMPA receptor antagonist NBQX (10 µΜ) or 
the GABAA receptor antagonist bicuculline (10 µΜ) that abolish respectively the sEPSCs 
and the sIPSCs. C. Percentages of recorded neurons that presented excitatory and 
inhibitory spontaneous synaptic events (no events 31%, n=5; only sEPSCs 31%, n=5; 
both sEPSCs and sIPSCs 38%, n=6). D. Percentages of the three main cell types 
identified through our clustering analysis of single cell RNA-sequencing data obtained 
from iPSCs-derived neocortical cells generated at the end of the differentiation 
paradigm, i.e. neocortical progenitor cells (NPCs), excitatory pyramidal neurons (Ex) and 
inhibitory interneurons (Int). 
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Chapter 6: Human neocortical neurons derived from 
induced pluripotent stem cells as a model 
system to investigate the effects of 7q11.23 
gene-dosage dependent dysregulation 
 
Copy number variations (CNVs) are major contributors to disorders of the central 
nervous system including intellectual disability, autism spectrum disorder (ASD), and 
schizophrenia (SCZ). To understand the pathophysiology of these disorders and develop 
effective therapeutic interventions, it is crucial both to determine the biological pathways 
and functional networks onto which multiple disease-associated genes converge and to 
identify critical genes within a CNV locus whose dosage imbalances drive specific 
neuronal phenotypes.  
 
The human spatiotemporal expression patterns of the 26-28 protein coding genes 
comprised in the 7q11.23 CNV have not been analyzed in great detail. Therefore, we 
first performed system-level analyses utilizing human brain transcriptomic and protein-
protein interaction data to investigate the molecular coordination and spatio-temporal 
expression specificity of genes comprised in this locus. Next, top functions for the 
identified modules of highly co-expressed genes were determined performing Gene 
Ontology enrichment analysis. Taken together these analyses provided evidence for 
prenatal gene regulation, postnatal synaptic transmission and mitochondrial respiration 
as potential contributors to 7q11.23 phenotypes.  
 
Building on this knowledge, two different lines of research were pursued. One was 
aimed to identify and functionally validate underexplored, yet central genes driving 
neurobiological processes uniquely affected in 7q11.23 syndromes. Pursuing single 
genotype-phenotype correlations is a promising strategy not only to understand disease 
mechanisms but also to make inroads toward developing novel treatments. Thus, 
considering the processes highlighted by our system biology analyses prospectively as 
therapeutic targets, the postnatal enrichment for mitochondrial GO terms, suggesting a 
role for mitochondrial function in the pathogenesis of 7q11.23 syndromes, seemed an 
extremely interesting finding.  Therefore, the genes driving these processes were 
identified and among them we decided to focus on unraveling the neurobiology of the 
previously uncharacterized gene DNAJC30. In this context, iPSCs-derived neocortical 
neurons, obtained using the previously extensively characterized differentiation protocol, 
and brain tissue samples were essential to demonstrate the involvement of 
mitochondrial dysfunction and the role played by DNAJC30 in mediating Williams 
syndrome, confirming in humans the morphological and functional alterations observed 
in a mouse knockout for Dnajc30. 
  
The goal of the other project undertaken was to provide new insights into the 
spatiotemporal activity of genes comprised in 7q11.23 CNV and to investigate in which 
cell types and neurodevelopmental periods 7q11.23 gene dosage imbalances exert 
major effects resulting in altered cellular phenotypes and functional deficits. To achieve 
this aim, single-cell RNA-sequencing has been performed on samples of iPSCs-derived 
neocortical neurons obtained from all the cell lines included in the cohort under study 
using 10X Genomics platform. Analysis of single-cell RNA-sequencing data and 
functional validation of the identified biological targets are still ongoing.  
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6.1 Integrated Co-Expression and PPI Analyses Identify Three 
7q11.23 Gene Clusters with Distinct Functions 
 
Given the paucity of information about the human spatiotemporal expression patterns of 
protein coding genes within 7q11.23 CNV, systems-level analyses utilizing brain gene 
expression and protein-protein interaction datasets have been performed as a first step 
to identify underexplored critical genes contributing to the altered neuronal phenotypes 
characteristic of 7q11.23 syndromes. To investigate the correlation in the expression 
patterns of the genes comprised in 7q11.23 CNV during human brain development, we 
analyzed RNA-seq data from the publicly available BrainSpan resource generated in the 
laboratory. This transcriptomic resource includes data obtained from 607 high-quality, 
histologically verified tissue samples representing sixteen regions (comprising 11 areas 
of the neocortex, hippocampus, amygdala, striatum, mediodorsal nucleus of thalamus, 
and cerebellar cortex) systematically dissected from 41 brains (18 females and 23 
males) of clinically and histopathologically unremarkable donors of different ancestry, 
ranging in age from 5 postconceptional weeks (pcw) to 40 years. For further information 
see the BrainSpan resource, www.brainspan.org. First, pairwise co-expression among 
all 7q11.23 genes was calculated, followed by hierarchical clustering. By visual 
inspection of the resulting dendrogram and heatmap, three clusters were identified 
(Figure 44 A). As evident by examining the position of genes belonging to the different 
clusters, the observed co-expression is unlikely explained by genomic adjacency given 
that the genes comprised in each cluster are scattered across the 7q11.23 locus (Figure 
44 B).  
 
To determine if genes in each cluster were merely co-expressed or represented a 
deeper molecular coordination with interacting proteins, the co-expression of each 
cluster with nearest neighbor interacting proteins was also explored. This analysis was 
performed using as a backbone interactome the publicly available biological General 
Repository for Interaction Datasets (BioGRID) protein-protein interaction (PPI) network, 
which provides a comprehensive collection of non-redundant physical protein-protein 
interactions [650]. In order to tailor the BioGRID PPI network to human brain 
development, the interactome space was confined based on the availability and the 
abundance of the BrainSpan RNA-seq dataset. All the nodes, i.e. proteins and 
corresponding genes, not profiled in the BrainSpan RNA-seq dataset were removed 
from the interactome. The analysis was further refined by removing genes with noise 
expression levels by grouping as expressed vs. non-expressed, using a mixture model. 
This resulted in a more brain-specific interactome network of 12,367 nodes and 159,353 
edges. Within the resulting interactome network, the pairwise co-expression of nodes 
significantly decayed over the shortest path distance between the nodes, consistent with 
several reports showing that the proximity of genes in the interactome network is 
indicative of the functional similarity of genes. 
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Figure 44: Analysis of pairwise co-expression among all 7q11.23 genes highlights 
three clusters that are independent of genomic adjacency. A. Dendrogram and 
heatmap of brain transcriptional similarities for all 7q11.23 genes identify three clusters. 
B. Schematic representation of the genes comprised in the 7q11.23 locus color coded by 
cluster, showing that cluster assignment does not depend on genomic location. Gene 
names are reported for cluster 1 and cluster 2.  
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No proteins encoded in 7q11.23 are known to directly interact with each other, but by 
extending the PPI network to second and third order interacting proteins, a high co-
expression for clusters 1 and 2 was still observed, while cluster 3 and intercluster 
interacting proteins were characterized by much lower co-expression values (Figure 45 
A). To further assess the molecular coordination of groups of genes belonging to a 
cluster, the significance of the observed mean pairwise co-expression of each gene set 
was tested against an empirical null expectation. To draw a null expected mean co-
expression for a set of genes in a cluster, we randomly sampled a set of matched 
number of genes having the same number of protein interacting partners from the 
interactome network and averaged the absolute value of the pairwise co-expression 
coefficients. These data indicate that the mean pairwise co-expression of cluster 1 and 
cluster 2 is higher than that of randomly sampled genes across the genome with 
matched number of interacting proteins, a further evidence that the molecular 
coordination of each of these two clusters could not be fortuitous  (Figure 45 B). On the 
other hand, the mean pairwise co-expression of cluster 3 resulted lower compared to the 
empirical null expectation, a finding that further confirms the results obtained from the 
pairwise co-expression and protein-protein interaction network analyses (Figure 45 B).  
 
 
 
Figure 45: Co-expression analysis of all genes in each cluster and their protein-
protein interaction (PPI) network highlights a deeper molecular coordination of 
clusters 1 and 2. A. Co-expression of all genes in each cluster and their nearest 
neighbors on the BioGRID PPI network. Data are plotted as mean ±SEM and outliers as 
points. All of the cluster 1 proteins are connected by a distance of 3 on the PPI network. 
B. Boxplots illustrating that the mean co-expression for cluster 1 and cluster 2 are higher 
than predicted based on randomly selected genes having identical numbers of protein-
protein interactors (null expectation), while cluster 3 is characterized by much lower co-
expression.  
 
Next, it was investigated more specifically where the expression of genes within these 
clusters might have more pronounced effects. The relative tissue-specific gene 
expression enrichment between groups of genes was examined using the Genotype-
Tissue Expression (GTEx) project RNA-Seq dataset (GTEx Consortium, 
https://gtexportal.org/home). This transcriptomic resource comprise RNA-seq data 
obtained from 11688 high quality tissue samples derived from 714 distinct donors (470 
males and 244 females) representing 53 different tissues, including 11 brain regions. 
Gene expression analysis performed across several non-central nervous system (CNS) 
tissues revealed tissue-specific variations in cluster expression (Figure 46 A).  
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Figure 46: Spatial expression analysis of 7q11.23 gene clusters highlights that 
cluster 1 and cluster 2 exhibit brain-enriched expression. A. GTEx-generated mean 
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expression levels for each cluster examined across many non-central nervous system 
(CNS) tissues identifies tissue-specific variations in cluster expression that did not reach 
statistical significance. Data are plotted as ±SEM and outliers as points. B. Boxplots 
representing the mean expression levels averaged by cluster based on BrainSpan RNA-
seq data. C. BrainSpan-generated expression levels for each gene comprised in 
7q11.23 CNV. D. Mean expression levels for each cluster examined across several CNS 
tissues calculated from GTEx dataset. Data are plotted as ±SEM and outliers as points.  
 
In the CNS, cluster 1 and cluster 2 are enriched over cluster 3, as indicated by gene 
expression analyses performed using both BrainSpan and GTEx datasets (Figure 46 B-
D). The whole brain enriched expression of clusters 1 and 2 with respect to cluster 3 is 
not driven by specific genes but rather results from a more coordinated increased 
expression of the majority of genes comprised in a cluster, as evident from boxplots 
representing mean cluster expression (Figure 46 B) and the analysis of single gene 
expression (Figure 46 C) of BrainSpan data. Applying a cutoff of log2 (RPKM+1) ≥1 to 
this dataset showed brain expression of five of six genes from cluster 1 and six of seven 
genes from cluster 2, while only six of fourteen genes from cluster 3 were expressed 
above the threshold (Figure 46 C). Moreover, we started to gain a finer spatial resolution 
by analyzing mean cluster expression across several adult brain regions using GTEx 
dataset. This analysis revealed that clusters 1 and 2 are significantly enriched over 
cluster 3 in the neocortex, amygdala, hypothalamus, hippocampus, nucleus accumbens 
and cerebellum, while in the caudate and substantia nigra the observed increased 
expression of clusters 1 and 2 compared to cluster 3 did not reached statistical 
significance (Figure 46 D).  
 
To further determine the spatiotemporal expression of each cluster, BrainSpan RNA-seq 
data were subdivided into 36 spatio-temporal intervals. Specifically, gene expression 
data were organized into four spatial groups, comprising the neocortex (NCX) (R1), 
hippocampus and amygdala (R2), striatum and thalamus (R3), cerebellum (R4) and nine 
time windows, to look for cluster expression specificity. Then, the specificity of gene 
expression of all genes in the interactome network was evaluated using gene 
Enrichment profiler, which provides a quantitative measure of up-down regulation in a 
given spatio-temporal interval with respect to all the rest intervals. The specificity scores 
were standardized with mean=0 and standard deviation=1 in each spatio-temporal 
interval. Therefore, the resulting gene-expression specificity score of each gene provides 
a deviation (Z-score) from the normalized specificity score distribution in a given spatio-
temporal interval. This analysis revealed that cluster 2 is enriched across all brain 
regions prenatally while cluster 1 is selectively enriched in the neocortex postnatally 
(Figure 47 A). In addition to its reduced expression in all brain regions and across all the 
time windows examined, cluster 3 does not show any clear expression patter (Figure 47 
A). While the magnitude of this result is less after repeating this analysis including also 
PPI partners, the same expression trend for each cluster remains (Figure 47 B). This 
result is consistent with the spatio-temporal enrichment observed previously [651], with 
slight differences in our results likely explained by the use of gene clusters, modified 
spatial groups, and specific interacting proteins.  
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Figure 47:  Spatiotemporal analysis reveals that cluster 1 is selectively enriched in 
the neocortex postnatally while cluster 2 is enriched across all brain regions 
prenatally. A. Spatio-temporal specificity of expression using genes in clusters. B. The 
same analysis was repeated including first-degree interacting proteins (PPI). In both 
graphs, specificity scores for each cluster are represented using the same color code as 
previously, i.e. red for cluster 1, light blue for cluster 2 and green for cluster 3. 
 
We next focused on clusters 1 and 2 given their enriched expression in the human brain. 
To investigate the molecular functions within these two clusters, the top 1000 co-
expressed genes for each gene in a cluster were identified and Gene Ontology (GO) 
enrichment analysis was performed for each set of genes. The lists of GO terms for each 
gene belonging to a cluster were then combined and summarized using REVIGO [652] 
to identify enriched GO terms for each cluster. For cluster 2, we found enrichment for 
gene regulation and mitosis processes. These processes were specifically driven by 
BAZ1B, RFC2, and GTF2I (Figure 48 A). These findings are in agreement with previous 
reports of transcription factor GTF2I has been reported to regulate some of the cognitive 
defects and separation anxiety in WS and ASD [608, 624]. By contrast, enriched 
processes for cluster 1 were synaptic transmission and mitochondrial respiration, the 
latter being a novel potential mediator of 7q11.23 phenotypes (Figure 48 B).  
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Figure 48: Top Functions of 7q11.23 brain-expressed genes are nuclear, synaptic, 
and mitochondrial. A. Gene Ontology enrichment analysis performed on the top 1000 
co-expressed genes for each gene in clusters 2. B. Gene Ontology analysis of the top 
1000 co-expressed genes for each gene in clusters 1. Larger nodes indicate higher term 
frequency. C. Summary schematic showing the spatio-temporal contributions of cluster 1 
and cluster 2 genes to neurodevelopmental processes.  
 
The identified genes driving the enrichment for these processes were STX1A, ABHD11, 
and DNAJC30. This was consistent using either BrainSpan’s RNA-seq dataset or an 
independent exon array dataset from developmental human brains [148]. This 
confluence of synaptic transmission and mitochondrial respiration ontologies is 
consistent with the high metabolic demand and necessarily coordinated calcium flux 
needed for proper neuronal excitation [653]. Taken together, these analyses provide 
evidence for prenatal gene regulation, postnatal synaptic transmission and mitochondrial 
respiration as potential contributors to 7q11.23 phenotypes (Figure 48).  
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6.2  Spatiotemporal expression and cellular localization of DNAJC30 
 
Considering these processes prospectively as therapeutic targets, prenatal gene 
regulation is not ideal given the several layers of upstream regulation and downstream 
targets. Furthermore, given that most 7q11.23 cases happen de novo and are not 
detected until after birth, that therapeutic option is impractical. These considerations lead 
to focus on genes comprised in cluster 1, as they exert their biggest effects in the 
neocortex after birth, when therapeutic options are more tractable following a diagnosis. 
In addition to synaptic transmission, GO enrichment analyses also identified 
mitochondrial processes as potentially novel mediators to 7q11.23 syndromes. Among 
the genes associated with mitochondria GO terms, it seemed interesting to investigate 
the previously uncharacterized gene DNAJC30 (DnaJ (Hsp40) Homolog, Subfamily C, 
Member 30) which belongs to the J-domain containing family of proteins that have a vast 
array of functions [654]. Therefore, DNAJC30 spatiotemporal expression was examined 
in more detail. Analysis of BrainSpan RNA-seq data proved that DNAJC30 mRNA is 
expressed throughout the developing human brain with its levels steadily increasing as 
development proceeds (Figure 49 A-B), consistent with postnatal enrichment of cluster 1 
genes in the neocortex (Figure 47 A-B). The developmental increase of DNAJC30 
protein was confirmed by immunoblotting lysates from human superior temporal cortex 
(STC, Brodmann area 22) (Figure 49 C-D), using that area because it was previously 
shown to have reduced asymmetric folding in WS patients [655]. The onset of 
appreciable levels of DNAJC30 protein was found during the perinatal period, which 
coincides with the peak period of neocortical dendritogenesis and synaptogenesis [15] 
(Figure 49 E).  
 
To identify neocortical cells that express DNAJC30, we performed in situ hybridization in 
the human superior temporal cortex (STC) and detected mRNA in virtually all excitatory 
projection pyramidal neurons and many interneurons, with the strongest signal 
noticeably in large pyramidal neurons of layer (L) 3C (Figure 50 A). The increased 
DNAJC30 signal in large layer 3C pyramidal neurons of the STC was also confirmed 
using immunohistochemistry (Figure 50 B). In contrast, DNAJC30 strongest 
immunoreactivity in the human primary motor cortex was detected in large pyramidal 
neurons of layer (L) 5B (Betz cells)  (Figure 50 C), but not layer 3 pyramidal neurons, 
which are smaller in size compared to pyramidal neurons in human STC and other 
association areas [656, 657]. Interestingly, Betz cells are among the largest neurons in 
the nervous system [656] and have the longest axons in the body, which extend to the 
spinal cord and form the corticospinal tract, which is altered in Williams syndrome [591]. 
Additionally, pyramidal neurons in L3C of the association areas, as STC, have the 
second largest somata in the NCX and form either ipsilateral or contralateral cortico-
cortical projections, the latter of which comprise the anterior commissure or the corpus 
callosum, both of which are smaller in size in Williams syndrome [591, 593, 656]. A 
similar laminar expression pattern was also observed in the adult neocortex of rhesus 
macaque (Macaca mulatta) (Figure 50 D). Co-immunofluorescent staining of macaque 
STC showed that DNAJC30 is present in virtually all neurogranin-(NRGN) positive 
pyramidal neurons (Figure 50 G), as well as glutamic acid decarboxylase 1-(GAD1) 
positive inhibitory neurons (Figure 50 H). In contrast, there was a paucity of DNAJC30 
signal in GFAP-positive neocortical astrocytes or CNP-positive oligodendrocytes, 
suggesting that DNAJC30 is not expressed in these cells or is below our level of 
detection (Figure 50 I-L).  
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Next, high-resolution immunogold electron microscopy (EM) was performed to precisely 
identify the subcellular localization of neocortical DNAJC30. In both dendrites and 
somata of pyramidal neurons, gold particles labeled the inner mitochondrial membrane 
(Figure 51 D-F), building upon recent high throughput studies that detected DNAJC30 in 
the mitochondrial proteome [658, 659] and supporting our hypothesis that mitochondria 
malfunction may contribute to 7q11.23 disorders.  
 
 
Figure 49: DNAJC30 expression increases during human postnatal brain 
development in neocortical neurons. A. BrainSpan-generated expression of 
DNAJC30 in the neocortex compared to other brain regions. B. BrainSpan-generated 
expression of DNAJC30 in the superior temporal cortex (STC) compared to other 
neocortical areas. C. Western blots from human superior temporal cortex (STC) lysates, 
monitoring DNAJC30 expression from prenatal periods to late adulthood. Legend: pcw = 
post-conceptional weeks, m = months, y = years. D. Quantification of Western blot data 
reported in C, plotted as 5th-95th percentile. E. Schematic of the neurodevelopmental 
processes overlapping with DNAJC30 expression.  
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Figure 50: Anatomical and cellular localization of DNAJC30. A. In situ hybridization 
for DNAJC30 in human superior temporal cortex (STC), scale bar: 250 µm. B. Human 
STC immunolabeled against DNAJC30 and visualized with DAB, scale bar: 500 µm. C. 
Human primary motor cortex (M1C) immunolabeled against DNAJC30 visualized with 
DAB, scale bar: 500 µm (inset scale bar: 50 µm). D-E. High-resolution immunoglod 
electron microscopy images of macaque dorsolateral prefrontal cortex labeled using 
anti-DNAJC30 and silver-enhanced 1.4nm gold. Red and white asterisks denote 
DNAJC30-reactive and unlabeled mitochondria, respectively. Scale bar D: 10 µm, scale 
bar E: 200 nm. F. High power electron micrograph captures DNAJC30 in the inner 
mitochondrial membrane (double arrowheads) where the outer mitochondrial membrane 
is fractured (arrowheads). Abbreviations: mit, mitochondrion; den, dendrite. Scale bar: 
100nm (inset scale bar: 20nm). G. Co-immunofluorescence in macaque STC shows 
DNAJC30 is expressed in neurogranin-(NRGN) positive excitatory neurons, scale bar: 
10 µm. H. Co-immunofluorescence in macaque STC shows DNAJC30 is expressed also 
in glutamic acid decarboxylase-(GAD1) positive inhibitory neurons, scale bar: 10 µm. I. 
No appreciable DNAJC30 signal was detected in GFAP-positive astrocytes, scale bar: 
20µm. J. No appreciable DNAJC30 signal was detected in CNP-positive 
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oligodendrocytes, scale bar: 20µm. In I-J, yellow arrows indicate (pyramidal) neurons, 
and white arrowheads indicate non-neuronal cell types. 
 
Overall, these results confirmed that DNAJC30 expression in the human neocortex 
begins around birth steadily increasing with age and is restricted to neurons. Because of 
its dynamic expression during brain development, its selective neuronal expression in 
the neocortex and unknown function, combined with the motivation to identify 
unexplored mechanisms of 7q11.23 syndromes, the neurobiology of DNAJC30 was 
investigated in greater detail. 
6.3 Immunocytochemical validation of iPSCs-derived neocortical 
neurons to investigate 7q11.23 dosage-dependent dysregulation 
 
In addition to the four human iPSCs control lines used also in the previous study aimed 
at validating the reproducibility and efficiency of the neocortical differentiation protocol in 
generating authentic neuronal populations at different in vitro differentiation stages, one 
clone for each of the nine iPSCs lines comprising 4 lines derived from patients affected 
by Williams syndrome (WS), 3 lines generated from 7q11.23 duplication syndrome 
individuals (7q11DUP) and 2 lines obtained from Williams syndrome patients unaffected 
relatives have been differentiated into neocortical neurons by applying the chemically 
defined monolayer-based differentiation protocol extensively characterized in the 
laboratory. To confirm the successful generation of iPSCs-derived pyramidal neurons 
populating both deep and upper neocortical layers accompanied by inhibitory 
interneurons at the end the differentiation paradigm, we have monitored through 
immunocytochemistry the expression of the same pan-neuronal and layer-specific 
markers adopted in the previous comprehensive protocol validation study. Also in this 
research, we examined the expression of the vesicular glutamate transporter 1 
(VGLUT1) to verify the generation of excitatory pyramidal neurons after 80 days of in 
vitro differentiation (Figure 51 C,C’,C’’) and the inhibitory neurotransmitter γ-aminobutyric 
acid (GABA) to validate the presence of inhibitory interneurons (Figure 51 F,F’,F’’). As 
pan-neuronal markers we selected three different cytoskeletal proteins including the 
microtubule element βIII-tubulin that is expressed in both immature and postmitotic 
neurons, neurofilament light (NF-L) which is expressed during axonal growth and the 
microtubule-associated protein 2 (MAP2) that is selectively expressed by postmitotic 
neurons. To discriminate the presence of neocortical neurons belonging to different 
layers, we evaluated the expression of layer specific transcription factors including TBR1 
to detect the presence of layer 6 corticothalamic projection neurons (Figure 51 A,A’,A’’), 
CTIP2 to identify layer 5 subcerebral projection neurons (Figure 51 B,B’B’’), CUX1 to 
distinguish upper layers neurons (Figure 51 D,D’,D’’) and SATB2 to assess the presence 
of callosal projection neurons (Figure 51 E,E’,E’’). Furthermore, we investigated the 
presence in culture of minor populations of glial cells by examining the expression of the 
intermediate filament protein glial fibrillary acidic protein (GFAP) (Figure 51 F,F’,F’’). All 
the 13 cell lines examined were found positive for all the above mentioned markers, 
indicating that disease-related genotypes did not completely impaired the differentiation 
toward any of the major neocortical neuronal subtypes investigated (Figure 51).   
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Figure 51: Immunocytochemical characterization of iPSCs-derived neocortical 
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neurons generated at the end of the in vitro differentiation paradigm. In the top 
panel (A-F), middle panel (A’-F’) and bottom panel (A’’-F’’) are reported representative 
images obtained from Williams syndrome, controls and 7q11.23 duplication syndrome 
iPSCs-derived neocortical neurons respectively. A-A’-A’’. Representative images 
showing the presence in culture of layer 6 TBR1-positive pyramidal neurons. B-B’-B’’. 
Representative pictures demonstrating the derivation of layer 5 CTIP2-positive pyramidal 
neurons. C-C’-C’’. Representative images indicating the successful generation of 
excitatory pyramidal neurons as proven by the widespread positivity for VGLU1 in 
combination with MAP2. D-D’-D’’. Representative pictures attesting the appearance of 
upper layer pyramidal neurons through CUX1 and MAP2 expression. E-E’-E’’. 
Representative images verifying the presence of SATB2-positive callosal projection 
neurons. F-F’-F’’. Representative pictures indicating that the successful generation of 
also inhibitory interneurons and minor proportions of glial cells as demonstrated by 
GABA and GFAP positivity. 
6.4 Morphological analysis of iPSCs-derived neocortical neurons   
from Williams syndrome patients and healthy subjects 
 
iPSCs-derived neocortical neurons generated from four patients affected by Williams 
syndrome and three healthy control lines in combination with human post-mortem brains 
tissue have been used to validate the neuronal morphological abnormalities observed in 
Dnajc30 knockout mice.  
 
Despite Williams syndrome is an hemizygous genetic condition, it was decided to 
investigate the homozygous KO mouse to provide the necessary resolution to 
understand Dnajc30 function. Validation of Dnajc30 decreased expression in 
heterozygous (Het) and knockout (KO) mice was confirmed by droplet digital PCR 
(ddPCR) (Figure 52 A). Macroscopic measurements revealed that Dnajc30 KO mice 
display ~20% decrease in body weight beginning at postnatal days (P) 9-10, persisting 
until at least 2 months old. Similarly, extracted brains from Dnajc30 KO mice were also 
~20% smaller compared to wild type (WT) littermates. To investigate the effects of 
Dnajc30 on neuronal morphology, Golgi staining was performed on neocortical sections 
of Dnajc30 knockout mice and then Neurolucida was used to reconstruct the neuronal 
morphology and quantify several parameters of the pyramidal neurons’ dendritic tree. 
Morphometric analyses on the principal apical dendrite showed that Dnajc30 KO mice 
have fewer spines (Figure 53 B), while the number of apical nodes, ends, and total 
length were also significantly reduced by roughly 50% % compared to wild types (WT) 
(Figures 53 C-E). Additionally, the number of basal dendrites (Figure 53 G), as well as 
the number of basal nodes, ends, and total dendritic length (Figures 53 H-J) were 
significantly reduced in KO mice, which also have smaller soma area (Figure 53 F). 
These findings suggest an essential role of Dnajc30 in promoting neocortical neurons 
dendritic arborization and morphological development. Furthermore, these results are 
also consistent with those found in mice hemizygous for all 26 genes comprised in 
7q11.23 CNV, which exhibit craniofacial and behavioral defects, and like Dnajc30 KO 
mice, have smaller brains and increased neuronal packing which reflects smaller neuron 
size.  
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Figure 52: Dnajc30 reduced expression in heterozygous and knockout mice, 
Williams syndrome cells and brain tissues A. ddPCR was used to confirm Dnajc30 
reduced expression in Dnajc30 heterozygous and KO mice. B. Expression ratio 
(DNAJC30:TBP) in human fibroblasts (Ctrl, n=3; WS, n=9). C. Expression ratio 
(DNAJC30:TBP) in human iPSC-derived neurons (Ctrl, n=3; WS, n=4). D. Expression 
ratio (DNAJC30:TBP) in human neocortical samples (n=3 for each genotype).  
 
To extend these findings to humans, we performed the same analyses on healthy 
controls and Williams syndrome iPSCs-derived neocortical neurons generated at the 
end of the differentiation protocol and human brain tissues. Before examining the 
morphology of human cell cultures, we confirmed using digital droplet PCR (ddPCR) that 
Williams syndrome iPSCs-derived neurons had a decreased expression of DNAJC30 
compared to controls of about 60% (Figure 52 C). To perform the morphometric 
analyses on iPSCs-derived neurons, cells were plated at low density and immunostained 
for the cytoskeletal marker MAP2 that was used for morphological quantifications along 
with CTIP2 (BCL11B), that was employed as a marker to distinguish layer 5 neocortical 
neurons (Figure 53 K). Also in this case Neurolucida was employed to reconstruct the 
neuronal morphology and quantify several parameters of the pyramidal neurons’ 
dendritic tree. These analyses confirmed that the number of nodes and the total dendritic 
length were significantly reduced in Williams syndrome neurons as seen in Dnajc30 KO 
neurons (Figure 53 M-N), while the soma of Williams syndrome neurons was decreased 
but its reduction did not reached statistical significance (Figure 53 L). After having 
confirmed DNAJC30 decreased expression also in post-mortem Williams syndrome 
neocortical tissues through digital droplet PCR (Figure 52 D), a modified Golgi-Kopsch 
stain was used to compare pyramidal neurons morphologies in situ (Figure 53 O). 
Analyses of Williams syndrome and healthy controls neuronal morphology performed on 
layer 5 human primary motor cortex (M1C) confirmed that Williams syndrome pyramidal 
neurons were characterized by a statistically significant reduction in apical dendrite 
nodes, ends, and total length (Figure 53 P-R), and displayed a trending reduction 
between 5%-15% in soma area and basal dendritic architecture (data not shown).  
 
Part II: Results 
 112 
 
 
Figure 53: Morphological analysis of Dnajc30 knockout mice and Williams 
syndrome (WS) pyramidal neurons. A. Representative images of Golgi-Cox stained 
WT and Dnajc30 KO pyramidal neurons illustrating the markedly reduced complexity of 
the dendritic arborization of Dnajc30 KO neocortical neurons. Scale bar: 100 mm. 
Neurons were analyzed using Neurolucida neuron tracing system. B-J Bar plots 
representing the results of the morphological analysis of spine density (B), apical and 
basal dendritic nodes (C, H), ends (D, I), and total dendritic length (E, J), as well as 
soma size (F) and number of basal dendrites (G), performed on WT and Dnajc30 KO 
neocortical neurons. All the morphometric parameter analyzed resulted significantly 
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reduced in Dnajc30 KO mice (WT: n = 64 neurons, 4 mice; Dnajc30: n = 93 neurons, 6  
mice). K. Representative images of human iPSC-derived neurons immunofluorescently 
labeled for morphological analysis, scale bar: 40 µm. L-N. Quantification of soma area, 
nodes, and total dendritic length, respectively, of MAP2- and CTIP2-positive neurons. 
While the soma of WS cells was only moderately reduced compared to controls, the 
number of nodes and total dendritic length of WS neurons were significantly reduced 
(Ctrl: n = 45, 3 lines; WS: n = 45, 4 lines). O. Representative images from Golgi-stained 
human primary motor cortex (M1C) deep layer neurons in Ctrl (n=3) and WS (n=3), 
scale bar: 100 µm. P-R. Quantification of neuronal apical architecture from Golgi-stained 
human M1C deep layer neurons. All the morphometric parameter analyzed resulted 
significantly reduced in Williams syndrome patients compared to controls (Ctrl, n=19 
neurons/3 specimens; WS, n=22 neurons/3 specimens). . Data are expressed as mean 
± SEM and compared using unpaired t-test, * p < 0.05, ** p < 0.01, *** p < 0.005, **** p < 
0.001. 
 
Overall, the comparison of the morphological abnormalities detected in Dnajc30 
knockout mice, Williams syndrome iPSCs-derived neocortical neurons and human brain 
tissues confirms that the same morphological abnormalities observed in Dnajc30 
knockout mice are also a distinctive cellular hallmark detected in patients affected by 
Williams syndrome, suggesting an essential role of Dnajc30 in mediating proper 
morphological maturation of neocortical neurons also in humans.  
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Discussion 
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Studies of human neurodevelopment are crucial to understand the regulatory 
mechanisms that give rise to the peculiar structure and functions of the human brain and 
to investigate the molecular basis of many neurological and psychiatric disorders that 
have a developmental origin. In this context, human pluripotent stem cells (PSCs) have 
attracted a lot of attention as their differentiation potential can be directed to generate 
with high efficiency the neural cell types of interest. Their competence to recapitulate in a 
dish the main in vivo neurodevelopmental events offers the possibility to reach an 
unprecedented spatial and temporal precision in the selection and analysis of specific 
neurodevelopmental stages, impossible to achieve employing other model systems such 
as human brain tissues and animal models. Among PSCs, especially induced pluripotent 
stem cells (iPSCs) have emerged as a powerful tool for disease modeling as they fully 
recapitulate the genetic background of diseased individuals allowing to bridge the gap 
between the genetic lesions and the clinical data. Furthermore, iPSCs can be easily 
experimentally manipulated through genetic engineering techniques to functionally 
validate the biological targets of interest. These unique advantages have fostered the 
development of many 2D and 3D human PSCs-based differentiation protocols to 
generate the neuronal populations of interest. 
 
In this study, in order to generate in vitro human neocortical neurons, iPSCs have been 
subjected to a monolayer chemically-defined PSCs-based directed neocortical 
differentiation protocol. The neocortical differentiation protocol adopted integrates 
several previously published neocortical differentiation strategies [176, 375, 376] in an 
optimized synthesis to generate with high efficiency excitatory pyramidal neurons 
belonging to all neocortical layers and inhibitory interneurons at the end of the 
differentiation paradigm, accompanied by minor populations of glial cells.  
Given the importance to rely on a solid and highly reproducible differentiation protocol 
that generates authentic neocortical neurons in vitro with high efficiency before applying 
it as a model system of human neurodevelopmental disorders, in the first phase of this 
study we have performed a comprehensive transcriptional, cellular and physiological 
characterization of the in vitro neurodevelopmental paradigm. Subsequently, we applied 
this extensively characterized differentiation paradigm to model in vitro two human 
neurodevelopmental disorders caused by symmetrical copy number variation (CNVs) of 
the Williams-Beuren syndrome chromosome region (WBSCR) located on the long arm 
(q) of chromosome 7 at position 11.23 (7q.11.23 locus). 
 
Refinement and extensive characterization of a pluripotent stem cells 
based differentiation protocol for the generation of authentic human 
neocortical neurons in vitro 
 
A comprehensive transcriptional, cellular and physiological characterization of the in vitro 
neocortical differentiation protocol adopted has been conducted on four iPSCs control 
lines derived from human fetal skin biopsies. Neocortical cells have been generated from 
two separate clones of each iPSCs line to better evaluate the reproducibility of the 
differentiation paradigm and to finely discriminate the degree of variability due to inter-
line and intra-line differences.  
 
Part II: Results 
 116 
The transcriptional dynamics regulating in vitro neocortical differentiation have been 
investigated by performing RNA-sequencing (RNA-seq) at both population and single-
cell level. Initially, we aimed to identify the contribution of different variables to the global 
transcriptional dynamics underlying in vitro neocortical differentiation. In order to answer 
this question we performed principal component analysis (PCA) on our RNA-sequencing 
dataset. Covariate analysis on the principal components revealed that the variable 
having the biggest effect on variability in our data is the differentiation stage. This finding 
was the first evidence confirming the correct progression of neocortical differentiation 
throughout the in vitro protocol and contributed to validate the quality of our data 
demonstrating that they are unrelated to sequencing-dependent variables. PCA also 
enabled to start addressing the question of protocol reproducibility and to discriminate 
the contributions to data variability due to inter-cell line and intra-cell line differences. All 
the iPSCs lines and clones examined followed the same neurodevelopmental trajectory 
as evident by their clustering mainly based on the differentiation stage. This finding 
constitutes the first evidence of the high reproducibility of our differentiation paradigm. 
Moreover, the absence of major differences in the neurodevelopmental dynamics of 
different cell lines indirectly suggested the homogeneity of the starting iPSCs lines. Only 
minor differences in neurogenesis progression were detected between the different 
iPSCs clones beginning from intermediate in vitro neurodevelopmental stages. This 
observation can be explained by the different differentiations rates at which in vitro 
neurons are maturing that becomes more evident at later differentiation time points. 
Considering also the contained data dispersion, this finding might be ascribed to 
biological variability even if it is not possible to definitely exclude specific iPSCs clone-
related contributions. 
 
A second set of questions we wanted to answer was to assess how well the 
transcriptional profiles of our iPSCs-derived neuronal cells reflected those of neurons 
obtained from human brain samples and to infer to which in vivo neurodevelopmental 
period were related the different in vitro differentiation stages. To address these points, 
we reperformed PCA including in the analysis transcriptional data obtained from both 
iPSCs-derived neuronal cells and human prenatal brain tissue specimens comprised in 
the reference brain’s transcriptome atlas BrainSpan, generated in the laboratory. This 
analysis revealed the close similarity between in vitro and in vivo neocortical neurons 
and allowed to determine to which in vivo neurodevelopmental period were related the 
different in vitro differentiation stages. Neuroepithelial progenitor cells generated after 
10-14 days of in vitro differentiation corresponded to neuroepithelial cells lining the 
central cavity of the neural tube at Carnegie stage 12 (4 pcw), iPSCs-derived neurons 
generated at intermediate stages of the differentiation protocol clustered closely with 
human early fetal dorsal telencephalon specimens (8 pcw) and neocortical neurons 
obtained at the end of the differentiation protocol were distinguished by transcriptional 
profiles similar to those characterizing human early mid fetal cortical tissues (13 pcw).  
 
To better investigate the transcriptional changes occurring along in vitro neocortical 
development, we performed differential gene expression analysis across the four 
selected in vitro differentiation stages that identified a total number of 28094 differentially 
expressed genes (DEGs). As many DEGs were overlapping across pairwise 
comparisons between the different differentiation stages, we examined their distribution. 
At first we explored the distribution of DEGs comparing the three representative 
differentiation time points to the pluripotent state (day 0) and subsequently we also 
investigated DEGs distribution between different in vitro differentiation time points, 
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always comparing more differentiated in vitro stages to less differentiated ones. Gene 
ontology enrichment analysis and KEGG pathway analysis performed on all DEGs lists 
provided the first confirmation of the successful generation of the expected cell types at 
each in vitro time point analyzed and of the progressive acquisition of mature neocortical 
neurons identities with the progression of the differentiation paradigm. To further 
corroborate these findings we also examined the functional organization of the 
transcriptional changes underlying in vitro differentiation by performing weighted gene 
co-expression network analysis (WGCNA), that identified 46 modules on our dataset. 
Many of these modules contained genes that had a clear peak of expression at specific 
in vitro differentiation stages and followed a definite developmental trajectory. In 
agreement with the cell types expected to appear during the differentiation paradigm, 
modules characterized by a peak of expression of their genes in the pluripotent state 
and a progressively decreased expression at subsequent neocortical differentiation 
stages were distinguished by top-ranking GO categories related to cell cycle, cell 
proliferation and mitosis. This finding reflected the active cellular proliferation typical of 
the pluripotent state and its progressively decreased rates along the differentiation 
protocol when more mature postmitotic neuronal phenotypes start to appear. The 
generation of neuroepithelial cells after 10-14 days of in vitro differentiation was 
substantiated by the enrichment in many GO terms related to the acquisition of 
telencephalic identities, cell differentiation and cell maturation in modules characterized 
by a peaked expression at the end of the neural induction phase. The presence in 
culture of neocortical progenitor cells was confirmed by the identification of top-ranking 
GO categories related to neural stem cells maintenance, neural plate regionalization and 
neurogenesis combined with terms associated to cell cycle, mitosis and Notch signaling 
pathway detected in modules distinguished by a peaked expression in the day 10-14 
and day 36-42 differentiation temporal windows. In these same modules, the presence 
of neocortical neurons was also suggested by the enrichment in multiple categories 
related to axonal growth, dendrite development, synaptogenesis and voltage-gated 
channels. Furthermore, in agreement with the successful generation of mature 
neocortical neurons at later stages of in vitro neurogenesis, modules distinguished by an 
increased expression along the differentiation paradigm or selectively at the end of the 
differentiation protocol displayed a marked enrichment in GO categories related to 
neocortical neurons development, development of complex neuronal morphologies and 
acquisition of physiologically mature neuronal phenotypes.  
To further reveal the distinct neuronal populations obtained at different differentiation 
stages, we also investigated the transcriptional signatures of more than 1000 iPSCs-
derived neuronal cells at single cell level. This analysis confirmed that differentiating 
cells become neuroepithelial progenitors (NEPs) and apical radial glial cells (vRGCs) at 
end of the neural induction phase, indicating the correct lineage-commitment and the 
onset of in vitro neurogenesis. The detection of later-born neocortical progenitors 
populations as intermediate progenitor cells (IPCs) and outer radial glial cells (oRGCs), 
intermingled with excitatory and inhibitory neocortical neurons starting from intermediate 
differentiation stages, confirmed the correct differentiation progression and successful 
generation of neocortical neurons after approximately 40 days of in vitro differentiation. 
Moreover, the presence in culture of additional excitatory and inhibitory neocortical 
neuronal subtypes combined with excitatory and inhibitory neurons and neocortical 
progenitors detected also at earlier time points, further proves the generation of a more 
complete set of mature neocortical neuronal populations belonging to both deep and 
upper layers by the end of differentiation paradigm.  
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These transcriptional results indicating the generation of specific neuronal cell types 
along the in vitro differentiation paradigm were validated by monitoring the expression of 
a selected panel of informative cell-fate and cell-stage specific markers through 
immunocytochemistry. The acquisition of neuroepithelial identities by the majority of cells 
in culture at the end of the neural induction phase was validated by their positivity for the 
transcription factors PAX6, SOX1 and OTX2 and the cytoskeletal marker Nestin. 
Moreover, the widespread positivity for the transcription factor FOXG1 confirmed their 
telencephalic commitment. Immuocytochemical analysis performed at intermediate 
stages of differentiation enabled also to assess the successful generation of deep layer 
neocortical pyramidal neurons intermingled with neocortical progenitor cells. The 
positivity for the transcription factor TBR2 and the cytoskeletal protein Nestin verified the 
presence in culture of neocortical progenitor cells while the generation of immature 
neurons was established by the co-expression of the transcription factor SOX1 and the 
microtubule element βIII-tubulin, which is a marker of both immature and postmitotic 
neurons. The presence in culture of iPSCs-derived pyramidal neurons was validated by 
the co-expression of VGLUT1, a protein involved in synaptic vesicles glutamate uptake, 
and the cytoskeletal postmitotic pan-neuronal marker MAP2. Furthermore, the 
appearance of postmitotic deep layer pyramidal neurons was confirmed by the co-
expression of the cytoskeletal protein MAP2 and the layer-specific transcription factors 
TBR1 and CTIP2 employed as markers of layer 6 corticothalamic projection neurons and 
layer 5 subcortical projection neurons, respectively. At the end of the in vitro 
differentiation paradigm, the highly efficient generation of pyramidal neurons populating 
both deep and upper neocortical layers and their morphological maturity was assessed 
by monitoring the expression of the same pan-neuronal and layer-specific markers 
previously examined to validate the presence of these cell types at intermediate 
differentiation stages. In addition, the generation of upper layer pyramidal neurons was 
validated by the expression of the transcription factor CUX1 and the derivation of 
callosal projection neurons was confirmed by SATB2 positivity. Furthermore, we also 
wanted to confirm the presence in culture of GABAergic interneurons and minor 
populations of glial cells, as detected from single cell RNA-sequencing analysis. The 
generation of these cell types was corroborated by the positivity for the inhibitory 
neurotransmitter γ-aminobutyric acid (GABA) and the cytoskeletal intermediate filament 
protein glial fibrillary acidic protein (GFAP). Interestingly, inspection of the pan-neuronal 
cytoskeletal markers βIII-tubulin and MAP2 revealed that iPSCs-derived neocortical 
neurons had acquired full morphological maturity by the end of the differentiation 
paradigm, as proven by their highly interconnected and arborized dendritic trees and 
axons projecting to distant targets. The development of complex neuronal morphologies 
was also confirmed through stainings for the additional cytoskeletal marker 
neurofilament light (NF-L) which highlighted the formation of extended axon bundles. 
Overall, the appropriate temporal expression profiles and the widespread positivity for 
the analyzed markers confirmed our transcriptional findings and provided further 
evidence that the applied neocortical differentiation protocol is an efficient system for the 
generation of both deep and upper layer pyramidal neurons and inhibitory interneurons 
starting from human iPSCs. 
 
To further assess the authenticity and the physiological maturity of our iPSCs-derived 
neocortical neurons obtained at the end of the in vitro differentiation protocol, we 
monitored their electrophysiological properties through whole-cell patch-clamp 
recordings performed both in current- and voltage-clamp mode. The ability to initiate at 
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least one action potential (AP) in response to the injection of progressively increasing 
steps of depolarizing currents displayed by the majority of iPSCs-derived neocortical 
neurons demonstrated that our neocortical cultures had reached functional maturity after 
80 days of in vitro differentiation. This finding was further confirmed by the presence of 
voltage-dependent inward and outward ion currents in the majority of recorded cells. To 
better assess the level of functional development of our iPSCs-derived neocortical cells, 
we also classified neurons on the basis of their firing properties in response to 
suprathreshold depolarizing steps of current. This analysis revealed that nearly 60% of 
in vitro-derived mature neurons were competent to generate and sustain trains of action 
potentials organized into characteristic repetitive firing patterns. The comparison of our 
data with reference values obtained from human primary neocortical cultures derived 
from 7 to 9 postconceptional week fetal brain tissues [647] revealed that a fewer number 
of mature iPSCs-derived neurons was able to fire APs with respect to primary cultures 
(iPSCs-derived mature neurons = 82.6%; primary cultures = 96.3%). However, our 
iPSCs-derived neurons that were functionally mature (66%) seemed even more 
physiologically evolved as suggested by the higher percentage of cells able to sustain 
repetitive firing (iPSCs-derived mature neurons = 56.5%, primary cultures = 14.8%). 
Moreover, the additional comparison of our results to data obtained from cortical plate 
(CP) brain slices of 16 to 22 gestational weeks (gw) [648] and postnatal neocortical 
slices [649] suggested that our mature iPSCs-derived neocortical neurons are more 
physiologically developed than CP neurons up to 22 gw (single AP: iPSCs-derived 
neurons =26.1%, CP neurons = 14.9 %; repetitive firing: iPSCs-derived neurons = 
56.5%, CP neurons = 14.3%) but do not acquired the full functional maturity of postnatal 
neurons (repetitive firing = 100%). Given the differences of culture environment between 
cell cultures and brain slices, the results obtained from these last comparisons should be 
interpreted just as an additional indication of the level of functional development reached 
by iPSCs-derived neocortical neurons at the end of the differentiation protocol. The 
further analysis of APs amplitude and duration revealed that iPSCs-derived neurons 
generated APs characterized by lower spikes amplitudes and significantly higher spike 
durations compared to gold-standard reference values obtained from human postnatal 
neocortical brain slices. Also this finding indicates that the majority of our iPSCs-derived 
neurons are functionally active but have not yet reached the full functional maturity 
distinguishing human neocortical postnatal neurons in agreement with the other 
electrophysiological analyses and the transcriptional data estimating a correlation of our 
in vitro-derived neurons with 13 pcw neurons derived from human brain tissues. Even if 
our iPSCs-derived neocortical neurons do not reach postnatal levels of physiological 
development, their functional maturity was also corroborated by recordings of their 
excitatory and inhibitory spontaneous activity. The majority of mature neurons (69%) 
was able to generate spontaneous excitatory postsynaptic currents (sEPSCs) and a 
substantial subgroup of these neurons (38%) presented also spontaneous inhibitory 
postsynaptic currents (sIPSCs) confirming the generation of a functional network of 
pyramidal neurons and inhibitory interneurons at the end of the differentiation paradigm. 
Overall, this articulated set of electrophysiological recordings allowed to prove that 
iPSCs-derived neocortical neurons differentiate appropriately to excitable cells able to 
fire APs, develop mature firing properties and sustain excitatory and inhibitory 
spontaneous activity by the end of in vitro neurogenesis confirming the transcriptional 
results.  
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Taken together the results obtained from this extensive panel of analyses enabled an in-
depth characterization of the transcriptional, cellular and physiological signatures of the 
neuronal populations obtained at different differentiation stages, providing a 
comprehensive assessment of the neocortical differentiation paradigm adopted with a 
previously unachieved integration of different levels of analysis and resolution to our 
knowledge. Data obtained from a wide collection of samples and with different 
techniques were in agreement with each other corroborating the quality of our findings. 
Therefore, through this study we were able to thoroughly validate the reproducibility of 
the differentiation protocol and its efficiency and reliability in generating physiologically 
mature authentic neocortical pyramidal neurons belonging to both deep and upper 
neocortical layers and inhibitory interneurons by the end of the differentiation paradigm.  
Human neocortical neurons derived from induced pluripotent stem 
cells as a model system to investigate the effects of 7q11.23 gene-
dosage dependent dysregulation 
 
After having established the quality of our differentiation strategy, we have applied it to 
model in vitro two human neurodevelopmental disorders caused by symmetrical copy 
number variations (CNVs) of the Williams-Beuren syndrome chromosome region 
(WBSCR). WBSCR is located on the long arm (q) of chromosome 7 at position 11.23 
(7q.11.23 locus) and comprise 26-28 genes. CNVs of 7q11.23 locus are especially 
interesting as the two disorders due to the deletion (Williams syndrome, WS) and 
duplication (7q.11.23 duplication syndrome, 7q11DUP) of this region display behavioral 
and cognitive phenotypes characterized by both similar features and symmetrically 
opposite traits. Moreover, association of 7q11DUP to complex neurodevelopmental 
disorders, such as autism spectrum disorder (ASD) and schizophrenia, while WS is a 
well-characterized syndrome without clear overlap to any complex neurodevelopmental 
disorder, make the study of this locus particularly interesting to investigate the molecular 
mechanisms unique to each clinical condition, common to both syndromes and shared 
with other complex neurodevelopmental disorders. Furthermore, in order to identify the 
most significant molecular mechanisms that may serve as therapeutic targets, it is also 
highly relevant to determine single genotype-phenotype correlations and to investigate 
the molecular mechanisms behind each genes’ contribution to the specific disease-
related neuroanatomical and cellular abnormalities of neocortical neurons that have 
been observed in patients affected by these two disorders.  
As the human spatiotemporal expression patterns of the 26-28 protein coding genes 
comprised in the 7q11.23 CNV have not been analyzed in great detail, we first 
performed system-level analyses utilizing human brain transcriptomic and protein-protein 
interaction datasets to investigate the molecular coordination and spatio-temporal 
expression specificity of genes comprised in this locus. Next, top functions for the 
identified modules of highly co-expressed genes were determined performing Gene 
Ontology enrichment analysis. Taken together, these analyses provided evidence for 
prenatal gene regulation, postnatal synaptic transmission and mitochondrial respiration 
as potential contributors to 7q11.23 phenotypes.  
Building on this knowledge, two different lines of research were pursued. One was 
aimed to delineate the contribution of single genes to specific phenotypes of 7q11.23 
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syndromes. The other had as objective to investigate with enhanced resolution the 
spatiotemporal activity of 7q11.23 gene dosage imbalances, highlighting neuronal 
subtypes specific genes and gene networks having the most statistically significant 
relationship to these disorders, through single cell RNA-sequencing analysis.  
To this aim, we have generated several iPSCs lines from a large cohort comprising four 
WS individuals, three 7q11DUP patients and two unaffected relatives of individuals 
presenting with typical WS, in addition to four control lines derived from unrelated 
individuals that were also used in the previous extensive protocol characterization study. 
The large size of our cohort and its composition, including in the control group also 
unaffected relatives of WS patients that share a similar genetic background with affected 
individuals, enables to identify disease-relevant molecular mechanisms with increased 
confidence.  
Successful reprogramming of skin fibroblasts into iPSCs has been achieved by applying 
a non-integrating reprogramming method based on the transfection of episomal plasmid 
vectors slightly modified from Okita et al. [544]. The selected reprogramming approach 
allowed to generate iPSCs with high efficiency and to reduce the risk of residual 
transgene expression and insertional mutagenesis. Pluripotency validation of all 13 
human iPSCs lines has been successfully accomplished. Briefly, the absence of residual 
transgene expression in our iPSCs clones was confirmed by analyzing their genomic 
DNA through PCR using a primer pair designed on a sequence common to all the 
nucleofected plasmids. Only transgene-free clones were further characterized to rule out 
the presence of chromosome abnormalities through karyotype analysis. To assess that 
iPSCs clones met the standard criteria for pluripotency definition, we checked through 
immunofluorescence the expression of a panel of classical pluripotency markers 
including the transcription factors OCT4, Nanog, SOX2 and the plasma membrane 
surface markers SSEA-4 and TRA-1-60. Moreover, human iPSCs differentiation 
potential was evaluated in vivo and for some lines also in vitro by performing teratoma 
formation assay and embryoid bodies formation assay respectively. Both assays 
confirmed that selected iPSCs clones were able to differentiate into cells belonging to all 
three germ layers. In addition to validate the pluripotency of our iPSCs clones, these 
results demonstrated that 7q11.23 CNVs do not prevent the successful reprogramming 
of patient-derived somatic cells into iPSCs, in agreement with other studies [470, 621].  
One clone of each iPSCs line has been subjected to the previously extensively 
characterized neocortical differentiation protocol. The successful generation of human 
neocortical neurons at the end of the differentiation paradigm has been validated by the 
correct expression of the same panel of informative cell fate and cell-stage specific 
markers applied also in the protocol integrative analysis. These findings confirm the 
quality of our differentiations and indicate that 7q11.23 CNVs do not completely impair 
the generation of mature pyramidal neurons, inhibitory interneurons and minor 
populations of glial cells after protracted periods of in vitro differentiation.  
To investigate with enhanced resolution if and to which extent specific neuronal 
subtypes are affected by 7q11.23 gene-dosage imbalances and to identify the molecular 
mechanisms having the most statistically significant relationship to these disorders, 
single-cell RNA-sequencing has been performed on samples of iPSCs-derived 
neocortical neurons obtained from all the cell lines included in the cohort under study. 
Analysis of single-cell RNA-sequencing data and functional validation of the identified 
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biological targets are still ongoing.  
At the cellular level, we verified that 7q11.23 gene-dosage imbalances impair neuronal 
morphologies. WS and control human iPSCs-derived neocortical neurons plated at low 
density were immunostained for the transcription factor CTIP2 that was adopted as a 
marker of neocortical pyramidal neurons and the pan-neuronal cytoskeletal marker 
MAP2, which was employed to perform the morphological quantifications using 
Neurolucida neuron tracing software. Morphometric analysis revealed that the total 
dendritic length and number of branching nodes were significantly reduced in WS 
neurons while the soma of WS neurons was reduced but the decrease in its size did not 
reached statistical significance. Similar results indicating diminished neuronal 
morphologies and less complex neuronal architecture were confirmed also by 
performing the same morphometric analyses in the primary motor cortex of healthy 
individuals and Williams syndrome patients. Results obtained in humans were compared 
to findings obtained from a Dnajc30 knockout mice in the framework of a study aimed at 
investigating the specific contributions to the onset of disease-related neural phenotypes 
of the critical and functionally uncharacterized gene Dnajc30 comprised in 7q11.23 CNV. 
The morphology of Dnajc30 knockout mice and wild types neocortical neurons was 
investigated using Golgi-stained sections and also in this case Neurolucida software was 
used for neuron tracing and subsequent analyses. Morphometric analysis showed that 
apical and basal dendrites of Dnajc30 knockout mice neocortical neurons were 
characterized by a significantly reduced total length and a significantly decreased 
number of branching nodes and ends compared to wild types. These findings are 
consistent with neuronal morphological alterations observed in mice hemizygous for all 
26 WBSCR genes [221] and suggest an essential role of Dnajc30 in promoting 
neocortical neurons dendritic arborization and morphological development. Overall, 
these findings confirm in humans many neuronal morphological abnormalities observed 
in Dnajc30 knockout mice, suggesting an essential role of DNAJC30 in mediating proper 
morphological maturation of neocortical neurons also in humans and a contribution 
DNAJC30 to specific aspects of the Williams syndrome phenotype.  
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Materials and Methods 
 
Human Tissues 
 
Human tissues procurement  
Human fetal brain tissue samples were obtained from tissue collections of the Newcastle 
Brain Tissue Resource, the Department of Neurobiology at Yale University School of 
Medicine and NIH Neurobiobank. Fetal tissues were collected from patients that 
requested pregnancy terminations. All procedures were approved by the local research 
ethical committees, the Research Services division of Yale University and the National 
Institutes of Health. Tissues were handled in accordance with ethical guidelines and 
regulations for the research use of human brain tissue set forth by the WMA Declaration 
of Helsinki (http://www.wma.net/en/30publications/10policies/b3/index.html) and NIH 
(http:// bioethics.od.nih.gov/humantissue.html).  
 
Selection criteria for brain specimens  
To better ensure brain tissue samples quality, specific selection criteria were established 
and strictly followed when deciding whether to exclude or include a brain specimen.  
• Brains with chromosomal or large-scale genomic abnormalities, detected by karyotype 
analysis and/or Illumina Human Omni-2.5, were excluded.    
• Only brains free of obvious malformations or lesions were collected. Disqualifying 
characteristics included any obvious abnormality of the neural tube, forebrain and 
brainstem. 
• Samples that tested positive for Hepatitis B, Hepatitis C or HIV were excluded.  
 
Tissue processing and dissections  
Depending on the condition and period of the procured specimens, different dissection 
methods were applied. Photos and/or video were used to document dissections using a 
digital camera and to ensure consistency between specimens. All dissections were 
performed by the same operator and the specific protocol applied to dissect brain 
regions and neocortical areas of interest depended upon the period of the specimen and 
its preservation method. During dissection, brains were placed onto a chilled plate on ice 
and dissected samples were collected in RLT buffer (Qiagen), immediately frozen in dry 
ice and stored at −80 °C for later RNA extraction. 
 
 
Cell Culture 
 
Human fibroblasts isolation and culture  
Primary fibroblast cell lines HSB 286, HSB 292, HSB 311, HSB 314 were derived in 
Sestan laboratory staring from skin samples. WS 1574, WS 5437 primary fibroblasts 
lines were obtained from NIH Neurobiobank while the other primary fibroblasts lines from 
Williams syndrome individuals, healthy controls relatives of Williams syndrome patients 
and 7q11.23 duplication syndrome subjects included in the cohort under study were 
obtained from the Genomic and Genectic Disorders Biobank (GGDB, Network of 
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Telethon Genetic Biobanks, project no. GTB07001G). Concerning the primary fibroblast 
cell lines derived in the laboratory, all biopsies and subsequent sample processing steps 
for deriving primary fibroblast cell lines were conducted in accordance with the WMA 
Declaration of Helsinki and NIH guidelines. Briefly, skin or meninges biopsies were 
rinsed in sterile DPBS 1X (Life Technologies, 14190-144) containing 1% 
Penicillin/Streptomycin (Life Technologies, 15140-122) and manually dissected into 
smaller pieces (1-2 mm). Biopsies pieces where then transferred into 6-well tissue 
culture treated plates coated with 1:50 diluted growth factor reduced Matrigel (Matrigel 
Basement Membrane Matrix Growth Factor Reduced, Corning, 354230) and grown at 37 
°C under hypoxic condition (5% CO2 and 5% O2) in low volumes of human fibroblasts 
medium (HF medium, volume < 800 uL for each well of 6-well plates) that was changed 
daily until tissue pieces were well adherent to the substrate. Then, media volumes were 
increased and changed every 2-3 days. All obtained and in-house derived primary 
human fibroblasts cell lines were cultured in human fibroblast (HF) medium composed of 
DMEM high glucose (Life Technologies, 11965-092) supplemented with 10% FBS (Life 
Technologies, 16140-071), 1% L-glutamine 200 mM (Life Technologies, 25030-081), 1% 
MEM Non-Essential Amino Acids solution (Life Technologies, 11140-050), 1% Sodium 
Pyruvate 100 mM (Life Technologies, 11360070), 1% Penicillin/Streptomycin (Life 
Technologies, 15140-122) for few passages before reprogramming. Once human 
fibroblasts cultures reached 90-100% confluence, cells were passaged using Trypsin-
EDTA 0.25% (Life Technologies, 25200-056), pelleted at 200 g for 5 minutes and plated 
at 6-8*103 cells/cm2.  
  
Human induced pluripotent stem cells generation  
Human iPSCs were generated by reprogramming human skin or meninges fibroblasts  
with episomal vectors. Episomal plasmids pCXLE-hOCT3.4-shp53-F (Addgene #27077), 
pCXLE-hSK (Addgene #27078), pCXLE-hUL (Addgene #27080), pCXLE-EGFP 
(Addgene #27082) were used for reprogramming. Human fibroblasts (2x106) harvested 
using Trypsin-EDTA 0.25% (Life Technolgoies, 25200-056) were nucleofected with 1.5 
ug of each episomal vector using Amaxa Nucleofector II (Program U-23 and U-20, 
Lonza) with the Amaxa NHDF nucleofector kit (VPD-1001, Lonza). Nucleofected cells 
were resuspended in fibroblasts medium and seeded at 25000-33000 cells/cm2 onto 
100-mm tissue culture dishes coated with 1:50 diluted growth factor reduced Matrigel 
(Corning, 354230). Starting from one day after reprogramming, cells were grown under 
hypoxic conditions in Essential 6 medium (Life Technologies, A1516401) [628] 
supplemented with bFGF 100 ng/mL (R&D Systems, 4114-TC), hydrocortisone 100 nM 
(Sigma Aldrich, H0888) and sodium butyrate 0.5 mM (Stemgent, 04-0005). 
Hydrocortisone was added to promote fibroblasts proliferation while bFGF and sodium 
butyrate were administrated to improve the reprogramming efficiency. Cell health and 
proliferation rates were checked daily by visual inspection and medium was routinely 
changed every day. Reprogrammed cells usually started to appear 3–5 days after 
transduction and monitoring of GFP expression from day 3-4 enabled to ensure that 
transfection efficiency was equal or greater than 30%. Hydrocortisone was added until 
cell density exceeded >50% confluence, a condition that was generally reached around 
day 7-10 after nucleofection. When reprogrammed cultures become confluent around 
day 10-14, cells were detached using Trypsin-EDTA 0.25% (Life Technologies, 25200-
056), replated at a density of 5000 cells/cm2 on tissue culture treated dishes coated with 
1:60 dilulted Matrigel (Corning, 354230) and maintained Essential 6 medium 
supplemented with bFGF 100 ng/mL. Sodium butyrate was removed from the medium 2-
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4 days after replating. iPSCs colonies intermingled with fibroblasts and partially 
reprogrammed cells started to form around 18–25 days after transfection. Prior to 
manual picking, colonies were inspected for GFP transgene expression and only those 
GFP-negative were chosen for further expansion. Selected individual iPSCs colonies 
were manually isolated between day 20–30 onto dishes coated with 1: 50 diluted 
Matrigel (Corning, 354230) in Essential 8 (Life Technologies, A1517001) or Essential 8 
Flex medium (Life Technologies, A2858501) supplemented with 10 µM rock inhibitor Y-
27632 (Stemcell, 72308). After manual picking, single clones were grown under 
standard iPSCs culture conditions. 
 
Induced pluripotent stem cells culture  
iPSCs lines were routinely cultured at 37 °C under hypoxic conditions (5% CO2 and 5% 
O2) in either Essential 8 (Life Technologies, A1517001) or Essential 8 Flex medium (Life 
Technologies, A2858501) on tissue culture treated plates coated with 1:100 diluted 
growth factor reduced Matrigel (Corning, 354230). Cells were generally passaged every 
4-5 days with a 0.5 mM EDTA solution when approximately 85% confluence was 
reached. Briefly, for passaging iPSCs were washed twice with DPBS 1X and incubated 
with 0.5 mM EDTA solution for 3-5 minutes at 37°C. The EDTA solution was then 
removed by aspiration and cells aggregates were collected with a small volume of 
corresponding media and directly replated. The suggested split ratio varies from 1:2 - 1:4 
for early passages iPSCs and 1:3 - 1:12 for established cultures [628, 631]. 
 
Neocortical differentiation protocol 
Human iPSCs directed differentiation into neocortical neurons was achieved by applying 
a monolayer feeder-free dual SMAD inhibition based [176] neocortical differentiation 
protocol modified from Shi et al. [375, 376]. Briefly, iPSC were dissociated to single cells 
through incubation with Accutase (Life Technologies, A11105-01) at 37 °C, seeded at 
0.7-2 x 105 cells/cm2 density on multiwall 6 plates coated with Matrigel diluted 1:50 
(Corning, 354230) and cultured in Essential 8 Flex medium supplemented with 10 µM 
ROCK inhibitor Y-27632 (StemCell, 72308). ROCK inhibitor was withdrawn the next day, 
and the iPSCs were allowed to expand in Essential 8 FLEX medium until the cells were 
nearly confluent. Neural differentiation was started by changing the culture medium to 
neural induction medium composed of a 1:1 mixture of DMEM/F-12 (Life Technologies, 
11330) and Neurobasal (Life Technologies, 21103-049) supplemented with N-2 (1:100, 
Life Technologies, 17502-048), B-27 (1:50, Life Technologies, 17504-044), 20 µg/ml 
Insulin (Insulin solution human, Sigma Aldrich, I9278), 1% L-glutamine 200 mM (Life 
Technologies, 25030-081), 1% MEM Non-Essential Amino Acids (Life Technologies, 
11140-050), 0.1 mM 2-mercaptoethanol (Life Technologies, 21985), 100 nM LDN-
193189 (Stemgent, 04-0074), 10 µM SB-431542 (TOCRIS, 1614) and 2 µM XAV 939 
(Stemgent, 04-0046). Cells were cultured in neural induction medium for 11 days 
changing the medium daily. The efficiency of neural induction was monitored visually by 
assessing the appearance of cells with characteristic neuroepithelial morphology and the 
formation of neural rosettes. On day 12, neuroepithelial cells were harvested through 
incubation with Accutase (Life Technologies, A11105-01) at 37 °C for approximately 15-
20 minutes and replated onto on 13 mm glass coverslips or 6-well plates previously 
coated with 10 µg/mL Poly-D-lysine (Sigma Aldrich, P6407) and 3 µg/mL Laminin 
(Natural Mouse Laminin, 23017-015) at 0.65-1.0 ×105 cells/cm2 density in neural 
induction medium supplemented with 100 nM LDN-193189 (Stemgent, 04-0074) and 10 
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uM ROCK inhibitor (StemCell, 72308). After replating, the medium was progressively 
switched through partial media changes to neural differentiation medium which 
contained Neurobasal (Life Technologies, 21103-049) supplemented with N-2 (1:100, 
Life Technologies, 17502-048), B-27 (1:50, Life Technologies, 17504-044), 1% 
Penicillin/Streptomycin (Life Technologies, 15140-122), 1% GlutaMAX (Life 
Technologies, 35050-061) and 30 ng/mL BDNF human recombinant protein (Life 
Technologies, PHC7074). Cultures were maintained for up to day 80 of differentiation 
changing the medium partially every 2-3 days.  
 
Pluripotency validation of iPSCs clones  
 
Nucleic acid extraction 
Genomic DNA was extracted from fibroblasts and iPSCs samples using DNeasy Blood 
and Tissue kit (Qiagen, 69506) according to manufacturer's instructions. The quality and 
concentration of DNA samples was assessed using a NanoDrop spectrophotometer 
(NanoDrop Technologies). 
 
Integration check 
To test for genomic integration and residual retention of episomal plasmids, PCR on 
iPSC clones (150 ng) grown at least until passage 4 was performed using GoTaq Green 
Master Mix (Promega, M712) and a primer pair designed to amplify a portion of the 
EBNA-1 sequence derived from Epstein-Barr virus that is a region common to all four  
episomal vectors utilized (FW: TTTGCAAGCAGCAGATTACGCGCAG, REV: 
TTTGCTCACCCAGAAACGCTGGTGAAAG). Genomic DNA isolated from day 14-30 
reprogramming samples (150 ng) and each episomal vector (1 ng) were used as positive 
controls, while genomic DNA isolated from fibroblasts (150 ng) was used as negative 
control. PCR products were separated on 1.5% agarose gels and visualised using 
ethidium bromide at ChemiDoc (Bio-Rad). 
 
Karyotype analysis 
Karyotype analysis was performed at the Molecular Cytogenetics Laboratory, Yale 
University School of Medicine (New Haven, CT). Chromosomes were classified 
according to the International System for Human Cytogenetic Nomenclature. At least 5 
metaphases were analyzed per cell line.  
 
Teratoma formation assay 
For teratoma formation, 70-80% confluent iPS cell plates were harvested using 0.5 mM 
EDTA solution, collected in Essential 8 or Essential 8 Flex medium and centrifuged at 
100 g for 5 minutes. iPSCs (1-2 × 106) resuspended in a 2:1 mixture of Essential 8 or 
Essential 8 Flex medium (Life Technologies, A2858501) and Matrigel (Corning, 354230) 
were subcutaneously injected into NOD-SCID mice (The Jackson Laboratory). Mice 
were housed normally and assessed regularly for tumor formation that started to appear 
4-6 weeks after cell injection. Around 2 weeks after teratomas were first detected, 
tissues were fixed in 4% paraformaldehyde. Samples were then OCT embedded, 
sectioned, stained with hematoxylin and eosin and analyzed at the Mouse Research 
Pathology Service, Yale University School of Medicine (New Haven, CT). 
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Embryoid bodies formation assay 
To perform the embryoid body formation assay, 70-80% confluent iPS cell plates were 
washed twice with DPBS 1X and incubated with pre-warmed Dispase solution (Life 
Technologies, Dispase II powder, 17105-041) for 15-20 minutes until cells began to lift 
up in small patches and float in the enzyme solution. Once iPSCs colonies were 
released into the enzyme solution they were harvested by adding 1:1 volume of 
Essential 6 medium (Life Technologies, A1516401) and transferred to 15 mL Faclon 
tubes to be centrifuged at room temperature twice at 100 × g for 2 minutes to completely 
remove Disapse residuals and to pellet the cells. The supernatant was carefully 
aspirated and the cell pellet was gently dislodged from the tube bottom by flicking it and 
resuspended in pre-warmed Essential 6 medium (Life Technologies, A1516401). iPSCs 
were then transferred into a 60-mm or a 100-mm non-tissue culture-treated dishes and 
let grown in suspension as embryoid bodies (EBs) under hypoxic conditions. EBs were 
cultured for 7 days changing their medium every other day by transferring the entire 
volume of the dish into a centrifuge tube and waiting until EBs had settled to the bottom 
of the tube, that took about 5-10 minutes, before removing the supernatant from the tube 
and transferring the EBs resuspended in fresh Essential 6 medium in new dishes.Then, 
EBs were mechanically dissociated, plated onto 0.1% gelatin-coated (Gelatin powder 
from porcine skin, Sigma, G1890-50DG) multiwells 12 and grown for 2 to 3 additional 
weeks in Essential 6 medium supplemented with 10% FBS (Life Technologies, 16140-
071) in a 37°C, 5% CO2 incubator prior to fixation and subsequent immunocytochemical 
analysis. 
 
Immunocytochemistry 
Cell cultures were fixed with 4% paraformaldehyde (wt/vol) for 10 minutes at room 
temperature or with ice-cold methanol at -20 °C for 20 minutes. Cells were 
permeabilized for 10 minutes at room temperature with PBS 1X supplemented with 0.5% 
(vol/vol) Triton X-100 (Sigma, 93443), 100 mg/L CaCl2 and 100 mg/L MgCl2. When 
required, antigen unmasking was performed according to supplier instructions. Blocking 
has been achieved using a PBS 1X solution supplemented with 5% fetal bovine serum, 
0.3% (vol/vol) Triton X-100, 100 mg/L CaCl2 and 100 mg/L MgCl2. Primary antibodies 
were incubated overnight at 4 °C diluted at the appropriate concentrations in PBS 1X 
supplemented with 3% fetal bovine serum, 0.2% (vol/vol) Triton X-100, 100 mg/L CaCl2 
and 100 mg/L MgCl2. Specifications of the primary antibodies used to assess the 
pluripotent state (Table 1) and iPSCs-derived neuronal cells identity (Table 2). For 
primary antibody detection, species-specific Alexa-dye conjugated secondary antibodies 
(Life Technologies) in combination with DAPI (Sigma, #10236276001) were incubated 
for 1 hour at room temperature diluted according to supplier instructions (1:250) in PBS 
1X  supplemented with 3% fetal bovine serum, 0.2% (vol/vol) Triton X-100, 100 mg/L 
CaCl2 and 100 mg/L MgCl2. For long-term storage a PSB 1X solution supplemented with 
100 mg/L CaCl2, 100 mg/L MgCl2  and 0.01% (wt/vol) Sodium Azide (Sigma Aldrich, 
S2002) was used. When staining cell cultures grow on a glass substrate, coverslips 
were mounted to a slide with droplets of Aqua Poly/Mount (Polysciences Inc, 18606). 
Images of iPSCs colonies and day 14 iPSCs-derived neocortical progenitors were 
acquired on Apotome.2 (Zeiss) combined with Observer.Z1 (Zeiss) inverted microscope 
at 10X and 20X magnification, respectively. Fluorescence images of day 40 and day 80 
iPSCs-derived neocortical neurons were acquired on Apotome.2 microscope combined 
Part III: References 
 129 
with AxioImager M2 upright microscope  (Zeiss) and confocal images at 20X and 40X 
were acquired at LSM 510 META (Zeiss). 
 
Antibody Company Code Species 
Nanog Abcam ab21624 Rabbit IgG 
Nanog  Stemgent 09-0020 Rabbit IgG 
OCT3/4 Abcam ab19857 Rabbit IgG 
OCT3/4  Stemgent  09-0023 Rabbit IgG 
SOX2 Millipore ab5603 Rabbit IgG 
SSEA4 BD 560218 Mouse IgG 
SSEA4  Stemgent 09-0006 Mouse IgG3 
TRA-1-60 BD 560122 Mouse IgM 
TRA-1-60  Millipore 09-0010 Mouse IgM 
 
Table 1. Primary antibodies used to validate the pluripotent state. 
 
Antibody Company Code Species 
AFP Santa Cruz sc-130302 Mouse IgG 
βIII-tubulin Covance MMS-43SP Mouse IgG 
CUX1 Santa Cruz sc13024 Rabbit IgG 
CTIP2 Abcam ab18465 Rat 
FOXA (HNF3β) Santa Cruz sc-6554 Goat 
FOXG1 NCFAB Stem Culture Rabbit 
GABA Sigma A2052 Rabbit 
GFAP Advanced ImmunoChemical 31223500 Guinea Pig 
MAP2 Sigma M4403 Mouse IgG 
MAP2 Millipore ab5622 Rabbit 
Nestin R&D MAB1259 Mouse IgG1 
Neurofilament 
light 
Millipore MAB1615 Mouse IgG 
OTX2 Millipore ab9566 Rabbit IgG 
PAX6 BD 561462 Mouse IgG 
Phospho-
vimentin 
Abcam Ab22651 Mouse IgG 
SATB2 GenWay 20-372-60065 Mouse IgG 
SMA (ASM-1) Millipore CBL171 Mouse  
SOX1 Cell Signaling 4194 Rabbit 
TBR1 Santa Cruz 48816 Rabbit IgG 
TBR2 Millipore ab15894 Chicken 
VGLUT1 Millipore MAB5502 Mouse IgG 
ZO-1 Invitrogen 61-7300 Rabbit IgG 
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Table 2. Primary antibodies used to characterize iPSCs-derived neuronal cell identity at 
different time points of the in vitro differentiation protocol. 
 
Antibody Company Code Species  
DNAJC30 Novus H00084277-B01P Mouse 
DNAJC30 Novus 48816 Rabbit 
NRGN R&D AF7947 Sheep 
GAD1 R&D AF2086       Goat 
GFAP Sigma G9269 Rabbit 
GFAP Encor RPCA-GFAP Rabbit 
CNP Encor CPCA-CNP Chicken 
 
Table 3. Primary antibodies used to characterize the cellular expression of Dnajc30. 
 
Electrophysiology  
All recordings were performed at 21-23°C using the whole-cell patch-clamp technique in 
voltage- and current-clamp configurations. The extracellular solution was composed by 
125 mM NaCl, 2.5 mM KCl, 26 mM NaHCO3, 15mM glucose, 1.3 mM MgCl2, 2.3 mM 
CaCl2, 1.25 mM NaH2PO4 (bubbled with 95% O2, 5% CO2). Cells were visualized 
using an Axioskop FS2 microscope equipped with a 5X scanning objective and a 40X 
water-immersion objective (Zeiss), and connected to a CCD camera. Pipettes were 
produced from borosilicate glass capillary tubes (Sutter Instruments) by means of a 
horizontal puller (P-2000, Sutter instruments) and filled with the following intracellular 
solution: 130 mM K-gluconate, 4 mM NaCl, 2 mM MgCl2, 1 mM EGTA, 5 mM creatine 
phosphate, 2mM Na2ATP, 0.3 mM Na3GTP, 10 mM HEPES (pH 7.3 with KOH). 
Membrane voltage was corrected off-line for a calculated liquid junction potential of -10 
mV. Series resistance was always compensated by 70–80% and monitored throughout 
the experiment. Recordings were made with a MultiClamp 700B amplifier (Molecular 
Devices) and digitized with a Digidata 1322 computer interface (Molecular Devices). 
Data were acquired using the software Clampex 9.2 (Molecular Device), sampled at 20 
kHz, and filtered at 10 kHz. Software Clampfit 10.2 (Molecular Devices) and OriginPro 8 
(Microcal) were used for data analysis. Cell capacitance (Cm) was calculated by 
integrating the capacitive current evoked by a −10 mV pulse. Resting membrane 
potential (Vm) was measured without current injection. Neuronal input resistance (Rin) 
was calculated in the linear portion of the I–V relationship during depolarizing voltage 
responses near the resting potential. Activation of inward and outward currents mediated 
by voltage-dependent sodium and potassium channels was obtained by stimulating the 
cell with steps of voltage of increasing amplitude. Firing properties were assessed by 
recording the voltage responses to a series of supra-threshold current steps starting 
from a potential of -70 mV. The spontaneous excitatory (sEPSCs) and inhibitory 
(sIPSCs) post-synaptic currents were recorded at the holding potentials of -70 mV and 0 
mV, respectively, and their nature was confirmed by bath application of specific synaptic 
blockers added to the extracellular solution. The GABAA receptor blocker bicuculline 
methiodide (10 µM) (bicuculline, Sigma-Aldrich) was used to abolish the sIPSCs, while 
the AMPA receptor agonist 2,3-dioxo-6-nitro-1,2,3,4-tetrahydrobenzo(f)quinoxaline-7-
sulfonamide (10 µM) (NBQX, Sigma-Aldrich) was used to abolish the sEPSCs. Data are 
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expressed as mean ± s.e.m. Statistical significance was evaluated using two-tailed 
unpaired homoscedastic Student’s t-test. 
 
mRNA sequencing 
 
RNA extraction from cell samples 
Total RNA was collected from undifferentiated iPSCs (day 0) and iPSCs-derived 
neocortical neural progenitors and neurons specimens obtained at day 10-14, day 36-42 
and day 80-83 of in vitro differentiation. Samples for RNA-sequencing were collected in 
RNAprotect cell reagent (Qiagen, #76526). Total RNA was extracted using the RNeasy 
plus mini kit (QIAGEN, #74136) according to manufacturer's instructions. Each sample 
was subjected to a DNase treatment (TURBO DNase, Ambion) as indicated in the 
product manual. Prior to perform cDNA library preparation, RNA quantity and quality was 
first checked using NanoDrop (Thermo Scientific) and then using High Sensitivity RNA 
ScreenTapes (Agilent, #5067-5578) at 2200 TapeStation (Agilent). 
 
RNA extraction from brain tissue samples 
A bead mill homogenizer (Bullet Blender, Next Advance) was used to lyse the pulverized 
tissue. Each pulverized tissue sample was transferred to a chilled safe-lock 
microcentrifuge tube (Eppendorf). A mass of chilled stainless steel beads (Next 
Advance, cat# SSB14B) equal to the mass of the tissue was added to the tube. Two 
volumes of lysis buffer were added to the tissue and beads. Samples were mixed in the 
Bullet Blender for 1 min at a speed of six. Samples were visually inspected to confirm 
desired homogenization and then incubated at 37 °C for 5 min. The lysis buffer was 
added up to 0.6 ml, and samples were mixed in the Bullet Blender for 1 min. Total RNA 
was extracted using RNeasy Plus Mini Kit (Qiagen, #74136). Each sample was 
subjected to a DNase treatment (TURBO DNase, Ambion) as indicated in the product 
manual. Prior to perform cDNA library preparation, RNA quantity and quality was first 
checked using NanoDrop (Thermo Scientific) and then using High Sensitivity RNA 
ScreenTapes (Agilent, #5067-5578) at 2200 TapeStation (Agilent). 
 
RNA-sequencing Library preparation and RNA-sequencing 
The TruSeq Stranded Total RNA LT Sample Prep Kit (Illumina) was used to prepare 
cDNA libraries according to manufacturer instructions. Briefly, 500 ng of total RNA was 
processed with Ribo-Zero Gold Set A-B to deplete samples of both cytoplasmic and 
mitochondrial rRNA. The remaining RNA was purified, fragmented, reverse transcribed 
into first strand cDNA and further processed to generate a second strand of blunt-ended 
cDNA. Blunt-ended cDNA fragments were adenylated, ligated to multiple indexing 
adapters and DNA fragments that have adapter molecules ligated to both ends were 
selectively amplified through PCR. Prior to samples submission for sequencing, the size 
and distribution of DNA library templates was assessed by loading 2 µL of each sample 
on High Sensitivity DNA 1000 ScreenTapes (Agilent, #5067-5584) read at 2200 
TapeStation (Agilent). cDNA libraries were provided to the Yale Center for Genomic 
Analysis where paired-end RNA sequencing was performed on Illumina Hi Seq2000 to 
an average depth of 100M reads per sample. 
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mRNA sequencing Quality Assessment 
 
Reads alignment, expression quantification, and quality assessment 
The generated FASTQ files were input to Illumina's CASAVA pipeline to purify the low-
quality and non-identified reads. Low quality reads defined as those that did not had at 
least 80% of bases with a quality score of 20 or more (conducted by fastq_quality_filter 
function) and reads left with > 10 bases after being trimmed with a quality score of < 20 
(conducted by fastq_quality_trimmer function) were filtered out. FastQC was used to 
report the fundamental quality parameters as raw reads number, sequencing base 
quality score distribution, duplication level, adapter contamination, and GC content 
(http://www.bioinformatics.babraham.ac.uk/projects/fastqc/), which will sever as co-
variables to perform association analyses to examine the unwanted batch effects.  
 
Reads filtered by quality score were then mapped to the human reference genome 
(GRCh38/hg38) with default parameters using the Spliced Transcripts Alignment to a 
Reference (STAR) software [639]. The aligned reads stored as BAM format were 
converted to MRF format, and the expression level of genes and exons were quantified 
by count number and RPKM (reads per kilobase of exon model per million mapped 
reads) [660] using RSEQtools. Only genes with count number greater than 5 and RPKM 
greater than 1 in either condition were included in the further analyses. The number and 
the percentage of uniquely mapped reads were calculated for each sample. Samples 
with less than 20 million uniquely mapped reads were excluded from further analysis or 
re- sequenced.  
 
Moreover, we developed some in-house R and Perl scripts and collaborated with some 
public available tool-kits to perform the in-depth quality assessment of our sequencing 
data sets, which were implemented throughout sample preparation and transcriptome 
data generation steps as described [148]. Samples that failed to pass the quality control 
measures were reprocessed or removed from the downstream analyses. For instances, 
the coverage by chromosome of the mapped reads was calculated using the depth 
function of the SAMtools version 0.1.19 module. Exon coverage was calculated by using 
the intersectBed function of the bedtools version 2.20.1 module. The density plots of 
RPKM values were generated by ggplot2 version 1.0.1 R package. RnaSeqMetrics 
function under Picard tools (v.1.102; http://picard.sourceforge.net) was used to compute 
the 5′–3′ coverage bias along gene body as well as the number of bases assigned to 
various classes of RNA. Subsequent data processing with the R package conditional 
quantile normalization (CQN) and ComBat function enabled to correct for gene length, 
gene GC content, sequencing site and batch effects respectively. 
 
 
mRNA Sequencing Data Analysis  
 
Hierarchical clustering and batch effect correction  
All statistical analyses were performed on data previously corrected for batch effects 
using R function ComBat [661]. Hierarchical clustering performed using the function 
hclust in R with 1-correlation as distance, clearly separated samples according to their 
differentiation stage.   
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Principal component analysis 
PCA was performed to visualize the relatedness of all the 35 cell samples separately 
and in combination with 6 brain tissue specimens using prcom package and the first two 
principal components were plotted using rgl package, both retrieved from R 
(http://www.r-project.org/). Our results showed that cell samples clustered by in vitro 
differentiation stage and clustered closely with human prenatal brain-derived neurons.  
 
Identification of differentially expressed genes (DEGs)  
DEGs genes were computed using R package DESeq2 [662]. In this package, the count 
data were modeled with a negative binomial distribution to address the problem of 
overdispersion. P values were calculated by a likelihood ratio test comparing models and 
DEGs genes were called at a false discovery rate (FDR) of 0.01 [663].  
 
Weighted gene co-expression network analysis (WGCNA)  
Signed co-expression networks were built using the WGCNA package [664] in R. For all 
genes included, a pair-wise correlation matrix was computed, and an adjacency matrix 
was calculated by raising the correlation matrix to a power. For each pair of genes, a 
robust measure of network interconnectedness (topological overlap measure) was 
calculated based on the adjacency matrix. The topological overlap based dissimilarity 
was then used as input for average linkage hierarchical clustering. Modules were 
generated by hybrid dynamic tree-cutting. To detect rare expression patterns, we set the 
minimum module size to 10 genes, deepSplit to 5, and the minimum height for merging 
modules to 0.2. Each module was summarized by an eigengene, which is the first 
principal component of the scaled module expression. Thus, the module eigengene 
explained the maximum amount of variation of the module expression levels. The 
module membership (also known as module eigengene based connectivity kME) is 
defined as the correlation between gene expression values and the module eigengene. 
To obtain modules with clear clustering of expression patterns, we iteratively reassigned 
genes to the module with largest kME and genes with maximum kME < 0.5 were 
assigned to the M0.  
 
Functional enrichment analysis  
Functional enrichment analysis was performed using GeneCodis [665] and DAVID 
Bioinformatics Resources (http ://david.abcc.ncifcrf.gov/). All reported p-values adjusted 
were calculated using the Benjamini-Hochberg method. Data were plotted using Excel. 
 
 
Single-Cell RNA-sequencing 
 
Single-Cell capture and cDNA synthesis 
Cells were captured with medium-sized (10-17µm) RNA-seq IFCs using the Fluidigm C1 
system according to the manufacturer’s instruction. Immediately before cell capturing, 
viability was accessed by trypan blue staining. In all experiment, the cell viability was 
close to 100%. A concentration of 1,000–3,000 cells/µL was used for cell loading. After 
capture, C1 chips were examined visually and the number of cells at each capture site 
was recorded manually. Cells captured by C1 were subsequently processed through 
lysis, reverse transcription and PCR amplification to generate single-cell cDNA libraries 
using the Smarter Ultra Low Input RNA kit for Fluidigm (Clontech). The cDNAs from all 
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capture sites were harvested the next morning in about 3 µL C1 harvest reagent and 
were transferred to a 96-well PCR plate in 10 µL C1 DNA dilution reagent. 
 
Single-Cell RNA-sequencing library preparation 
cDNA concentration was quantified with Quant-iT PicoGreen (Invitrogen, P7589). 
Samples were diluted to 200 ng/µL with C1 harvest reagent. The resulting cDNA 
samples were indexed using Nextera XT Library Prep Kit (Illumina). All sequencing 
libraries were assessed for quality by Agilent Bioanalyzer, using high sensitivity dsDNA 
assay. 
 
Single-Cell RNA-sequencing 
Libraries of single cells pooled from each C1 IFC were denatured using the Illumina 
protocol. The denatured libraries were diluted to 6 pM, followed by cluster generation on 
a single-end HiSeq flow cell using an Illumina cBOT, according to the manufacturer's 
instructions. The HiSeq flow cell was run for 100 cycles using a single-read recipe 
according to the manufacturer's instructions. We used Illumina CASAVA to purify the low 
-quality and non-identified reads and FastQC to report the fundamental quality 
parameters as raw reads number, sequencing base quality score distribution and GC 
content (http://www.bioinformatics.babraham.ac.uk/projects/fastqc/). To avoid adapter 
contamination and higher error rates in reads boundary, we trimmed 12 nucleotides in 
5’-end and 13 nucleotides in 3’-end, leaving 75 nucleotide long reads for sequence 
alignment.  
 
Reads alignment and gene expression quantification 
STAR (v2.4.0) [639] was employed to uniquely align the filtered reads to human 
reference genome (GRCh38/hg38) with default parameters. The gtf formatted 
annotations for human (GENCODE, released version v21) were retrieved from 
GENCODE project. We used RSEQtools and SAMtools to calculate the gene expression 
[666, 667]. We used HTSeq (v0.6.1) to calculate the gene reads count values for each 
annotation entry. The gene RPKM values were calculated using in-house R scripts. 
 
Data quality assessment  
In addition to FastQC, we implemented a series of quality control measures. First, we 
counted uniquely mapping reads per cell and used only cells with at least 100,000 
unique reads, which is also at least 10% of total reads, mapped to coding sequences. 
Next, we checked the reads distribution across different chromosomes. Cells with more 
than 10% unique reads mapped to mitochondrial chromosome were considered low 
quality and removed. Furthermore, we checked the reads aligned to exonic, intronic and 
intergenic regions. High quality cells should have at least a percentage of 30% on total 
reads mapped to exons. We checked gene coverage uniformity and chose those cells 
with fold change of average reads coverage within gene less than 2. The gene coverage 
uniformity is considered as an indicator for RNA degradation. Read counts were 
converted to RPKM and log2 transformed for downstream analysis. 
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Single-Cell RNA-sequencing data analysis  
 
Identification of variable genes 
To reduce computational burden, we sought to select variable genes for further analysis. 
Variable genes were defined as those that have higher coefficient of variation comparing 
to empirically predicted value. Briefly, means of log transformed expression level of each 
gene in all single cells were calculated, as well as the observed coefficient of variation of 
each gene. Then, a log linear regression model was used to generate a predicted 
coefficient of variation for each gene. Genes whose observed coefficient of variation was 
greater than estimation were considered as variable genes and were used for t-SNE. 
 
Clustering analysis and t-SNE plots 
We used t-distributed stochastic neighbor embedding [108] to present data in two 
dimensional coordinates. Graphs were generated using R package ggplot2. To identify 
different neuronal subtypes and cell states we used pcaReduce package in R [641] 
which adopts an agglomerative unsupervised clustering approach that integrates 
principal components analysis (PCA) and hierarchical clustering. Number of samples 
(nbt) was set to 1, and number of dimensions (q) was set to 30. Sampling based 
merging was applied. 
 
Expression and protein network analysis of 7q11.23 CNV genes 
Gene expression analysis was performed on the exon array [148] and publicly available 
BrainSpan RNA-seq datasets (www.BrainSpan.org) using the RNA-seq data for data 
presentation. The pairwise co-expression coefficient (Pearson correlation coefficient) 
among all 7q11.23 CNV genes was calculated and hierarchical clustering (Ward’s 
method) was performed with the distance being defined as 1 - co-expression coefficient. 
Log2 transformed RPKM values were used for the co-expression calculation. The three 
clusters were identified by visual inspection of the dendrogram and heatmap.  
 
Integration of the brain transcriptome and protein-protein interaction network was done 
using the non-redundant physical BioGRID protein-protein interaction network (3.4.132, 
Jan. 2016) as a backbone interactome. The interactome space was confined based on 
the availability and the abundance of the BrainSpan RNA-seq dataset. First all the nodes 
(proteins and corresponding genes) that are not profiled in the BrainSpan RNA-seq 
dataset were removed from the interactome. The analysis was further refined by 
removing genes with noise expression levels by grouping as expressed vs. non-
expressed using a mixture model. This resulted in an interactome network of 12,367 
nodes and 159,353 edges. Within the resulting interactome network, the pairwise co-
expression of nodes significantly decayed over the shortest path distance between the 
nodes. This observation is consistent with several reports showing that the proximity of 
genes in the interactome network is indicative of the functional similarity of genes. 
Similar results were found when using expression level cutoff of RPKM>1 (data not 
shown). The data presented are without removing non-expressed genes to demonstrate 
the contribution of all genes comprised in the 7q11.23 locus. The significance of the 
observed mean pairwise co-expression of gene set (i.e. the group of genes belong to a 
cluster) was tested against an empirical null expectation. To draw a null expected mean 
co-expression for a set of genes in a cluster, we randomly sampled a set of matched 
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number of genes having the same number of protein interacting partners from the 
interactome network and averaged the absolute value of the pairwise co-expression 
coefficients. The significance p-value of the co-expression of the cluster was then 
determined by 1 - the number of times the mean absolute co-expression of null sets 
larger than that of a cluster gene set divided by the number of randomly sampled null 
sets. Here 1000 null sets were used.  
 
The relative tissue-specific gene expression enrichment between groups of genes was 
examined using Genotype-Tissue Expression (GTEx) project RNA-Seq dataset 
(Consortium, 2013). We downloaded GTEx V6 Analysis RNA-Seq dataset available from 
http://www.gtexportal.org/home/datasets/GTEx_Analysis_v6_RNA-seq_RNA- 
SeQCv1.1.8_gene_rpkm.gct.gz. We summarized the expression values of genes per 
tissue group and performed the Wilcoxon rank sum test between two groups (i.e., C1 
and C2 combined vs. C3 cluster) upon the quantile-normalization of the per-tissue mean 
expression values.  
 
Identifying spatio-temporal context of 7q11.23 genes was done by grouping all the 
BrainSpan RNA-seq dataset into 36 spatio-temporal intervals: 4 spatial groups ((i) 
neocortex, (ii) hippocampus and amygdala, (iii) striatum and thalamus, and (iv) 
cerebellum) and 9 temporal windows (8 pcw – 40 years; see www.BrainSpan.org). The 
specificity of gene expression of all genes in the interactome network was evaluated 
using geneEnrichment profiler [668], which provides a quantitative measure of up-down 
regulation in a given spatio-temporal interval with respect to all the rest intervals. We 
standardized the specificity scores with mean=0 and standard deviation=1 in each 
spatio-temporal interval. Therefore, the resulting gene-expression specificity score of 
each gene provides a deviation (Z-score) from the normalized specificity score 
distribution in a given spatio-temporal interval.  
 
Analysis of co-expressed genes was performed by retrieving normalized log2 signal 
intensity and RPKM values from BrainSpan datasets (exon array and RNA-seq, 
respectively), and then using a Pearson correlation, identifying the top 1000 correlation 
coefficients for each 7q11.23 gene. These gene lists were analyzed for Gene Ontology 
terms using the Functional Annotation Tool within DAVID v6.7 [669]. We reached similar 
observations from both exon array and RNA-seq platforms. All results were then filtered 
for FDR <0.01, and all subsequent Gene Ontology terms associated with genes from 
one cluster were submitted simultaneously to REVIGO [652], using medium similarity 
(0.7), and SimRel semantic similarity measures. The provided .xgmml files were 
imported into Cytoscape v3.3 for plotting [670].  
 
Western blotting  
Cells or tissues were lysed by sonication in PBS or TBS supplemented with 0.01% 
Tween-20, protease and phosphatase inhibitors. Following centrifugation at 20,000xg, 
supernatant protein concentrations were quantified and mixed with Laemmli loading 
buffer, boiled, electrophoresed on NuPage Bis-Tris gels and transfered to polyvinylidene 
fluoride (PVDF) membranes. Membranes were blocked and then incubated with primary 
and secondary antibodies, in 5% skim milk or 5% BSA, and subsequently developed 
using chemiluminescence. Bands were imaged using G:Box Chemi XRQ and quantified 
using GeneTools software.  
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Immunohistochemistry  
Post-mortem brain tissue from adult humans, rhesus macaque, or mouse was used for 
immunohistochemistry (IHC), immuno-electron microscopy (immuno-EM), and 
immunofluorescence (IF). Standard procedures were followed for each application. For 
IHC, human sections were pre-treated with 0.3% H2O2 followed by incubation in 
blocking buffer (5% BSA, 1% normal donkey serum in PBS + 0.05% Tween-20) at room 
temperature and then incubation for 24-48 hours at 4°C in primary antibodies. Tissue 
was then incubated with biotin- labeled secondary antibodies, conjugated with Avidin-
Biotin-Peroxidase Complex, and visualized with DAB-nickel following the manufacturer’s 
recommended protocol. Developed sections were mounted on Superfrost Plus charged 
slides, dehydrated through an ethanol series, cleared with xylenes, and preserved with 
Permount and glass coverslips. Images were taken using Aperio ScanScope digital 
scanner. For immunofluorescence, a block of adult rhesus macaque STC was fixed and 
incubated in 30% sucrose. The block was then embedded in agarose, sectioned at 
25µm, and perforated by sucrose-protected freeze/thaw treatment. Sections were 
blocked in blocking buffer using 0.05% n-Dodecyl β-D-maltoside, which was used for 
subsequent antibody dilutions. DAPI was used at 1ng/µL. Finished sections were 
mounted on slides and covered with Aqua-Poly/Mount. Fluorescent images were 
acquired on a Zeiss LSM 510 multi-photon microscope and modified using Zen software.  
 
Droplet digital PCR  
RNA was isolated from cells and tissues essentially as previously described [148]. 
Briefly, for frozen Dnajc30 mouse cortices and WS neocortex, tissues were pulverized in 
a chilled mortar and pestle, and homogenized using chilled steel beads and a bead mill 
homogenizer. All lysates were then subjected to RNA purification using the RNeasy Plus 
Mini Kit. Concentration and RNA integrity number (RIN) values were obtained using R6K 
ScreenTape and a TapeStation 2200. One µg of total RNA was used to create cDNA 
with SuperScript III reverse transcriptase. One ng of cDNA was used for template in 
droplet digital PCR.  
 
Neuronal morphometric analysis on mouse brains, human iPSCs-derived 
neocortical neurons and human brain tissues 
Neuronal morphometric analysis was performed on mice neocortical sections obtained 
from WT (n=4) and Dnajc30 KO (n=6) mice aged 9-10 days stained with a FD Rapid 
GolgiStain kit (FD NeuroTechnologies Inc., PK401) by analyzing approximately 15 
neurons per mouse. For the Golgi-Kopsch stain of human neocortical slices, a previously 
described protocol was followed (Riley, 1979). Briefly, blocks ~0.5-1.0cm3 of cortex were 
incubated in 3.5% potassium dichromate, 15% sucrose, and 0.6% formaldehyde for 7 
days, followed by incubation in 0.75% silver nitrate for 3 days, and finally dehydrated 
overnight in 95% ethanol. Blocks were then sectioned on a vibratome at 200µm, cleared 
in Histo-Clear, and mounted on microscope slides with Permount and coverslips. Silver 
impregnation was generally poor in STC areas of all brains. The best cells that appeared 
fully impregnated (several branched apical and basal dendrites from easily identifiable 
soma) were in the deep layers of M1C, and for this reason only these cells were 
analyzed. The impregnation was not sufficient to reliably quantify spines/dendritic 
protrusions. The same morphological analysis was performed also on immunolabeled 
human iPSCs-derived neocortical neurons obtained from 3 healthy controls and 4 WS 
individuals after 80 days of in vitro differentiation, measuring also in this case about 15 
neurons per cell line. Both mouse neocortical slices, human brain slices and day 80 
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iPSCs-derived neocortical neurons coverslips were viewed on a Zeiss Axio Imager.A1. 
Neuronal morphology analysis was performed using Neurolucida software (MBF 
Bioscience) that enabled to quantify the number of dendrites and nodes, dendrites 
lengths and soma area. For all these in person-based quantifications, researchers were 
blinded to mice and cell lines genotypes before their analyses.  
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